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Industrial interest is focused on the development of new pharmaceutical 
and nutraceutical formulations aimed at the enhancement of bioavailability 
of poorly water-soluble active compounds. Various factors influence the 
bioavailability of an active principle in a solid formulation, such as the 
particle size distribution, the solid state and the morphology. In order to 
enhance bioavailability, two different approaches were investigated in this 
thesis: particle size reduction of pure ingredients and production of 
amorphous formulations consisting of the dispersion of the hydrophobic 
molecule into a hydrophilic matrix (carrier). Supercritical fluid (SCFs) 
based techniques demonstrated to be a valid alternative to traditional 
processes, given the SCFs specific properties, such as liquid-like density, 
very fast mass transfer similar to gas, near-zero surface tension, effective 
solvent elimination. Among SCFs techniques, Supercritical Assisted 
Atomization (SAA) was successfully used to produce controlled micro and 
sub-microparticles of pure compounds, but also composite systems. The 
enhancement of bioavailability of active ingredients is still poorly 
investigated in the SAA literature. The ability of the SAA process in 
crystallinity control and particle size reduction is investigated in order to 
enhance the bioavailability of new active principles, often not feasible 
through conventional methods. This Ph.D. work is the most recent advance 
in the application of this supercritical fluid technology for the production of 
new and stable pharmaceutical and nutraceutical formulations. 
 
Industrial companies are very interested in the development of these 
feasible formulation technologies. In fact, this Ph.D. work was supported 
and granted by Cerbios Pharma, a Swiss pharmaceutical company located in 
Lugano and specialized in the development and production of chemical and 
biological active principles. In the frame of the research collaboration 
between Cerbios Pharma and the Department of Industrial Engineering 
(DIIN) of the University of Salerno, a part of this thesis concerned the 
development of pharmaceutical formulations based on active principles 
suggested by the Company for its world-wide partners, in order to scale up 
this process for industrialization purposes. Due to secrecy agreements, the 
proposed active substances were presented using acronyms and no further 
detailed information was herein reported. Different kinds of active principles 
were tested on behalf of Cerbios Pharma: BRI (an alpha adrenergic agonists 
drug), FUL (an anti-estrogen drug), DAS (an anticancer drug), NAP (a non-
steroidal anti-inflammatory drug) and GPB (an anticholinergic agent). These 
drugs were previously unsuccessfully tested using traditional techniques. For 
each active principle, during this Ph.D. work, a series of SAA experiments 
was performed in laboratory scale to optimize process conditions, in order to 
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reach the targets requested by the Company. BRI, FUL and NAP were 
micronized alone, whereas DAS and GPB were dispersed in different carrier 
matrices producing coprecipitates (Chapter III). In particular, the study 
performed on NAP compound allowed to validate the SAA industrial plant 
in Cerbios Pharma and obtain the SwissMedic authorization for Good 
Manufacturing Practice (GMP) production, on January 2017. 
 
To investigate in depth the applicability of the SAA process in the 
development of new and stable pharmaceutical formulations, curcumin, 
luteolin, palmitoylethanolamide and nifedipine were selected as active 
principles, for their therapeutic and healing properties. All these substances 
showed low water-solubility and remarkably fast crystallization rates, 
interfering with the micronization processes; therefore, they were difficult to 
handle in an industrial perspective. Polyvinylpyrrolidone, hydroxypropyl-β-
cyclodextrin and dextran were investigated as carrier since they are non-
toxic, water-soluble, biodegradable, biocompatible, Food & Drug 
Administration-approved and crystal growth inhibitors. The study was 
focused on the role of the carrier in influencing particle size distribution, 
morphology, solid state, and mostly in inhibiting recrystallization of the 
active principles and enhancing their bioavailability. In particular, the 
selected carriers demonstrated to be very efficient in controlling the 
tendency of active principles to crystallize and agglomerate, by producing 
SAA stable particles over time. Indeed, well-separated and amorphous 
microspheres were obtained by SAA process with diameters lower than 1.8 
µm and high active principle loading efficiencies, up to 100% in most of the 
experiments performed. Dissolution tests confirmed improvements of 
bioavailability up to 12 times, due to the coprecipitation of the 
pharmaceutical compounds and carrier: the produced composite particles 
showed active principle dissolution rates much faster compared to the 
physical mixtures. The active principle/carrier weight ratio and chemical 
interactions in the coprecipitates revealed to be controlling parameters for 
dissolution rates (Chapter IV). 
 
The production of composite microspheres loaded with bioactive 
compounds has been another important challenge handled in this Ph.D. 
work. In particular, beta-carotene and extracts obtained from propolis and 
saffron petals (normally considered as industrial wastes) were selected in 
this framework for their nutraceutical properties. The main outcome of this 
investigation was not only the improvement of the bioavailability, but also 
the protection of the antioxidant activity of the bioactive compound. Defined 
and spherical particles were produced by means of the SAA technique using 
polyvinylpyrrolidone and hydroxypropyl-β-cyclodextrin as carriers, with 
mean diameters influenced by the concentrations under test. The UV-vis 
analyses confirmed high loading efficiencies (up to 94-100%) and preserved 
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antioxidant activity against light, heat and oxygen. In particular, the study on 
saffron petals extracts demonstrated that SAA produced particles, using 
polyvinylpyrrolidone as carrier, were able to preserve the antioxidant power 
over time. After three months, the values of scavenging activity were 
practically confirmed for SAA coprecipitates and reduced by 35% for crude 
saffron extracts. As result, the antioxidant-rich particles produced can be 
used as natural sources of antioxidants and for food supplements, thus 
proving that it is possible to enlarge the application field of the SAA process 
to the production of nutraceutical formulations (Chapter V and Chapter VI). 
 
In conclusion, the SAA technique was successfully applied both in 
pharmaceutical and nutraceutical fields, demonstrating to be an attractive 











Bioavailability of pharmaceuticals 
Many of the newly developed pharmaceuticals, as well as a significant 
proportion of the drugs on the market, are classified as poorly water-soluble, 
according to the Biopharmaceutics Classification System (Lipinski et al., 
2001, Merisko-Liversidge and Liversidge, 2011, Baghel et al., 2016, 
Sigfridsson et al., 2009, Rodriguez-Aller et al., 2015). Since approximately 
65% of the human body consists of water, a drug must have a good water 
solubility and an acceptable bioavailability level. The bioavailability is 
defined as the rate at which the relative amount of an administered dose of 
an active principle is absorbed from a pharmaceutical form and becomes 
available at the site of action (Chow, 2014). Generally, the rate-limiting step 
for absorption of drug poorly water-soluble is the liberation that corresponds 
to the release of drug from pharmaceutical formulation and its dissolution 
(Junyaprasert and Morakul, 2015). A limited absorption of these active 
principles leads to slow onset of action, beyond excessive and frequent 
dosage of drugs to reach the therapeutic concentration in blood. These 
increased dosages may cause several negative effects including inefficient 
treatment, higher patient costs, undesirable side effects on human health, 
poor patient compliance and more risks of toxicity or even death (Kawabata 
et al., 2011). The improvement of active principle bioavailability is one of 
the most challenging features of the drug development process, especially 
for oral drug delivery systems. 
Several approaches have been proposed to overcome these limitations 
and to improve the dissolution rate of pharmaceutical compounds in aqueous 
media (Fu et al., 2017, Gupta et al., 2013). These approaches can be 
classified as chemical and physical modifications. Among the chemical 
modifications, for example, the synthesis of soluble pro-drugs and salts 
starting from the pure active principle is one of the most used. However, 
these approaches cannot be used for neutral molecules and the improvement 
of dissolution in water of the salt than free drug is not always guaranteed 
(Kalepu and Nekkanti, 2015, Junyaprasert and Morakul, 2015). On the other 
hand, physical modifications include: complexation or solubilization (using 
Introduction 
XVIII 
cyclodextrins, surfactants, conjugation with dendrimers), particle size 
reduction (micronization and nanonization techniques), changes of the 
crystal habit (polymorphs) and preparation of drug solid dispersions in 
different type of carriers (for examples, polymeric and polysaccharide 
matrices, liposomes, micelles) (Sharma et al., 2016, Stella and He, 2008, 
Savjani et al., 2012, Merisko-Liversidge and Liversidge, 2011, Chen et al., 
2011). As reported in several works in the literature, the time of dissolution, 
hence, the dissolution rate may change due to several factors, such as the 
solid state, the particle size, the type of formulation, etcetera (Merisko-
Liversidge and Liversidge, 2011, Kalepu and Nekkanti, 2015, Junyaprasert 
and Morakul, 2015). 
According to the Noyes-Whitney equation, the dissolution rate is directly 
proportional to the drug solubility and its interfacial surface area (Hancock 
and Parks, 2000, Savjani et al., 2012, Mosharraf and Nyström, 1995, Khadka 
et al., 2014). 
 
dm/dt = DA*(Cs-Cbulk)/h      (1) 
 
where dm/dt is the dissolution rate of drug, D is its diffusion coefficient, A is 
its surface area, Cs is its saturation concentration in the solvent, Cbulk is its 
concentration in the bulk, and h is the thickness of the hydrodynamic 
boundary layer. 
Nevertheless, the drug solubility fundamentally depends on the solvent 
used as well as on temperature and pressure. It is an equilibrium parameter 
and it is almost the same for all sizes of a drug, in crystalline or amorphous 
state: given enough time, even large particles eventually dissolve up to the 
saturation concentration in the specific solvent (Sun et al., 2012, Savjani et 
al., 2012). In addition, the solid state of the drug can affect the dissolution 
rate of an active principle. A crystalline and poorly water-soluble drug, when 
in the amorphous state tends to have higher release rate, since no energy is 
required to break up the crystal lattice during the dissolution process. 
Therefore, the amorphous pharmaceuticals show markedly higher 
dissolution rate than their crystalline counterparts (Sun et al., 2012, Savjani 
et al., 2012, DiNunzio et al., 2008, Alonzo et al., 2010). Some 
thermodynamic aspects explain the reason: unlike crystalline material, an 
amorphous solid is characterized as having a molecular arrangement that 
lacks long-range order. Consequently, the entropy (∆S) and the free energy 
(∆G) of an amorphous solid is higher than that of its crystalline arrangement. 
This energy difference explains the reason why significantly faster 
dissolution can be obtained for amorphous formulations compared to their 
crystalline equivalents. By manipulating the solid state and producing 
polymorphs (thanks to the use of different solvents and/or operating 
conditions during the production), it is possible to develop the best stable 
arrangement of the drug to assure an improved bioavailability and a long 
shelf-life. When a solid is in an amorphous state, it exhibits only molecular 
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vibrations; therefore, amorphous one-phase formulations can be used to 
improve dissolution rates of poorly water-soluble drug, and, at the same 
time, to produce long-term stability of dried powders (Hancock and Parks, 
2000, Savjani et al., 2012, Baghel et al., 2016, Kalepu and Nekkanti, 2015). 
The particle size reduction approaches to prepare stable micro and 
nanoparticles have emerged to increase the bioavailability of poorly water-
soluble compounds. Indeed, the micronization method increases the surface 
area to volume ratios of drug powders allowing greater interactions with the 
solvent and, hence, enhancing the dissolution rates (absorption) (Chen et al., 
2011). The surface area of a drug, indeed, increases as the size of the active 
principle particles is decreased from bulk to a micro to a nano scale. The 
smaller particle size results in a large surface area that is proportional to the 
dissolution rate, as described by the Noyes-Whitney equation (Kogermann et 
al., 2013, Mosharraf and Nyström, 1995, Sun et al., 2012). Althoug the 
particle size reduction is one of the oldest strategies for improving the 
dissolution rate, micro and nanoparticles of active substances may be 
affected by aggregation or recrystallization phenomena; therefore, they are 
difficult to handle in an industrial perspective. For this reason, the 
pharmaceutical companies have long recognized the advantages of multi-
composite systems in order to improve the pharmacokinetic behavior and 
enhance the bioavailability of the active principles in the formulations 
(Junyaprasert and Morakul, 2015, Savjani et al., 2012, Khadka et al., 2014). 
Solid dispersions represent a useful pharmaceutical technique and consist of 
at least two different compounds, generally a hydrophobic drug and a 
hydrophilic matrix that acts as a carrier. The composite system can be 
produced in form of microspheres or microcapsules. In the first case, the 
carrier and the active compounds are uniformly dispersed within the same 
particle (composites), whereas in the second case, the compound of interest 
is surrounded by a carrier shell (core-shell systems or encapsulates) (Cocero 
et al., 2009). The carrier has to be soluble in water, biocompatible, 
biodegradable, non-toxic, FDA (Food and Drug Administration)-approved; 
furthermore, it has to protect the active principle, to inhibit its 
recrystallization and to improve its dissolution. The most widely used 
carriers for solid dispersions include hydroxypropylmethyl cellulose, 
polyvinylpyrrolidone, hydroxypropylmethyl cellulose acetate succinate, 
sugars and polyethylene glycols. These carriers have high glass temperature 
transitions (Tg), thus they are in glassy state at room temperature (Merisko-
Liversidge and Liversidge, 2011, Savjani et al., 2012, Sinha et al., 2010, 
Vasconcelos et al., 2007, Alonzo et al., 2010). Carriers capable of interacting 
with some active principles, such as through hydrogen bonding or steric 
hindrance, have been demonstrated to inhibit crystallization at very low 
concentrations. These physical or chemical interactions can restrict the 
molecular mobility of the drug molecules and provide stability to the system 
(Baghel et al., 2016). 
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Conventional methods, including emulsion/solvent evaporation, thermal 
gelation, hot homogenization technique, coacervation, spray drying, freeze-
drying, antisolvent precipitation, jet milling have been used to obtain particle 
size reduction and solid dispersions of poorly water-soluble active principles 
in different carriers. However, these strategies are not always suitable or 
feasible and may show some drawbacks (Campardelli et al., 2015), such as 
the production of coarse and large particles with broad particle size 
distribution, the degradation of the product due to mechanical or thermal 
stresses, or its contamination with organic solvents or other toxic substances, 
low loading efficiencies and difficulty in scale up (Martín and Cocero, 2008, 
Temelli, 2018). In particular, emulsification and solvent evaporation need a 
large use of heavy and toxic organic solvents; furthermore, to reduce the 
residual organic solvent below the safety limits, many downstream 
processes, such as additional drying step, have to be performed. Even spray 
drying has some limitations: uses of large amount of toxic organic solvents, 
high temperatures to remove solvents, possible degradation of the active 
product due to the thermal stress and production of large particles with wide 
particle size distribution. Furthermore, some drugs result to be difficulty 
processed by conventional methods, due to their fast tendency to crystallize 
and to agglomerate. 
 
In recent years, the application of supercritical-carbon dioxide (SC-CO2) 
based processes has attracted great attention as a valid alternative to 
traditional techniques (Cocero et al., 2009, Campardelli et al., 2015). These 
SC-CO2 based techniques have been successfully applied in several fields: 
among them, micronization, membranes, scaffold production (Cocero et al., 
2009, Campardelli et al., 2015, Baldino et al., 2014a, Baldino et al., 2014b, 
Reverchon and Della Porta, 2003, Prosapio et al., 2015, Franceschi et al., 
2008, Adami et al., 2017b, Adami et al., 2012, Adami and Reverchon, 2012, 
Martin et al., 2013, Meneses et al., 2015, Reverchon et al., 2015, Wu et al., 
2009). Among the SC-CO2 based processes, Supercritical Assisted 
Atomization (SAA) is an efficient technique that has been used until now to 
produce micro and sub-microparticles of several kinds of compounds: active 
molecules, salts, catalysts, proteins and polymers (Reverchon et al., 2003, 
Adami and Reverchon, 2012, Della Porta et al., 2006, Reverchon and Spada, 
2004a, Adami et al., 2011, Liparoti et al., 2012, Adami et al., 2012, Martin et 
al., 2013). In SAA process, SC-CO2 is solubilized in a solution containing 
the compound to be micronized forming an expanded liquid, characterized 
by reduced viscosity and surface tension that is subsequently atomized. SAA 






Bioavailability of nutraceuticals 
Nowadays, a significant interest in incorporating micronutrients 
(bioactive compounds) into functional food and beverage products has 
increased to benefit human health and wellness through the diet (Handford et 
al., 2014). These micronutrients include vitamins, minerals, flavors, 
antioxidants, antimicrobials, polyphenols, probiotics, prebiotics and 
preservatives. Some of these micronutrients are essential for human well-
being (such as vitamins), whereas other substances derived from food 
sources provide health benefits in addition to diet (nutraceuticals) (Joye et 
al., 2014, Handford et al., 2014). Various bioactive compounds have been 
obtained from natural sources, for examples vegetables, fruits, legumes, oil 
and have shown beneficial effects on human health including antioxidant, 
anti-inflammatory, and antibacterial activities (Recharla et al., 2017). A 
recent tendency is the recovery of these bioactive compounds also from 
wastes derived by food industry. Indeed, the processing of plant foods results 
in the production of a large volume of by-products that is still rich in 
bioactive compounds that can be recovered. These residues could be an 
alternative source for obtaining natural antioxidants, which are considered 
completely safe in comparison with synthetic ones (Murthy and Naidu, 
2012, Lafka et al., 2007, Balasundram et al., 2006, Guamán-Balcázar et al., 
2019, Meneses et al., 2015). 
However, bioactive compounds cannot be incorporated in their pure state 
into commercial food products, due to their susceptibility to physical, 
chemical and enzymatic degradation (Coronel-Aguilera and San Martín-
González, 2015). Furthermore, the performance of these substances can be 
affected by light, heat, water and oxygen exposure, compromising their 
activity and shelf-life (Handford et al., 2014). Moreover, some bioactive 
compounds have strong taste and aroma, such as propolis (Nori et al., 2011, 
Kalogeropoulos et al., 2009), and show low water solubility and, hence, 
limited oral bioavailability (de Souza Simões et al., 2017). 
In order to improve bioavailability of these micronutrients, the production 
and the use of nanoparticles of pure compounds is rare for food applications; 
whereas, several advantages are associated with the production of composite 
delivery systems and, particularly, with microencapsulation or dispersion of 
the bioactive compounds in a wide variety of food-grade materials (Joye and 
McClements, 2013, Puligundla et al., 2017, Franceschi et al., 2008, Priamo 
et al., 2011). First, these strategies allow the easier incorporation of 
functional components into food systems; second, it may preserve the 
activity of micronutrients from chemical reactions and degradations 
(oxidation, hydrolysis); third, the delivery systems may release the active 
substances in a particular site of action, and protect them to the various 
stresses for food during its production, storage, transport and consumption 
(Joye and McClements, 2013, Joye et al., 2014). Therefore, one important 
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application of nanotechnology in food and nutrition is to design and develop 
novel functional food ingredients with improved oral bioavailability, and 
thermal and mechanical stability (Huang et al., 2010). Engineered materials, 
for a variety of agro-food applications such as food additives, are developed 
using polymers, polysaccharides, micelles, liposomes, polyelectrolyte 
complexes and hydrogel particles (Puligundla et al., 2017, Priamo et al., 
2011, Temelli, 2018, Joye et al., 2014). 
Solid formulations consisted of the incorporation of bioactive compounds 
in polymeric matrices are gaining increasing interest by food industry, 
representing a suitable method to stabilize and protect the bioactive 
compound from environmental conditions (Champagne and Fustier, 2007, 
Franceschi et al., 2008, Janiszewska-Turak, 2017, de Paz et al., 2012, Priamo 
et al., 2011, Guamán-Balcázar et al., 2019). Different processes are being 
applied in order to produce micro- and nanosystems for functional foods 
using “top down” and “bottom up” approaches or the combination of both 
strategies. The wide range of available techniques that can be employed for 
food application includes spray drying, emulsion, coacervation, antisolvent 
precipitation (Guamán-Balcázar et al., 2019, de Souza Simões et al., 2017). 
These traditional processes suffer from several well-known drawbacks, such 
as excessive use of solvent, thermal and chemical solute degradation, high 
residual solvent concentration and difficulty in controlling the particle size 
distribution during processing, low loading efficiencies and in some cases 
difficulty in scale up the process (Temelli, 2018). In recent years, the 
encapsulation of bioactive compounds by supercritical technology using SC-
CO2 is considered as a suitable technique for natural products encapsulation 
(Temelli, 2018, Janiszewska-Turak, 2017). According to Cocero et al. 
(Cocero et al., 2009), the application of SC-CO2 based processes is a 
promising alternative to conventional techniques since they can eliminate or 
reduce the use of organic solvents, the separation of supercritical fluid can be 
easily accomplished by depressurization, hence obtaining solvent-free 
products. Furthermore, SC-CO2 based processes allow working at lower 
temperatures compared to the conventional ones, avoiding degradation of 
bioactive compounds that are thermo-sensitive. 
In this field, the SAA process may be an efficient alternative for the 
production of formulations based on bioactive compounds loaded in 
different carrier matrix in order to develop novel functional food ingredients 
with improved bioavailability, thermal stability and preserved antioxidant 
activity. The challenge is to apply the SAA process in a very poorly explored 




Aim of the thesis 
The aim of this work is to adopt SCF-based process, able to enhance the 
bioavailability and the stability of some active principles. Up to now, the 
Supercritical Assisted Atomization (SAA) process has been successfully 
used to produce controlled micro and submicroparticles of pure compounds, 
but also composite systems. The enhancement of bioavailability of active 
ingredients is, instead, poorly investigated and discussed in the SAA 
literature. Therefore, this Ph.D. work regards the recent advances in the 
application of this supercritical fluid technology for the production of new 
solid formulations to improve active principle dissolution rates. Two 
approaches are investigated to reach such a goal: the particle size reduction 
of pure ingredients and the production of amorphous formulations consisting 
of the dispersion of the hydrophobic molecules into a hydrophilic matrix 
(carrier), named coprecipitates. The ability of the SAA process in 
crystallinity control and particle size reduction is investigated in order to 
enhance the bioavailability of new active principles, often not reachable with 
conventional methods. 
 
This Ph.D. work has been supported and granted by Cerbios Pharma, a 
Swiss pharmaceutical company located in Lugano and specialized in the 
development and production of chemical and biological active principles. 
Cerbios Pharma has funded this research project with the aim to invest in an 
atomization plant for particle engineering using SCFs. In the frame of the 
research collaboration between Cerbios Pharma and the Department of 
Industrial Engineering (DIIN) of the University of Salerno, a part of this 
work of thesis has concerned the development of pharmaceutical 
formulations based on active principles proposed by the Company, in order 
to scale up SAA process for industrialization purposes. Due to secrecy 
agreements, these active substances are presented using acronyms and no 
further detailed information is reported. Different kinds of active principles 
are tested on behalf of Cerbios Pharma: BRI (an alpha adrenergic agonists 
drug), FUL (a antiestrogen drug), DAS (an anticancer drug), NAP (a non-
steroidal anti-inflammatory drug), GPB (an anticholinergic agent). For each 
of these drugs, a systematic study is performed to optimize SAA process 
conditions aimed at the specific targets requested by the Company. In 
particular, the Chapter IV of this work of thesis presents the results achieved 
in the frame of this research collaboration, which are aimed to validate the 
SAA industrial plant in Cerbios Pharma and obtain the SwissMedic 
authorization for Good Manufacturing Practice production. 
 
To investigate in depth the applicability of SAA process in the 
development of new and stable pharmaceutical formulations, curcumin 
(CUR), luteolin (LUT), palmitoylethanolamide (PEA) and nifedipine (NIF) 
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are selected as active principles, for their therapeutic and pharmacological 
properties. All these active principles show fast tendency to crystallize and 
low dissolution rates in aqueous media. A series of coprecipitation tests is 
performed to study the role of the carrier in influencing PSD, morphology, 
solid state, and, particularly, in inhibiting recrystallization of the selected 
active principles and enhancing their bioavailability. Three different carriers 
are investigated: polyvinylpyrrolidone (PVP), hydroxypropyl-β-cyclodextrin 
(HPβCD) and dextran (DEX), since they are water-soluble, biodegradable, 
biocompatible, Food & Drug Administration-approved and crystal growth 
inhibitors. 
Another aspect still poorly explored in SAA literature regards the 
application of this well-known technology in a new research field, like the 
nutraceutical one. Therefore, the aim of this part of Ph.D. work has been to 
test the applicability of the SAA process in the production of nutraceutical 
formulations based on the dispersion of bioactive compounds, such as beta-
carotene and extracts obtained from propolis or saffron petals, in matrices 
like PVP and HPβCD. For these systems, in addition to the improvement of 
bioavailability, the most important aspect has concerned the role of the 
carrier in protecting the antioxidant activity of the bioactive compound. 
 
Outline of the thesis 
The dissertation is organized as follows. 
 
In Chapter I, a brief review on micronization and coprecipitation 
technologies is followed by an introduction on the scientific relevance and 
the innovative aspects of SAA process and, in particular, by an in-depth 
review of the SAA literature. 
 
The description of the analytical methodologies used to study the 
characteristics of the SAA produced particles and raw materials (including 
size, solid state, morphology, dissolution behavior, loading efficiency and 
antioxidant activity) are described in Chapter II. 
 
In Chapter III, the results achieved in the frame of the research 
collaboration between Cerbios Pharma and the Department of Industrial 
Engineering (DIIN) of the University of Salerno are discussed. These 
scientific results are not published due to secrecy agreements. 
 
In Chapter IV, several applications concerning SAA laboratory scale 
production of composite systems, loaded with hydrophobic and crystalline 
compounds with pharmacological properties, are proposed and investigated 
to reach an improved bioavailability and control of the crystalline behavior 




In Chapter V and Chapter VI, the application of the SAA process in the 
still poorly-investigated field of the nutraceutical compounds is presented 
and discussed, thus endorsing the SAA technique as a reliable alternative to 
conventional processes. 
 
Finally, some conclusions are drawn on the main results achieved by this 
Ph.D. work. 
 
The dissertation contains three chapters (IV-VI) presenting results 
published in journal and conference proceedings. The complete citations for 
these papers are provided in the Publication List. 
 
Fruitful cooperations contributed to validate the results discussed in this 
work of thesis, including the scientific collaboration with Italian and foreign 
research groups (like the Italian Departments of Pharmacy and of Chemistry 
& Biology of the University of Salerno, the Chilean Institute of Fraunhofer 
and the French Laboratory of Mechanics, Modeling & Clean Processes of 
the University of Marseille) and pharmaceutical companies (like the Swiss 






































I.1 Introduction  
The bioavailability of pharmaceuticals and nutraceuticals in solid 
formulation strongly depends on the size, particles size distribution and solid 
state of materials. Due to this, there is an increasing interest in the 
development of efficient micronization technologies (Martín and Cocero, 
2008). There are different micronization techniques proposed in literature, 
classified in two classes: top down and bottom up. The “top down” processes 
provide the reduction of the original materials by involving a physical or 
chemical process of breaking down larger particles into smaller ones, for 
examples grinding or milling. The “bottom up” techniques can create more 
complex molecular structures of compounds, for examples the precipitation 
of particles from a liquid phase, crystallization process, self-assembly 
method (Reverchon and Adami, 2006, Chiou et al., 2006, Handford et al., 
2014). An important current alternative to the micronization of a pure 
compound is based on the production of composite systems consisted of the 
active principle and a carrier system. There are different kinds of carrier: 
biopolymer matrices, polysaccharides, cyclodextrins, lipids, micelles, 
liposomes (Handford et al., 2014). The composite system can be produced in 
form of microspheres or microcapsules. In the first case, the carrier and the 
active compounds are uniformly dispersed within the same particle 
(composites), whereas in the second case, the compound of interest is 
surrounded by a carrier shell (core-shell systems or encapsulates) (Cocero et 
al., 2009). These kinds of particles have demonstrated to be very useful in 
both nutraceutical and pharmaceutical field. In particular, these solid 
formulations are easier to handle than the pure particle of an active principle 
that may be affected by crystallization or oxidation phenomena with a 
possible loss of activity. Furthermore, the carriers used can allow achieving a 
controlled delivery of the active compound on time and in the site of action, 
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protecting it against degradation/oxidation and loss of activity, enhancing its 
dissolution rate and inhibiting its recrystallization. Moreover, some active 
substances can have a distinct off-flavor or a strong and unpleasant taste and 
aroma, thus their application as a food ingredient or in pharmaceutical 
industries can be limited. The loading/encapsulation of these compounds in a 
carrier can be an option to overcome these negative aspects (Joye et al., 
2014, Handford et al., 2014, Temelli, 2018). 
 
I.1.1 Conventional techniques 
Spray drying 
This process consists of the atomization of a liquid solution containing 
the substrate to be micronized. The spray formed is then dried using a heated 
gas flow (compressed air or nitrogen) in order to remove the solvent. Using 
cyclones or filter it is possible to recover the final product from the gaseous 
stream. The main limitations of spray drying are the difficulty in controlling 
the particle size distribution (which are very wide), the high tendency to 
agglomerate, low loading efficiencies and possible degradation of active 
principle due to high temperatures used to remove the solvent (Martín and 
Cocero, 2008, Ishwarya et al., 2015, Vandana et al., 2014). 
 
Spray freeze drying 
In this process, the solution containing the substrate to be micronized is 
sprayed directly in a cryogenic liquid (liquid nitrogen or a cold gaseous 
stream). The frozen droplets are thus lyophilized and fine particles are 
produced. The low temperatures used allow to process also thermal sensitive 
compounds avoiding possible degradation. The limitations are comparable to 




In this process, the precipitation of particles proceeds in steps of mixing 
of solution and anti-solvent, generation of supersaturation, nucleation, and 
growth by coagulation and condensation, followed by agglomeration in case 
of uncontrolled growth. The solution containing the compound to be 
micronized is mixed with an anti-solvent; the solute has to be insoluble in 
this mixture and, consequently, it precipitates. The drawbacks of this 
technique are the high residual solvent in particles produced, the wide 
particle size distribution obtained and the longtime of process (Betancourt et 
al., 2007, Alshamsan, 2014). 
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High pressure homogenization 
The production of drug nanoparticles via the top-down approach of 
disintegration mechanism involves the high pressure homogenization (Chen 
et al., 2011). This process is performed in water or in a non-aqueous media 
in the case of water sensitive drugs. A suspension of crystalline drug and 
stabilizers is passed through the narrow gap of a homogenizer at high 
pressure (500-2000 bar). The high pressures create some disruptive forces, 
such as collision and shearing that cause the disintegration of the starting 
material. The particles produced show size depending of the number of 




This technique is applied to physically break down coarse particles to 
finer ones due to mechanical energy applied to the system; hence, it is a 
“top-down” method (Loh et al., 2015). Generally, milling may be conducted 
in different conditions: dry state (dry milling) or in a liquid medium (wet 
milling). In particular, in the jet milling method, a high velocity medium gas 
(nitrogen or air) passing through a nozzle carries coarse particles into the jet 
mill causing their disintegration due to the impact and the collision against 
the wall of the vessel. By this technique, particles of 1-20 µm can be 
produced (Hoyer et al., 2008, Nykamp et al., 2002, Chen et al., 2011). The 
lack of control over particle size distribution and the possible chemical 
degradation of material due to the mechanical energy applied to the system 
represent the main limitations of the application of this type of micronization 
technique in pharmaceutical fields.  
 
Emulsion/Solvent evaporation 
This process is mainly used to produce composite particles starting from 
an emulsion. The polymer is dissolved in a suitable water immiscible solvent 
and the drug is dispersed or dissolved in this polymeric solution. The 
resultant solution is then emulsified in an aqueous phase to form droplets. 
The emulsion is continuously stirred and heated (at a fixed temperature) to 
remove the organic solvent for evaporation. At the end, microspheres can be 
recovered as a cake. This technique, however, generally provide limited 
control over the particles size and particle size distribution. Furthermore, to 
reduce the residual organic solvent, many downstream processes, such as 





I.1.2 Supercritical techniques 
Conventional micronization processes reported show several drawbacks: 
high process temperatures, possible degradation of the active product due to 
mechanical and thermal stresses, production of irregular particles with broad 
PSD, low encapsulation efficiencies, large use of heavy and toxic organic 
solvents with further treatments required to reduce solvent residues below 
the safety limits. Furthermore, some molecules are often difficult to be 
processed using conventional techniques, due to their high crystallization 
rates or fast tendency to agglomerate (Martín and Cocero, 2008). 
Supercritical fluids (SCFs) based processes for the precipitation of 
pharmaceutical and natural compounds have demonstrated to be a valid 
alternative to traditional processes, given the SCFs hybrid liquid-like gas-
like properties: very fast mass transfer, near zero surface tension and 
effective solvents elimination. Therefore, SCFs technologies can play a 
relevant role in micronization and coprecipitation fields. The most 
commonly used supercritical fluid is carbon dioxide thanks to the more 
accessible critical point (Pc=73.8 bar and Tc=304.25 K), furthermore it is 
non-combustible, non-toxic, ecofriendly and cheap; it is also easily available 
as it occurs naturally as well as being the by-product of many industrial 
processes. 
These techniques can be classified according to the role of SCF in the 
process: solvent (RESS, PGSS, RESOLV), solute (SAA) and anti-solvent 
(SAS, ASES, SEDS, GAS) (Martín and Cocero, 2008, Campardelli et al., 
2015, Reverchon and Adami, 2006, Reverchon et al., 2009, Fahim et al., 
2014). 
 
Precipitation from Gas Saturated Solution 
In this process, well known as PGSS, the supercritical fluid is dissolved in a 
melted solute to create a saturated solution that is then expanded to 
atmospheric pressure. This expansion causes a fast release of the dissolved 
gas producing a fast solidification of the solute in form of particles avoiding 
the use of organic solvents. In order to apply this technology, solids have to 
be immiscible in the supercritical fluid and no thermal sensitive (Martín and 
Cocero, 2008, Reverchon et al., 2009). 
 
Rapid Expansion of Supercritical Solution 
This process, well known as RESS, consists of the saturation of the 
supercritical fluid with a solid solute; then, this solution is sprayed through a 
heated injector into a low pressure vessel producing a rapid nucleation of the 
substrate in form of very small particles that are collected from the gaseous 
stream. Depending of process parameters, such as temperature, pressure 
drop, type of nozzle etc., different kind of morphology can be obtained. 
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When the supercritical solution is expanded directly in a liquid, the process 
is named RESOLV. These processes show some drawbacks: difficulty in 
controlling the particle size of the precipitates, possible coalescence of 
particles produced. However, the main limitation is that the application of 
this technique requires high solubility of the compound in the supercritical 
fluid to be processed (Martín and Cocero, 2008, Campardelli et al., 2015). 
 
Supercritical Emulsion Extraction 
This technique, well known as SEE, uses supercritical fluid for the 
extraction of the organic phase from a single or double emulsion producing 
nano and microparticles and microcapsules. A solute is dissolved in a 
suitable solvent to form a solution; the solution is then dispersed into an 
immiscible or partially miscible liquid to form an emulsion. Extracting 
selectively the solvent from the oil phase of the emulsion, the SEE process 
produces an aqueous colloidal suspension of particles. SC-CO2 extraction 
has a relatively faster extraction rate compared to extraction rates of other 
conventional techniques (processing in minutes instead of several hours), 
and this allows the formation of relatively smaller particles, with narrow size 
distributions, and very small solvent residues. SEE process has been applied 
to produce nanocarriers, such as polycaprolactone, poly(L-lactide) and 
polylactic-co-glycolic acid, but, also, to prepare particles encapsulating 
magnetite, proteins, peptides and drugs (Campardelli et al., 2015, Reverchon 
et al., 2015, Reverchon et al., 2009). 
 
Supercritical Antisolvent precipitation 
The Supercritical Anti-solvent (SAS) has been proposed using various 
acronyms (SEDS, ASES); but, the process is substantially the same in all 
cases. In SAS, the supercritical fluid is used as an anti-solvent that causes the 
precipitation of the solute in a liquid solvent in form of empty shells 
(balloons), micro and nanoparticles depending of the operating conditions 
investigated. The key phenomena of SAS process are the jet break-up at the 
exit of the nozzle, the high-pressure vapor-liquid equilibrium and mass 
transfer in and out of the droplet. If the precipitation occurs from a 
supercritical phase, nanoparticles are obtained since droplets do not form and 
the material precipitates from the gas. In subcritical single-phase conditions, 
the droplets are formed and the competition between surface tension and jet 
break-up is responsible of the process evolution. The droplet expansion 
followed by the solute precipitation leads to the production of empty 
particles (ballons). At intermediate conditions (near critical critical point), 





Supercritical Assisted Liposome formation 
The Supercritical Assisted Liposome formation (SuperLip) has used to 
create lipid nanovesicles, starting from the production of water nanodroplets 
and, then, nanosomes are formed around them. For this reason, the process 
consists of a first step of atomization of water based solutions directly in a 
supercritical solution in which phospholipids are dissolved. Then generally, 
ethanol is added to increase solubility of phospholipids in SC-CO2. Since 
micelle formation is a fast and spontaneous process, the lipids contained in 
the expanded liquid formed tend to organize themselves in a layer around the 
water nanodroplets. Studies have demonstrated that different drugs and 
antioxidants can be encapsulated with efficiencies around 80% (Campardelli 
et al., 2015). 
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I.2 Supercritical Assisted Atomization 
SAA technique is a micronization process patented by Reverchon 
(Reverchon, 2002) in 2002, in which the supercritical fluid is used as an 
atomizing medium enhancing the atomization process. The process is based 
on the solubilization of the SC-CO2 in a liquid solution, where one/or more 
compounds to be micronized are previously dissolved, forming an expanded 
liquid in a saturator. The subsequent atomization of this expanded liquid 
through a thin wall nozzle allows the production of droplets smaller than 
those produced using traditional similar micronization techniques and, after 
drying, smaller particles (Reverchon, 2002). The typical solvents used in this 
process are water and organic solvents, such as ethanol, methanol, and 
acetone. The possibility to use water as solvent makes the process clearly 
environmental friendly. SAA process allows obtaining microparticles and 
sub-microparticles ranging between 0.2 and 5 µm, with narrow particle size 
distribution and no residual solvent. Moreover, composite systems formed 
by two or more compounds can be produced with high loading efficiencies. 
 
I.2.1 Apparatus 
The homemade equipment used for the experimentation is shown in 
Figure I.1a, whereas the GMP industrial plant owned by Cerbios Pharma is 
reported in Figure I.1b. 
 
a.     b. 
   
Figure I.1 a) SAA plant in laboratory T8 at UNISA; b) GMP industrial plant 
(Cerbios Pharma, Lugano). 
In Figure I.2, a scheme of the SAA laboratory plant used for the 




Figure I.2 Schematic representation of a SAA apparatus. S, saturator; P, 
precipitator; H, heat exchanger; C, liquid condenser. 
 
SAA plant consists of two high-pressure pumps (mod. 305, Gilson) 
delivering liquid solution and CO2 to the saturator. The saturator is a high-
pressure vessel (50 cm3 internal volume) loaded with stainless steel 
perforated saddles, that assures a large contact surface between the liquid 
solution and CO2. The expanded liquid obtained in the saturator is sprayed 
through a thin wall injection nozzle (80 μm internal diameter) into the 
precipitator (3 dm3 internal volume). A controlled flow of N2 is taken from a 
cylinder, heated in an electric heat exchanger (mod. CBEN 24G6, Watlow) 
and sent to the precipitator to induce droplets evaporation. The saturator and 
the precipitator are electrically heated using thin band heaters (Watlow, mod. 
STB3EA10). A stainless steel filter, located at the bottom of the precipitator, 
allows powder collection and the gaseous stream flow out. A condenser that 
separates liquids from the gas stream completes the system. 
 
I.2.2 Process parameters 
The process parameters influencing the efficiency of the atomization 
process, the particle size (PS) and particle size distribution (PSD) are: 
 
 the mass flow ratio (GLR) between CO2 and liquid solution,  
 the operating pressure (Pmix) and temperature (Ts) in the saturator, 
 the solute concentration in the liquid solution (C), 
 the temperature in the precipitator (Tp), 
 the nozzle diameter, 
 the active principle/carrier ratio in the liquid solution. 
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The operating conditions are selected considering the binary vapor-liquid 
equilibrium (VLE) diagram solvent-CO2. The molar fraction of CO2, the 
temperature and the pressure selected at the saturator ensure large CO2 
solubility in the liquid. The solubilization of CO2 in the liquid solution 
reduces the viscosity and the surface tension allowing an increased jet 
breakup efficiency and, hence, a more effective atomization. In particular, 
CO2 shows good solubility in solvents like ethanol, therefore, it is possible to 
operate in the one-phase region in the saturator. Whereas CO2 is not 
completely soluble in water and, in this case, a discontinuous region is 
formed. The no dissolved CO2 reduces the section for the passage of the 
liquid improving the efficacy of the atomization. Therefore, the particles 
obtained in ethanol are smaller than those produced using water as solvent, 
since the largest decrease of cohesive forces due to the viscosity and the 
surface tension (Caputo et al., 2012). The SAA literature has demonstrated 
the key role of dissolved CO2 in reducing the cohesive forces that have the 
most influence on particle size (Liparoti et al., 2015). Therefore, the 
atomization strongly depends on the GLR. At low value of GLR (lower than 
2) larger droplets are obtained, whereas at higher GLR droplets size rapidly 
decreases. For GLR values higher than 3, the droplets size is not more 
sensitive to further increments. 
Moreover, the droplet sizes slightly decrease with a decrease in injector 
diameter (Caputo et al., 2012, Adami et al., 2013). However, the particle size 
is also influenced by the solute concentration; larger particles are produced 
when high solute concentrations are processed. Typically, this effect can be 
related to the increase of viscosity of the starting solution due to a higher 
concentration. Since viscosity is a cohesive force, its increase tends to 
produce larger droplets below the nozzle and an overall result of 
enlargement of particle size (Reverchon and Antonacci, 2007b). 
The injection of the solution (solvent+solute+SC-CO2) through the nozzle 
allows the formation of the droplets that are dried in the precipitation vessel. 
After the formation of the droplets, the drying of the solvent takes place 
thanks to the nitrogen flow (N2). It is possible to apply the theory proposed 
by Vicente and Vehring (Vehring, 2008, Vicente et al., 2013) on the drying 
process in the spray drying. The evaporation of the droplets involves mass 
and heat transfer mechanisms, influenced by the drying temperature and the 
solute concentration. During drying, the precipitation of the solid starts from 
the droplet surface and a thin layer is formed through which the solvent can 
diffuse. If this diffusion is fast (when high temperatures are used), particles 
with internal void space can be obtained; these thin layers can be sometimes 
fragile, depending on the material, and the particles can collapse (shrinking 
effect). When the drying is not too fast, the solutes tend to precipitate 
homogeneously inside the droplets and the produced particles show no void 
spaces (Vehring, 2008, Vicente et al., 2013).  
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The nitrogen flow and the temperature fixed in the precipitator do not 
affect the atomization process in the nozzle. However, these two parameters 
can influence the spray shape, removing the solvent and avoiding the 
recondensation of the liquid in the precipitator. The particle sizes can be 
influenced by the temperature in the precipitator because of the shrinking 
effect above mentioned.  
Furthermore, the presence of the solutes could modify the VLE diagram 
solvent-CO2; consequently, there will be the possibility that the solutes could 
precipitate in the saturator because of the anti-solvent effect. The anti-solvent 
effect occurs when the solvent, in which the compound to be micronized is 
solubilized, has very high solubility in SC-CO2. Consequently, when the 
solute reaches the supersaturation in the mixture liquid solvent- SC-CO2, it is 
possible to observe an undesired precipitation of the compound on the 
packings in the saturator. This condition must be avoided in order to have a 
successful SAA micronization or coprecipitation (Reverchon et al., 2009). 
 
 
I.2.3 State of the Art of SAA process 
Micronization 
Different kinds of materials have been successfully micronized by SAA, 
such as pharmaceutical compounds, superconductors and catalyst precursors, 
dyes, polymers, enzymes, etc (Della Porta et al., 2006, Reverchon, 2002, 
Reverchon and Adami, 2006, Reverchon et al., 2005, Reverchon and 
Antonacci, 2006b, Reverchon and Della Porta, 2003, Wu et al., 2015, Wu 
and Yang, 2011, Wu et al., 2014). 
Among polymers processed by SAA process, Reverchon and Antonacci 
(Reverchon and Antonacci, 2007b) micronized polymethylmethacrylate 
(PMMA) and poly-L-lactide (PLLA) testing the effect of process parameters 
(such as GLR, precipitation temperature and solute concentration). PMMA 
and PLLA size-controlled microparticles were produced ranging between 
0.05 and 1.6 µm and between 0.1 and 3.5 µm, respectively. Particle size 
distribution of PMMA and PLLA microparticles showed a dependence on 
the GLR and the solute concentration. Increasing the GLR, smaller polymer 
particles were produced; whereas, an increase of the solute concentration 
produced larger particles due to an increase of viscosity and surface tension 
of the liquid solution processed. Also Wu and Yang (Wu and Yang, 2011) 
processed PMMA in order to prepare nanoparticles (mean diameters of 
about 250 nm) using acetone as solvent. The hydroxypropyl methylcellulose 
(HPMC) was micronized using water as solvent; particles produced were 
spherical and well-defined. A significant increase in particles size was 
observed when C varied from 0.5 to 5 mg/mL, with particles ranging 
between 0.1 and 1 µm at C=0.5 µm and between 0.3 and 3 µm at C=5 
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mg/mL. A less marked increase in particle size was obtained increasing C up 
to 10 mg/mL; in this case, indeed, the larger particles are collapsed losing 
the spherical shape (Reverchon et al., 2008). Chitosan in 1% acetic acid 
aqueous solutions was successfully micronized producing non-coalescing 
spherical microparticles with diameters ranging between 0.1 and 1.5 μm. A 
decrease in chitosan crystallinity was observed when higher precipitation 
temperatures were used (Reverchon and Antonacci, 2006a). Also Wu et al. 
(Wu et al., 2015) studied the SAA micronization of chitosan hydrochloride 
using 50% (v/v) ethanol aqueous solution as the solvent. Produced particles 
were regular and spherical varying chitosan concentration from 1 and 7 
mg/mL with diameters lower than 1 µm. Liparoti et al. (Liparoti et al., 2015) 
studied the influence of the solvent and process parameters, such as 
temperature and pressure inside the saturator, on the micronization of 
polyvinylpirrolidone (PVP) using SAA. Spherical and non-coalescing PVP 
microparticles were produced using different kind of solvents: ethanol, 
water, and mixture water–acetone. The experimental evidences demonstrated 
that the amount of solubilized CO2 is one of the main factor that influences 
the particle size distribution. The smallest PVP particles were obtained when 
ethanol was used as solvent and they showed a mean diameter of 0.5 μm and 
a standard deviation of 0.2 μm (Liparoti et al., 2015). 
Adami and Reverchon (Adami and Reverchon, 2012) investigated the 
application of SAA process to the formation of polymer microparticles 
loaded with magnetite nanoparticles, starting from suspensions of 
nanoparticles in polymer-solvent solutions. Dextran and chitosan were used 
as dispersing matrix. The encapsulation in a polymeric coating makes the 
nanoparticles biocompatible. Nanostructured chitosan microspheres were 
successfully obtained, with mean diameters ranging between 1.2 and 2 μm 
and with nanoparticle loading up to 24.4% w/w (nanoparticles/polymer).  
SAA was used to micronize also pharmaceutical compounds, such as 
griseofulvin (GF) using acetone as solvent. GF spherical particles with mean 
diameters ranging from 0.5 to 2.5 µm were produced with crystalline nature. 
No drug degradation was observed after SAA process and a solvent residue 
less than 800 ppm was measured. Dissolution tests demonstrated that SAA 
GF showed a faster dissolution rates compared to GF particles obtained by 
jet milling technique (Reverchon et al., 2004). Ampicillin particles suitable 
for aerosol delivery in the size range 1–5 μm were obtained using buffered 
water by SAA process (Reverchon et al., 2003). Tetracycline and rifampicin 
microparticles were produced using water and methanol as solvent, 
respectively. Spherical particles with controlled particle size ranging 
between 0.5 and 3 μm were obtained for both drugs operating at 97 bar and 
85°C in the saturator and at 60 °C in the precipitator. The X-ray traces 
revealed that all the SAA micronized powders were amorphous whereas the 
untreated material were crystalline (Reverchon and Della Porta, 2003). SAA 
process was used to micronize also Erythromycin using different solvents. 
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Spherical micrometric and non-coalescing particles of the drug were 
obtained with diameters smaller than 3 μm using methanol and ethanol. No 
degradation of SAA erythromycin and a maximum solvent residue in the 
processed material of 90 ppb were obtained (Reverchon and Spada, 2004b). 
Dexamethasone and dexamethasone acetate microparticles were obtained 
using SAA technique by Della Porta et al. (Della Porta et al., 2006). 
Spherical corticosteroid particles with mean diameters ranging from 0.5 to 
1.2 μm were produced with no drug degradation and solvent residues of 300 
and 500 ppm for acetone and methanol, respectively. SAA-glucocorticoids 
retained the activity of the untreated compounds and, particularly in the case 
of dexamethasone, SAA processing improved drug performance (Della Porta 
et al., 2006). Cromolyn sodium (CS) micrometric particles for aerosol 
delivery were micronized using SAA technique. The CS particles obtained 
were spherical, with a volumetric percentage of particles with a diameter 
ranging between 1 and 5 µm of 50% to 66%. The micronized product was 
stable after 12 months of storage, and no modifications in structure, 
morphology, or crystallinity were detected (Reverchon et al., 2007). 
Beclomethasone dipropionate (BDP) was micronized by SAA using 
methanol, acetone, acetone + water 9% v/v, and methanol + water 4% v/v as 
liquid solvents. Particles with narrow size distributions (PSD) were obtained 
by changing the SAA process operating conditions. In particular, using 
acetone + water 9% v/v with a BDP concentration of 90 mg/mL, crystalline 
particles ranging between 0.2 and 4.7 μm were produced and 70% by 
volume of these particles ranged between 1 and 3 μm. The results obtained 
on the laboratory scale plant were successfully reproduced on a pilot plant 
and a further refinement of the operating conditions was performed. About 
30 g of BDP microparticles were produced per batch and a recovery of about 
93 w % of the micronized powder with respect to the injected quantity was 
obtained (Reverchon et al., 2010). Reverchon et al. (Reverchon et al., 2015) 
tested SAA process in the attempt of reducing palmitoylethanolamide (PEA) 
particle size and crystallization. The best results in terms of powder 
morphology were obtained using ethanol and isopropanol as liquid solvent; 
but, irregular particles were produced in the micrometric range, due to the 
high PEA tendency to crystallize forming flat particles (Reverchon et al., 
2015).  
SAA technique was performed to produce lysozyme microparticles by 
Adami et al. (Adami et al., 2009) using water, buffered water at pH 6.2 and 
water-ethanol mixtures at different volume percentages. Precipitated 
lysozyme particles were spherical, with a narrow particle size distribution 
ranging between 0.1 and 4 µm. No degradation and lysozyme activity were 
verified; depending on the process conditions, lysozyme retained from 95% 
to 100% of the biological activity compared to the untreated enzyme. 
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Composite systems by SAA coprecipitation 
SAA was proposed to produce HPMC based composite microparticles 
using ampicillin trihydrate as model drug (Reverchon et al., 2008). 
Amorphous and spherical or “doughnut-like” HPMC-drug microparticles 
with particle sizes ranging between 0.05 and 5.45 µm were produced. 
Ampicillin was released in more than 72 h from tablet formulation based on 
HPMP-drug particle allowing a slower drug release compared to the 
untreated material (Reverchon et al., 2008). Ampicillin trihydrate and 
chitosan were selected as model drug and carrier, respectively, and 1% v/v 
acetic acid aqueous solution was used as solvent, to produce a drug-
prolonged delivery system using SAA by Reverchon and Antonacci 
(Reverchon and Antonacci, 2007a). Non-coalescing and spherical 
microparticles formed by chitosan-ampicillin were produced with sharp 
particle distribution (diameters ranging between about 0.1 and 6 µm). A 
prolonged release from SAA coprecipitates with respect to raw drug and 
physical mixtures of chitosan and ampicillin was obtained; moreover, the 
polymer/drug ratio revealed to be a controlling parameter for drug release 
(Reverchon and Antonacci, 2007a). Della Porta et al. (Della Porta et al., 
2010) produced bovine serum albumin (BSA) microspheres charged with 
Gentamicin sulfate (GS). SAA precipitation temperature was selected in the 
range 100-130°C to generate protein coagulation and to recover micronized 
BSA in form of hydrophobic aggregates with GS encapsulation efficiency in 
SAA powders reached 100%. In all cases, spherical and non-coalescing 
particles were successfully produced with a mean particle size of 2 µm. The 
release profiles of the entrapped drug were monitored using Franz cells to 
evaluate the possible application of the produced microspheres in wound 
dressing formulations. Particularly, the microspheres with a BSA/GS ratio of 
4:1 after the first burst effect (of 40% of GS loaded) were able to release the 
GS continuously over 10 days. Aquino et al. (Aquino et al., 2013) proposed 
SAA process for the production of topic carrier microsystems based on 
alginate-pectin blends. GS was loaded as high soluble and hygroscopic 
antibiotic. The micronized particles showed spherical shape and narrow 
particle size distribution (mean diameter about 2 µm). GS loading 
efficiencies were up to 100% with a burst release of 6 h followed by a GS 
release continuous for 6 days. De Cicco et al. (De Cicco et al., 2014) used 
SAA process to prepare microparticulate carriers based on high-mannuronic 
alginate and amidated pectin blend loaded with GS, able to move rapidly 
from dry to soft hydrogel. Particles with very high loading efficiencies (up to 
100%) and small diameters (less than 2 µm) were obtained. Release tests 
demonstrated a first burst release of GS followed by prolonged release up to 
10 days. Reverchon and Adami (Reverchon and Adami, 2013) produced 
coprecipitates formed by hydroxyapatite nanometric particles and chitosan 
by SAA process. The best operating conditions for particle diameter and 
coprecipitate stability were: precipitation temperature 110 °C, chitosan 
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concentration in the starting solution 10 mg/mL, that produced spherical 
composite microparticles with a mean diameter of 0.6 μm and a loading 
efficiency of about 91%. Liparoti et al. (Liparoti et al., 2013) produced SAA 
coprecipitates dispersing a corticosteroid (dexamethasone) in a PVP matrix 
with the aim to enhance the dissolution rate of the drug. The experiments 
were performed using ethanol as solvent, operating at 40°C and 76 bar in the 
saturator and 70°C and 1.6 bar in the precipitator. Produced composite 
particles were amorphous and showed a regular, spherical shape and a mean 
diameter ranging from about 0.8 to 1 µm, with loading efficiences up to 
95%. Dissolution analyses demonstrated that microparticles show a higher 
dissolution rate compared to the untreated drug (Liparoti et al., 2013). 
Nanostructured microparticles of BSA loaded with lincomycin 
hydrochloride (lincoHCl) were prepared by Adami et al. (Adami et al., 
2017b). SAA precipitation temperature was set as 100°C to obtain BSA 
coagulation and efficient entrapping of lincoHCl. Spherical microparticles 
showed no coalescence and were produced in all cases studied, with a mean 
particle size in the range 1–2 μm and loading efficiencies between 87 and 
90%. The microspheres produced by SAA showed a controlled release of the 
drug over about 6 days. 
Aliakbarian et al. (Aliakbarian et al., 2017) proposed for the first time the 
application of SAA process for the encapsulation of phenolic compounds 
extracted from olive pomace in maltodextrins. Spherical particles with 
average diameter of 712 nm with high total polyphenol content (105.0 ± 0.1 
mg of caffeic acid equivalent/g dry powder) and antiradical power (98.8 ± 
3.0 mg of DPPH/ mL of extract) were obtained (Aliakbarian et al., 2017). 
 
 
Modification of SAA apparatus 
Cai et al. (Cai et al., 2008) introduced a hydrodynamic cavitation mixer 
(HCM) in SAA process (SAA-HCM) to improve mass transfer. 
Levofloxacin hydrochloride was selected as a model drug to investigate the 
effects of cavitation generator on morphology, size and distribution of 
precipitated particles. Spherical and amorphous microparticles were obtained 
with diameters smaller than 2.1 μm. Wang et al. (Wang et al., 2010) 
investigated the same technique to produce sodium cellulose sulfate (NaCS) 
microparticles. Spherical NaCS particles with mean diameters ranging from 
0.3 to 3.0 μm were produced. No changes in the primary structure and 
stability of the NaCS processed by SAA-HCM were verified by Fourier 
transform infrared spectroscopy, whereas X-ray and thermo-gravimetric 
analyses demonstrated a slight change in crystalline state with higher 
thermal stability. Using the same process, insulin microparticles were 
produced from acidic solution with mean diameters increasing from 1.4 μm 
to 2.7 μm when protein concentration increased from 3 g/L to 50 g/L. HPLC 
chromatograms showed no degradation of insulin after SAA–HCM 
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processing (Du et al., 2013). Shen et al. (Shen et al., 2014) used SAA-HCM 
to prepare chitosan microparticles with diameters ranging between 0.2 and 5 
μm. Analyses demonstrated a decrease in crystallinity and no changes of the 
original structure of polymer. Furthermore, Shen et al. (Shen et al., 2015) 
studied the micronization of trypsin and the production of chitosan-trypsin 
particles from aqueous solutions. Various morphologies were found for 
precipitated trypsin particles (spherical and pseudo-spherical, deflated 
particles) with diameter ranging between 0.2 and 4 μm. Looking at the 
coprecipitation of trypsin with chitosan, amorphous, non-coalescing and 
spherical composite microparticles with particle sizes ranging between 0.2 
and 3 μm and loading efficiencies up to 90% were obtained (Shen et al., 
2015). SAA-HCM was also used to prepare BSA microparticles using water 
as solvent by Wang et al. (Wang et al., 2011). Under the different conditions 
investigated, the prepared BSA particles showed various morphologies, such 
as corrugated particles, smooth hollow spherical particles and cup particles, 
with particle diameters ranging from 0.3 to 5 μm. 
In order to improve the processability of the thermolable compunds such 
as BSA, Adami et al. (Adami et al., 2011) proposed a modified process 
configuration of SAA apparatus to operate the precipitation process below 
the atmospheric pressure, and to perform the drying process at lower 
temperatures without any damage to thermal sensitive materials. Two model 
thermolable compounds were investigated: PLLA and BSA producing well-
defined spherical particles. PLLA microparticles coalescence was avoided 
using a precipitation pressure from 0.65 to 0.5 bar producing particles with a 
mean diameter between 1 and 1.5 μm, and a standard deviation of about 0.4. 
BSA spherical particles with a mean diameter of about 1 μm, and a standard 
deviation of about 0.7, were obtained operating at 0.8 bar in the precipitator. 
Fourier transform infrared analysis on BSA microparticles revealed that no 
modification on protein secondary structure took place during SAA process, 
thus, protein denaturation was avoided. In this new SAA arrangement, also 
two types of polyethylene glycol (PEG10000 and PEG6000, thermo-
sensitive polymers) were micronized at reduced pressure and precipitation 
temperatures as low as 5°C. When PEG6000 was processed particles tended 
to collapse; however, when PEG10000 was processed spherical and not 
aggregated particles were obtained with mean diameters ranging between 2 
and 3.3 μm and characterized by sharp particle size distribution. X-ray 
powder diffraction analysis showed that SAA processed PEG retained the 
same crystalline structure of the unprocessed material (Liparoti et al., 2012). 
Also well-defined and sub-microparticles of PEG–PLA copolymers were 
produced using SAA under reduced pressure by Adami et al. (Adami et al., 
2012). The microparticles obtained showed a lower degree of crystallinity 
compared to the untreated materials, with no modifications of the original 
structures (Adami et al., 2012). This SAA configuration was successfully 
used also for the encapsulation of rotenone in different cariers (PEG, PVP 
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and sodium alginate) (Martin et al., 2013). The best results, in terms of 
encapsulation efficiency, were obtained for the system alginate/rotenone 
(close to 100%) and for the system PEG/rotenone (98%). PVP-rotenone 
composite microparticles showed the lowest coprecipitation efficiency 
ranged between 30% and 50%. The particles obtained were spherical with 
the mean diameters ranging between 0.6 and 1.5 μm (Martin et al., 2013). 
Labuschagne et al. (Labuschagne et al., 2014) used the same technique for 
the coprecipitation of poly(d,l-lactide) (PDLLA) and rifampicin for sustained 
release applications. Spherical PDLLA/rifampicin nanoparticles with mean 
diameter ranging from 123 to 148 nm and with rifampicin loadings up to 
50.5% were produced. X-ray diffraction revealed that the encapsulated 
rifampicin is in an amorphous state, while NMR spectra indicated no 
structural modifications after SAA process. In-vitro release studies showed 
an initial burst release of 80–87% of total rifampicin loaded, necessary to 
suppress the generation of resistance by the microorganism, followed by 
first-order sustained release between 0.4 and 0.8 mg/L rifampicin per day 
over a period of 17 days (Labuschagne et al., 2014).  
Hijazi et al. (Hijazi et al., 2014) proposed a SC-CO2 assisted 
solubilization and atomization process (SCASA) that did not use any organic 
solvent. In the process, the acidifying strength of pressurized CO2 enabled 
the dissolution of chitosan, and the atomization process generated spherical 











II.1 Analyses on morphology 
II.1.1 Field Emission Scanning Electron Microscope 
The morphology of the powder was observed by a field emission-
scanning electron microscope (FESEM, mod. LEO 1525, Carl Zeiss SMT 
AG). SAA powders were dispersed on a carbon tab previously stuck to an 
aluminum stub (Agar Scientific, Stansted) and coated with gold (layer 
thickness 250Å) using a sputter coater (mod. B7341, Agar Scientific 
Stansted). Approximate composition of particles was observed using 
FESEM coupled with an energy dispersive X-ray spectroscopy (EDX, INCA 
Energy 350). 
 
II.1.2 Fluorescent microscope 
Fluorescent microscopy (FM) were performed to analyze produced 
powders with a Zeiss Axiophot fluorescence microscope, equipped with a 20 
× 1.4 NA no-oil immersion plan Apochroma objective (Carl Zeiss Vision, 
München-Hallbergmoos). DAPI (4’, 6-diamidino-2-phenylindole) optics 
absorbing violet radiation (λmax 372 nm) and emitting a blue fluorescence 
(λmax 456 nm) was used. 
 
 
II.2 Particle size distribution (PSD) 
PSD was calculated also by FESEM photomicrographs using Sigma Scan 
Pro Software (release 5.0 Aspire Software international, Ashburn, VA, 
USA). The diameters of about 1000 particles were measured for each 
particle size distribution calculation. The obtained histograms represented 
the particle size distribution and were fitted using Microcal Origin Software 
to compare well the results (release 8.0, Microcal Software, Inc., 
Chapter II 
18 
Northampton, MA). PSDs values are expressed as d10, d50 and d90 indicating 
the diameters at 10th, 50th and 90th percentile; these percentiles indicate the 
amount of particles with diameters smaller then d10, d50 and d90. 
 
 
II.3 Analyses on solid state 
II.3.1 Differential Scanning Calorimetry 
The thermal behavior of powders was measured by a Differential 
Scanning Calorimeter (DSC, model TC11, Mettler Toledo, Inc., Columbus, 
USA), using Mettler STARe system. Fusion temperature and enthalpy were 
calibrated with an indium standard (melting point, 156.6°C, enthalpy of 
fusion 28.52 J/g). 3 mg of the sample were accurately weighed, crimped into 
an aluminum pan that was heated from 25 to 350°C under a nitrogen purge 
(flow rate 50 mL/min), at 10°C/min.  
 
II.3.2 X-Ray Diffraction 
Solid state analysis of the samples (XRPD=X-ray powder diffraction) 
was performed using an X-ray diffractometer (mod. D8 Discover, Bruker 
AXS, Inc., Madison, WI) with a Cu sealed tube source. Samples were placed 
in the holder and flattened with a glass slide, to assure a good surface 
texture. The measuring conditions were as follows: Ni-filtered CuKα 
radiation, λ=1.54 A, 2θ angle ranging from 3 to 50° with a scan rate of 3 
s/step and a step size of 0.02°. 
 
II.3.3 Fourier Transform Infrared (FTIR) 
The measurement of FTIR spectra was carried out with a FTIR 
spectrophotometer (IR-Tracer100, Shimadzu). The powder samples were 
ground and mixed thoroughly with small amount of potassium bromide 
(KBr) and pressed to 10 tons for 10 minutes in a manual press. The scan 
analysis was performed at 25°C, in a scan wavenumber ranging between 
4000 and 450 cm-1 at a resolution of 1 cm-1; 32 scan signals were averaged to 
reduce the noise of measurements. 
 
 
II.4 Loading efficiency and dissolution tests 
II.4.1 Spectophotometer UV-vis 
Active principle (API) loading in SAA particles was evaluated by UV-vis 
spectrophotometer (model Cary 50, Varian, Palo Alto, CA), measuring the 
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absorbance in correspondence of API characteristic wavelength. The carriers 
used for SAA coprecipitation experiments is not visible at these wavelengths 
by spectrophotometer. Then the absorbance was converted into API 
concentration, using a calibration curve. Each analysis was performed in 
triplicate and the results were expressed as the mean value. The loading 
efficiency is calculated as the ratio of the effective loading to the theoretical 
loading. The theoretical loading is the mass ratio of active principle/carrier 
(w/w) in the solution injected into the SAA plant. The effective loading is 
the actual mass ratio of active principle/carrier (w/w) in the SAA particles. 
The same instrument was used to perform in vitro dissolution tests in 
order to study the properties of SAA microparticles as drug delivery system. 
API release experiments were conducted in a 0.1 M Phosphate Buffer 
Solution (PBS) at pH 7.4, as dissolution medium. Accurately weighted 
samples containing an equivalent amount of drug (5 mg/L) were suspended 
in1.5 mL of PBS and placed into a dialysis membrane that was immersed in 
400 mL of PBS continuously stirred at 200 rpm and 37°C. Each dissolution 
test was carried out in triplicate and the proposed dissolution curves are the 
mean profiles. 
 
II.4.2 High Performance Liquid Chromatography 
The separation and the identification of extracted compounds from 
saffron petals was performed in an Agilent HPLC-UV/vis (High 
Performance Liquid Chromatography, Hewlett-Packard model G131-132). 
The column used is a reverse phase C18 column (4.6 mm x 100 mm, 3.5 µm). 
The eluents were: 0.1% (v/v) formic acid in water (A) and 0.1% (v/v) formic 
acid in methanol (B) with the following gradient: 20% B, 1 min; 80% B, 13 
min; and 20% B, 20 min. The flow rate was 0.8 mL/min and the detector 
was set at 270 nm. All of the analyses were performed in duplicate. 
 
 
II.5 Antioxidant activity 
II.5.1 DPPH method 
DPPH+ (2,2-diphenyl-1-picrylhydrazyl) is a stable free radical that 
assumes a purple color in solution, with an absorption band around 517 nm. 
When this radical reacts with a hydrogen donor, the reduced form of DPPH 
is formed and a discoloration of the violet color is obtained. The 
spectrophotometric method described in literature (Brand-Williams et al., 
1995) with minor modifications was used to study the reduction of DPPH 
and, hence, the antioxidant capacity. 1 mL of the tested sample at a fixed 
concentration was placed in 3 mL of 10-4 M of DPPH solution (9.9 mg of 
DPPH in 250 mL of MetOH) and left under dark at room temperature. The 
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discoloration of the solutions from purple to yellow is clearly visible and the 
absorbance reduction was measured at 517 nm using an UV/vis 
spectrophotometer (model Cary 50, Varian). The scavenging activity (SA, 
%) was expressed according to the equation:  
 
SA = (1-As/Ab)*100       (2) 
 
where: 
 As: sample absorbance; 
 Ab: blank absorbance. 
 
The antioxidant capacity were also expressed in terms of Trolox 
equivalent (TE) by gram of powder, where higher value means higher 
antioxidant power. 
 
II.5.2 Total polyphenol content 
Total phenolic content was determined in triplicate with the Folin 
Ciocalteau method, as described by Singleton and Rossi (Singleton and 
Rossi, 1965) with minor modifications. Approximately 10 mg of each 
propolis powder sample was dissolved in 5 mL of ethanol (70% v/v), an 
aliquot of 100 µL of this solution was mixed with 4900 µL of distillated 
water, 0.5 mL of the Folin Ciocalteau reagent and 1700 µL of a 20% 
carbonate solution (prepared 24 h before). The mixture was filled with 
distilled water to a 10 mL graduated volumetric flask, shaked for 30 min 
under dark, and then transferred 225 µL to a 96-well microplate for the 
determination of its absorbance in a Tecan (Infinite PRO200R) microplate 
reader at 760 nm. Calibration was performed using Gallic Acid as reference 
compound and the results were expressed in mg of Gallic Acid Equivalents 
(GAE) per gram of powder.  
 
II.6 Synthesis of FITC-labeled dextran 
In a 50 mL reaction flask, FITC (9.2x10-5 mol) and N,N’-
carbonyldiimidazole (9.2x10-5 mol) were dissolved in 15 mL of THF and 
stirred at room temperature under N2 atmosphere over night. Then, 1 g of 
DEX (43 kDa, 2.33x10-5 mol) and 1.38 mL of triethylamine (9.95x10-6 mol) 
were added, and the reaction mixture was kept under stirring for 24 h. The 
product was purified by dialysis against distilled water using a cellulose 
membrane (cutoff = 6000−8000 g/mol). The solution was lyophilized and an 
orange solid was recovered (700 mg, 1.63x10-5 mol). The content of FITC in 
the conjugate was measured by UV-vis and the degree of labeling was 











III.1 Agreement with Cerbios Pharma 
Some active principles have been studied as proposed by Cerbios Pharma 
within the research project “Production of pharmaceutical formulations for 
improvement bioavailability using supercritical assisted atomization". The 
Swiss company Cerbios Pharma funded the research project supporting this 
Ph.D. work with the aim to invest in a GMP atomization plant for particle 
engineering using SCFs. As part of the agreement between the company and 
the Department of Industrial Engineering (DIIN) of the University of 
Salerno, this part of thesis was focused on the development of formulations 
based on active principles directly proposed by Cerbios for its world-wide 
partners, in order to scale up the process for industrialization. This section, 
due to secrecy agreements, will be presented using acronyms and no further 
detailed information will be reported. 
 
Investigations and studies were performed on drugs previously tested 
using traditional techniques by other groups of research with no satisfying 







First, for each compound a feasibility study was carried out in order to 
investigate the applicability of SAA process to different classes of 
compounds; different solvents and concentrations were investigated. Then, 
SAA operative conditions was optimized to reach the targets requested by 
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Cerbios. A series of characterization analyses was performed according 
methods suggested by Cerbios Pharma and by our analytical experiences. 
Finally, grams of powders were produced by SAA and sent to the company 
for further pharmaceutical considerations. 
 
Materials 
Polyvinylpyrrolidone (PVP, Mw: 10,000), dextran from Leuconostoc 
mesenteroides (DEX, average MW 43,000), ethanol (EtOH, purity 99.9%), 
acetone (Ac, purity 99.8%), tetrahydrofuran (THF, purity >99.9%), dimethyl 
sulfoxide (DMSO, purity >99.9%), ethyl acetate (AcEt), 1-Methyl-2-
pyrrolidinone (NMP, purity 99.5%) were supplied by Sigma Aldrich (Italy). 
Carbon dioxide (CO2, 99.9%) was purchased by Morlando Group (Italy) and 
nitrogen (N2, 99%) by SOL (Italy). 
 
 
III.2 Compound #1: BRI 
BRI is an alpha adrenergic agonists drug. The objective of this 
experimentation was to produce BRI crystalline particles, in form of 
agglomerates with D90 < 1 µm and with no residual solvents, thus reaching 
the desired target for the customers. 
 
 
III.2.1 Experimental results on BRI 
BRI is a crystalline pharmaceutical compound, as shown in Figure III.1, 
where it is possible to observe long crystals of 30-70 µm. In Table III.1, BRI 
solubilities in different solvents are summarized. 
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A first set of experiments was performed using methanol as solvent and 
the process conditions used were: BRI concentration 0.9 mg/mL; GLR of 
1.8, injection pressure of 80 bar in the saturator, saturator temperature (Ts) of 
60°C and precipitation temperature (Tp) of 70°C. An example of particles 
obtained is shown in Figure III.2. 
 
 
Figure III.2 FESEM image of SAA BRI powders produced using methanol 
as solvent at Ts=60°C, Tp=70°C. 
 
Produced particles were irregular and partly coalescent; moreover, 
powder collection was very complicated. Therefore, methanol was not a 
good candidate solvent for this experimentation. Another solvent tested for 
BRI micronization was THF, in which BRI is soluble up to 3 mg/mL. 
Operative conditions investigated were: GLR of 1.8 and 2.5, pressure of 80 
bar and temperature (Ts) of 60-80°C in the saturator and precipitation 
temperature (Tp) of 80°C. No powders were collected in these three tests. 
Ac:DMSO (80:20 v/v), NMP:Ac (80:20 v/v), AcEt:DMSO (80:20 v/v) 
mixtures were investigated for BRI micronization; however, no satisfactory 
results were obtained using these mixtures.  
BRI micronization was attempted used ethanol as solvent and a drug 
concentration fixed at 0.87 mg/mL. Trying to take advantage of SAA 
previous experiences (Liparoti et al., 2015), the process conditions used 
were: GLR 1.8, injection pressure of 80 bar, saturator (Ts) and precipitation 
(Tp) temperature varying between 60 and 80°C. Figure III.3 reports some 
examples of particles obtained at different operating conditions tested. 
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Figure III.3 FESEM images of SAA BRI powders produced at: a) Ts= 
Tp=60°C; b) Ts=60°C, Tp=70°C; c) Ts=60°C, Tp=80°C; d) Ts=Tp=80°C. 
 
 
The precipitates were formed by irregular particles; the presence of 
submicronic/nanometric crystalline particles was evident in all samples, by 
satisfying the targets of Cerbios Pharma. This is not the typical morphology 
exhibited by SAA precipitates, which usually show collapsed spherical or 
spherical particles resulting from droplet evaporation formed during 
atomization (Liparoti et al., 2015, Adami et al., 2017a, Di Capua et al., 
2017b). However, similar morphologies have been observed when a 
superposition of crystallization processes take place during droplet drying in 
SAA precipitator (Liparoti et al., 2012, Martin et al., 2013, Reverchon et al., 
2005). SAA BRI particles was suspended in heptane and after 10 minutes of 
sonication analyzed using DLS technique (as indicated by Cerbios). In Table 
III.2, PSDs values, expressed as d10, d50 and d90 indicating the diameters at 
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Table III.2 PSD data of BRI particles produced by SAA. 
 







Ts=60°C, Tp=60°C 394 672 1036 
Ts=60°C, Tp=70°C 162 218 288 
Ts=60°C, Tp=80°C 165 204 252 
Ts=80°C, Tp=80°C 225 297 396 
 
III.2.2 Characterization of BRI particles 
XRPD analyses were carried out to study the crystallization behavior of 
untreated BRI and SAA powders produced. In Figure III.4, a comparison of 
spectra obtained on untreated BRI and SAA particles produced at different 
operative conditions is reported. The analyses showed the crystalline nature 
of BRI that was preserved also in the micronized particles. These results 
were confirmed by calorimetry analyses, reported in Figure III.5. 
 
 





Figure III.5 DSC thermograms related to untreated BRI and SAA particles. 
 
BRI thermogram showed an endothermic peak around 262°C (melting 
point) and an exothermic peak around 284°C (crystallization temperature). 
The absence of peaks in the range 80-120°C demonstrated that BRI is not a 
hygroscopic compound. From all the calorimetric diagrams, it was possible 
to denote the absence of water in the range 80-110°C. In thermograms 
related to SAA particles, the characteristic peaks of BRI were confirmed but 
slightly translated at lower temperatures. 
 
Residual solvent and purity 
These analyses were performed to verify the limits requested by 
customers. Ethanolic samples showed values below 0.04%, whereas 
methanolic samples did not present residual solvent. Furthermore, SAA 
process was able to remove all solvent and produced powders preserved BRI 
purity. 
The particles produced satisfied the targets indicated by Cerbios Pharma. 
 
 
III.3 Compound #2: FUL 
FUL is an antiestrogen used to treat the breast cancer in postmenopausal 
women. The goal to produce sub-microparticles of FUL with mean diameter 
ranging between 0.3 and 0.7 µm was investigated with the aim to improve its 
dissolution rate. In literature, only SAS process was used to micronize FUL 
using DMSO until now; however, no satisfactory results were obtained, as it 
is possible to observe in Figure III.6. 
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Figure III.6 FESEM images of micronized FUL using SAS technique 
(article not cited for secrecy agreements). 
 
Irregular crystals with broad distribution were produced using SAS 
technique. On the basis of the state of the art on FUL micronization, SAA 
process was attempted to reach Cerbios targets.  
 
III.3.1 Experimental results on FUL 
Figure III.7 shows FUL crystalline morphology, in forms of long crystals 
with size ranging between 10 and 30 µm. 
 
 
Figure III.7 FESEM image of untreated FUL. 
 
The solvents used for this experimentation were selected based on their 
boiling temperature, to guarantee the evaporation of the droplets in SAA 
precipitator. Ethanol and acetone are solvents often used for the SAA tests, 
and FUL is very soluble in both of them, as summarized in Table III.3. 
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First, FUL micronization was attempted using ethanol as solvent; on the 
basis of previous experience (Liparoti et al., 2015), the SAA operative 
conditions studied were: concentration in ethanol ranging between 10 and 50 
mg/mL; GLR varying between 0.5 and 1.8, injection pressure around 85-88 
bar in the saturator, saturator (Ts) and precipitation (Tp) temperature of 80°C. 
However, ethanol was not a good solvent to micronize this drug, due to FUL 
fast tendency to sublimate at the temperatures used during SAA tests; no 
powders, indeed, were produced and all tests failed. 
 
Therefore, acetone was selected to carry out a new set of experiments, 
since acetone is more volatile than ethanol. This aspect allowed using lower 
temperature in SAA precipitator and, consequently, to inhibit FUL tendency 
to sublimate. After a set of failed tests using acetone, finally SAA operating 
conditions optimized were: GLR 2.5, injection pressure around 70 bar in the 
saturator, saturator temperature 60°C and precipitation temperature 40°C. 
FUL concentrations in acetone investigated were 20, 40 and 60 mg/mL. The 
particles produced in these experiments consisted of defined, perfectly 
spherical submicrospheres, as shown in Figure III.8, where examples of 
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Figure III.8 FESEM images of micronized FUL using SAA technique at a) 
20 mg/mL, b) 40 mg/mL and c) 60 mg/mL. 
 
 
Spherical and non-coalescing microparticles were obtained. As it is 
possible to observe, increasing FUL concentration up to 60 mg/mL particles 
were still spherical but a little coalescent. Comparing the PSDs of the 
microparticles obtained, it was observed that, increasing the concentration, 
the mean diameter increased and the PSDs enlarged (Figure III.9).  
PSDs values related to these three different concentrations are also 






Figure III.9 PSDs of FUL particles obtained at different concentrations. 
 
 










20 mg/mL 0.24 0.43 0.67 
40 mg/mL 0.37 0.71 1.16 
60 mg/mL 0.58 1.00 1.69 
 
 
This behavior is commonly observed in the SAA results, since increasing 
the solute concentration, the viscosity of solution increases and larger 
droplets are formed at the exit of the injector, with the consequent 
production of larger particles (Liparoti et al., 2015). Using the concentrations 
20 and 40 mg/mL, the desired diameters by the customers were obtained. 
 
 
III.3.2 Dissolution tests 
In order to test the effectiveness of FUL precipitates in improving the 
dissolution rate of the drug, experiments in a physiological solution (0.9% 
p/v of NaCl in water) were performed. As an example, in Figure III.10, the 
dissolution profile of micronized FUL by SAA (at 40 mg/mL) is compared 
with that of the untreated FUL. 
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Figure III.10 Dissolution profiles of FUL in physiological solution at 37°C. 
 
It is clearly possible to observe the different dissolution rates comparing 
the slopes of the two curves reported. In particular, the curve related to the 
FUL micronized by SAA (40 mg/mL) shows a larger slope and a complete 
dissolution in about 94 hours. Around 60% of the untreated FUL, instead, is 
dissolved after 140 hours. This result confirms that FUL dissolution rate is 
improved 4 times compared to the untreated drug. 
The particles produced satisfied the targets indicated by Cerbios Pharma. 
 
 
III.4 Compound #3: DAS 
DAS is a potent inhibitor of multiple oncogenic kinases, classified as an 
API. It is insoluble in water (0.008 mg/mL), slightly soluble in ethanol (> 4 
mg/mL) and very slightly soluble in acetone. The goal of this research was 
to produce solid dispersions of DAS in a polymeric matrix with the aim to 
prepare sub-micrometric particles loaded with the drug and to improve its 
bioavailability. 
 
III.4.1 Experimental results on DAS 
Figure III.11 shows native DAS morphology characterized by large flat 




Figure III.11 FESEM image of untreated DAS. 
 
The polymer selected for the coprecipitation is PVP, because it is an 
ingredient present in a patented pharmaceutical formulations based on DAS. 
Furthermore, PVP is soluble in water and in organic solvents, a crystal 
growth inhibitor and approved by FDA (Paradkar et al., 2004). PVP is 
already micronized in previous studies (Liparoti et al., 2015) using different 
solvents and operative conditions. Furthermore, it was already verified PVP 
processability by SAA technique. 
 
PVP micronization 
The solvent used for this experimentation was ethanol. First, PVP alone 
was micronized by SAA using two different process conditions (Table III.5): 
60 or 80°C in the saturator; 70 or 80°C in the precipitator; GLR 1.8 or 2.5. 
These process conditions were selected to assure a good solubility of CO2 in 
ethanol (Liparoti et al., 2015, Adami et al., 2017a) and to identify the best 
results for the following coprecipitation.  
Table III.5 summarizes the main tests performed. In Figure III.12 FESEM 
images of micronized PVP at different operative conditions are reported. 
 
Table III.5 Operating conditions used SAA micronization experiments. (Ts: 
saturator temperature; Tp: precipitator temperature; Ps: saturator pressure; 




















PVP01 10 60 70 84 1.5 1.8 0.29 0.66 0.99 
PVP02 10   90 1.6 2.5 0.17 0.38 0.68 
PVP03 10 80 80 88 1.5 1.8 0.37 0.77 1.16 
PVP04 20   88 1.5 1.8 0.41 0.79 1.37 
PVP05 30   89 1.4 1.8 0.52 0.91 1.57 
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Figure III.12 FESEM images of PVP micronized at a) Ts=60°C, Tp=70°C, 
GLR=2.5, 10 mg/mL; b) Ts=80°C, Tp=80°C, GLR=1.8, 20 mg/mL. 
PVP was perfectly micronized by the SAA process, as seen in Figure 
III.12, obtaining spherical and regular particles for each operative conditions 
used. The morphology of particles is not influenced by the saturator 
temperature. However, mean diameter variations were relatively small when 
the saturator temperature changed (see Table III.5). PSD analyses 
demonstrated that smaller particles were produced using a GLR of 2.5. This 
result is typical for SAA micronization (Liparoti et al., 2015) and is due to 




According to some patents (not cited for secrecy agreements), the recent 
pharmaceutical formulations contain a quantity of DAS ranging between 10 
and 70% (w/w). Therefore, for SAA coprecipitation tests, a fixed DAS 
concentration was selected (1.5 mg/mL) to assure a complete dissolution in 
ethanol, and two DAS/PVP mass ratios (R) were investigated (1/20 and 1/5), 
corresponding to a DAS weight percentage of 5 and 17%, respectively. The 
SAA tests performed were summarized in Table III.6. 
 
Table III.6 Operating conditions used for SAA coprecipitation experiments; 
PSD data in terms of volume of particles (Ts: saturator temperature; Tp: 
precipitator temperature; Ps: saturator pressure; Pp: precipitator pressure; 


















DAS01 1/20 60 70 78 >>>3 1.8 - - - 
DAS02 1/20 60 70 80 >>>3 2.5 - - - 
DAS03 1/20 80 80 83 1.5 1.8 0.33 0.75 1.38 
DAS04 1/5 80 80 83 1.5 1.8 0.39 0.85 1.54 
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The first experiments on DAS-PVP were performed using a precipitation 
temperature of 70°C (varying GLR from 1.8 and 2.5). In both cases, the 
results were not satisfactory, since no material was collected due to drying 
problems. An increase of precipitator pressure, indeed, did not allow 
obtaining a complete evaporation of solvent at temperature used. As 
consequence, the following experiments were performed using higher 
temperatures in the saturator and in the precipitator (Ts=80°C and Tp=80°C, 
GLR=1.8), obtaining dried powders as result. Examples of these precipitates 
are shown in Figure III.13, where SEM photomicrographs taken at the same 
enlargement are reported. 
Particles produced at R=1/20 were spherical and more regular than those 
obtained at R=1/5; this effect was due to the major quantity of PVP used that 
stabilized DAS compound. Nevertheless, defined and separated particles 
were produced also increasing R. 
PSD diagrams are reported in Figure III.14 and PSD values are 
summarized in Table III.6. PSD was influenced by DAS/PVP mass ratio; the 
particles produced at R=1/5 resulted smaller than those obtained at R=1/20. 
The mean diameter variations were relatively small by varying R (see Table 
III.6 and Figure III.14). However, the DAS-PVP coprecipitates diameters 
were consistent with PVP particles sizes. 
 
   
Figure III.13 FESEM images of DAS-PVP particles produced at Ts=80°C, 
Tp=80°C, GLR=1.8, and at a) R=1/20, b) R=1/5. 
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Figure III.14 Cumulative volumetric particle size distribution of DAS-PVP 
powder obtained by SAA at different R (see Table III.6). 
 
 
III.4.2 Characterization of DAS-PVP particles 
In order to attest DAS presence in SAA particles produced, EDX 
analyses were performed to give a chemical characterization of powders. In 
particular, this technique allowed detecting the characteristic elements of 
DAS (not present in PVP structure): chlorine (Cl) and sulfur (S). Figure 
III.15 shows an example of EDX diagram for sample R=1/20. These 
analyses confirmed DAS presence in both coprecipitates produced, since 
peaks related to S and Cl were clearly evidenced. Furthermore, the key 
chemical elements were uniformly distributed in the microparticles, 
confirming the hypothesis that DAS was intimately mixed in each particle at 




Figure III.15 EDX analyses related to DAS-PVP particles produced at 
R=1/20. 
 
However, EDX analyses is not a quantitative analysis. For this 
information, DAS-PVP batches were sent to Cerbios Pharma to perform 
HPLC analyses and further studies, that cannot be reported in this thesis. 
The particles produced satisfied the targets indicated by Cerbios Pharma. 
 
 
III.5 Compound #4: NAP 
NAP is a non-steroidal anti-inflammatory drug. It is very soluble in water 
(200 mg/mL) and ethanol (25 mg/mL). The objective of this experimentation 
was to identify the optimized process conditions to micronize NAP and to 
control its crystallization tendency, in order to validate SAA industrial plant 
purchased by Cerbios Pharma and obtain SwissMedic authorization for GMP 
(Good Manufacturing Practice) production. Furthermore, the study aimed at 
starting the plant to produce powders. 
 
III.5.1 Experimental results on NAP 
Figure III.16 shows raw NAP morphology characterized by large flat 
crystals with size ranging between 10 and 60 µm. 
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Figure III.16 FESEM image of untreated NAP. 
 
Particles produced using water as solvent 
The first part of NAP micronization experiments was performed using 
water as solvent. SAA operating conditions were: drug concentration in 
water 15 or 30 mg/mL; GLR varying between 1 and 2.5, injection pressure 
of about 90 and 100 bar in the saturator, saturator temperature 85°C and 
precipitation temperature 100°C. These conditions were optimized in a 
previous works (Adami et al., 2017b). In Table III.7, a list of the main 
operative conditions investigated in water is reported. 
 
Table III.7 Operating conditions used for SAA experiments on NAP using 
water; PSD data in terms of volume of particles (C: NAP concentration; 











30 2.5 0.6 1.3 2.3 
15 1.8 0.8 1.7 2.9 
15 1 1.2 2.3 3.6 
 
At the end of all SAA tests using water, foaming materials were found in 
the saturator. This drawback may be related to an antisolvent precipitation 
phenomenon. In SAA process the choice of the proper conditions in the plant 
and the solvent is fundamental to produce microparticles, since SC-CO2 
solubilization in the liquid feed to form an expanded liquid is the key of the 
technique. However, some compounds may be not completely soluble in this 
expanded liquid and, consequently, may precipitate in the saturator, as 
shown in the picture in Figure III.17. This drawback may take place when 
the system enters into the two-phase region where gas phase coexists with 
the liquid phase and NAP precipitation may occur from the gas phase (Della 




Figure III.17 Photographs of foaming materials in the saturator. 
However, a white powder was collected on the filter located in SAA 
precipitator and some examples of micronized NAP were shown in Figure 
III.18. Produced particles were partly spherical with a no smooth surface. 
NAP tended partially to crystallize: probably the water evaporation rate was 
comparable to that of drug crystallization.  
 
   
 
 
Figure III.18 FESEM images of micronized NAP at a) Ts=85°C, Tp=100°C, 
GLR=2.5, 30 mg/mL; b) Ts=85°C, Tp=100°C, GLR=1.8, 15 mg/mL; c) 
Ts=85°C, Tp=100°C, GLR=1, 15 mg/mL. 
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However, PSD data are summarized in Table III.7. As it is possible to 
observe, keeping constant NAP concentration (15 mg/mL) and decreasing 
GLR down to 1, d50 increased, as SAA typical result (Liparoti et al., 2015, 
Adami et al., 2017a). When GLR, indeed, is decreasing, there is a decrease 
of the amount of CO2 dissolved in the saturator, hence, of CO2 content in the 
liquid system forming the expanded liquid, with the formation of larger 
droplets in the spray and consequently of particles formed (Adami et al., 
2017a). Unfortunately, NAP micronization in water was ineffective, due to 
the loss of material in the saturator (antisolvent effect). In order to overcome 
these limitations, subsequent tests were performed using ethanol as solvent. 
 
Particles produced using ethanol as solvent 
Process conditions investigated using ethanol were: NAP concentration 
10 and 20 mg/mL, saturator temperature 60-80°C, precipitator temperature 
70-80°C, GLR varying between 1 and 1.8. In Table III.8 process parameters 
considered are reported. 
 
Table III.8 Operating conditions used for NAP micronization using ethanol; 
(C: NAP concentration; Ts: saturator temperature; Tp: precipitator 











20 80 80 83 1.8 
20   72 1.3 
20   90 1 
10   85 1.8 
20 60 70 82 1.8 
 
In Figure III.19, some exemplificative SEM images related to samples of 
NAP particles produced using ethanol are reported. No material was found 
in the saturator at the end of SAA tests, as in the previous experiments 
performed in water. Produced particles were perfectly spherical with smooth 
surface and no crystallization phenomenon was evidenced from FESEM 
image in Figure III.19a, when Ts=80°C, Tp=80°C and GLR=1.8 were 
investigated. These NAP particles showed a relatively narrow distribution, 
with d10=0.6 µm; d50=1.2 µm; d90=2.0 µm. In Figure III.19 (a, b, c) the 
influence of GLR on SAA processed NAP can be qualitatively evaluated. In 
particular, at lower GLR (1.3 and 1) particle coalescence and less regular 
morphologies were evinced. When operating at lower temperatures in the 
saturator and in the precipitator (Ts=60°C, Tp=70°C) drug particle 
recrystallization was observed (Figure III.19d), probably caused by partial 




   
 
   
Figure III.19 FESEM images of NAP micronized using ethanol at 20 mg/mL 
and a) Ts=Tp=80°C, GLR=1.8; b) Ts=Tp=80°C, GLR=1.3; c) Ts=Tp=80°C, 
GLR=1; d) Ts=60°C, Tp=70°C, GLR=1.8. 
 
 
Therefore, the best results in terms of precipitated particle morphology 
and size were obtained operating at Ts=80°C, Tp=80°C and GLR=1.8 when 
ethanol was used as solvent. Similar morphology was obtained using a lower 
NAP concentration keeping constant the operative conditions (figure not 
reported). The PSDs in terms of cumulative volumetric percentage showed 
an effect of concentration that is evidenced in Figure III.20. 
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Figure III.20 Comparison of cumulative volumetric PSDs of NAP particles 
obtained by SAA at different concentrations. 
 
 
Decreasing the concentration down to 10 mg/mL, smaller particles were 
produced with d50 of about 0.9 μm. This behavior is commonly observed in 
SAA powders, since decreasing the solute concentration, the viscosity of the 
injected solution decreases and smaller droplets are formed at the exit of the 
nozzle, with the consequent formation of smaller microspheres (Liparoti et 
al., 2015, Di Capua et al., 2018). 
All SAA powders were characterized by X-Ray and DSC analyses. 
Generally speaking the spherical shape of SAA micronized particles may 
indicate an amorphous solid state. However, for some compounds it has been 
observed that SAA precipitates are formed by spherical particles constituted 
by smaller crystals (Della Porta et al., 2006). Therefore, X-Ray and DSC 
analyses revealed that the micronized NAP is semi-crystalline. As an 
example, in Figure III.21 X-ray traces of untreated and processed NAP in 





Figure III.21 X-ray traces of untreated NAP and SAA processed NAP. 
 
It can be observed that micronized NAP partially retained the crystalline 
structure after SAA process. This result was consistent with Cerbios 
Pharma’s targets. 
 
Before NAP experimentation, no atomized powders were produced using 
the SAA industrial plant (at Cerbios Pharma). This study on NAP 
micronization was fundamental in order to validate the industrial plant and 
obtain SwissMedic authorization for GMP production on January 2017.  
 
 
III.6 Compound #5: GPB 
GPB is an anticholinergic agent used to treat chronic obstructive 
pulmonary disease. It is soluble in water (45 mg/mL) and in ethanol (30 
mg/mL). The goal of this project was the production of stable particles with 
d90 higher than 3 µm; this objective was not reached with conventional 
techniques, as spray drying. GPB is, indeed, very difficult to micronize since 
it has a very fast crystallization rate and tends quickly to agglomerate. 
 
III.6.1 Experimental results on GPB 
GPB shows a morphology characterized by large flat crystals (Figure 
III.22) with size ranging between 20 and 80 µm. This crystalline behavior 
was confirmed by DSC analyses (Figure III.23): the raw GPB shows an 
endothermic peak at about 196°C, due to the fusion of crystalline structure, 
and another broad endothermic peak ranging between 250 and 300°C. 
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Figure III.22 FESEM image of untreated GPB. 
 
 
Figure III.23 DSC thermogram related to untreated GPB. 
 
Preliminary SAA tests were performed to precipitate GPB alone, using 
ethanol and water as solvents that are commonly used for SAA process 
(Della Porta et al., 2006, Reverchon and Della Porta, 2003). GPB 
concentration in ethanol was fixed at 25 mg/mL. Process conditions studied 
were: saturator temperature changing between 40 and 80°C; precipitator 
temperature between 55 and 70°C; GLR varying between 1.8 and 3. GPB 
concentration in water was fixed at 20 mg/mL. Process conditions studied 
were: saturator temperature 85°C; precipitator temperature between 100 and 
110°C; GLR set at 1.8. However, no powders were collected both in ethanol 
and in water, probably due to a fast crystallization phenomenon in the 
precipitator. In order to reduce the precipitator temperature and inhibit the 
crystallization phenomenon, a different configuration of SAA plant, using 




In the literature, patents related to GPB (not cited for secrecy agreement) 
described dry powder formulations of GPB using for examples dextran, 
lactose, and magnesium stearate as excipients. For this reason, the research 
project was continued producing composite systems. First, SAA tests were 
performed processing suspensions based on GPB and magnesium stearate 
both in water and in ethanol; however, no powders were still collected as in 
the previous experiments described. Then, solid dispersions of GPB in 
carrier able to inhibit drug crystallization and promote the stabilization of 
powder were explored. Two carriers very soluble in water were proposed to 
Cerbios Pharma: polyvinylpyrrolidone (PVP) and dextran (DEX) both 
classified as crystal growth inhibitor and accepted by the Food & Drug 
Administration (Mehvar, 2000, Kamada et al., 2000). 
 
 
GPB-PVP particles produced using ethanol 
SAA coprecipitation tests were carried out using water and ethanol as 
solvents. However, SAA tests using water were unsuccessful. Two polymer 
concentrations and three drug/polymer mass ratios (R, 1/5, 1/3 and 1/2) were 
investigated. The operative conditions studied, based on the literature, were: 
GPB concentration 2 and 8 mg/mL, PVP concentration 10-20-40 mg/mL 
saturator temperature 80°C, precipitator temperature 80°C, GLR 1.8 (Adami 
et al., 2017a, Adami et al., 2019, Di Capua et al., 2017b). Examples of GPB-
PVP particles produced in ethanol are shown in Figure III.24. 
Spherical and regular particles were obtained, at R=1/5 and varying PVP 
concentration from 10 to 40 mg/mL. PSDs in terms of volumetric 
cumulative percentage showed that no significant differences in size were 
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Figure III.24 FESEM images of GPB-PVP particles (R=1/5), using a PVP 
concentration in ethanol of: a) 10 mg/mL; b) 20 mg/mL; c) 40 mg/mL. 
 
 
Table III.9 Concentrations used for GPB-PVP coprecipitation using 
ethanol; PSD data in terms of volume of particles (CPVP: PVP concentration; 













2 10 1/5 0.5 1.0 1.8 
4 20 1/5 0.5 1.0 1.7 
8 40 1/5 0.5 1.0 1.9 
 
 
Fixed PVP concentration at 10 mg/mL, two higher R were investigated 
(1/3 and 1/2) at the same process conditions; these SAA tests produced 
powders with no regular morphology (Figure III.25), probably due to the 





   
Figure III.25 FESEM images of GPB-PVP particles produced using ethanol 
and a PVP concentration of 10 mg/mL and: a) R=1/3, b) R=1/2. 
 
 
GPB-DEX particles produced using water:ethanol (70:30 v/v) 
First, GPB-DEX coprecipitation tests were performed using a mixture of 
water:ethanol (70:30 v/v) as solvent, on the basis of SAA experiments on 
DEX (Di Capua et al., 2017a). Three DEX concentrations and three 
drug/polysaccharide weight ratios (R) were investigated. The operative 
conditions studied, based on the literature, were: GPB concentration 2 and 8 
mg/mL, DEX concentration 10-20-40 mg/mL saturator temperature 85°C, 
precipitator temperature 100°C, GLR 1.8 (Adami and Reverchon, 2012, Di 
Capua et al., 2017a). Examples of GPB-DEX particles produced in 
water:ethanol (70:30 v/v) were shown in Figure III.26. 
 
GPB-DEX coprecipitation in water:ethanol was very promising. 
Spherical and well-separated particles, using different R weight ratios, were 
obtained. PSDs in terms of volumetric cumulative percentage showed a 
significant effect of DEX concentration on particle size (see Table III.10 and 
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Figure III.26 FESEM images of GPB-DEX particles produced using 
water:ethanol (70:30 v/v) at R=1/5 and a DEX concentration of: a) 10 
mg/mL; b) 20 mg/mL; c) 40 mg/mL. 
 
 
Table III.10 Operating conditions used SAA coprecipitation experiments for 
GPB-DEX particles produced in water:ethanol (70:30 v/v); PSD data in 
terms of volume of particles (CDEX: DEX concentration; CGPB: GPB 













2 10 1/5 0.3 0.9 1.3 
4 20 1/5 0.6 1.8 3.0 




Figure III.27 Comparison of cumulative volumetric PSDs of GPB-DEX 




In order to obtain large particles, DEX concentration was fixed at 40 
mg/mL and several R were investigated (1/5, 1/4, 1/2 and 1/1) at the same 
process conditions. Examples of these produced particles at different 
drug/DEX weight ratios are shown in Figure III.28. 
Regular morphology and perfect particles (Figure III.28) were obtained 
also increasing drug concentration up to 20 mg/mL, corresponding to a 
weight ratio of R=1/2 (where the mass percentage of active ingredient is 
33.3%). Only for R=1/1 the coprecipitation test failed, probably due to the 
low amount of polysaccharide (in weight percentages) that was not able to 
inhibit GPB crystallization. 
PSDs data in terms of volumetric cumulative percentage are summarized 
in Table III.11. 
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Figure III.28 FESEM images of GPB-DEX particles produced using 
water:ethanol at DEX concentration of 40 mg/mL and: a) R=1/4, [GPB]=10 
mg/mL, b) R=1/2, [GPB]=20 mg/mL. 
 
 
Table III.11 PSD data in terms of volume of particles (CDEX:DEX 














8 40 1/5 0.6 2.1 3.4 
10 40 1/4 0.6 1.9 3.2 
20 40 1/2 0.7 1.6 2.7 
40 40 1/1* - - - 
 
 
PSD data showed that increasing the weight ratio GPB/DEX (hence, 
increasing GPB concentration in the solution injected during SAA process) 





GPB-DEX particles produced using water 
GPB-DEX coprecipitation tests were performed also using water as 
solvent and the same operative conditions, on the basis of SAA experiments 
on DEX (Adami and Reverchon, 2012). 
Examples of GPB-DEX particles produced in water were shown in 
Figure III.29. PSDs data in terms of volumetric cumulative percentage are 
summarized in Table III.12. 
 
   
 
   
Figure III.29 FESEM images of GPB-DEX particles produced using water 
at: a) [DEX]=10 mg/mL, R=1/5; b) [DEX]=20 mg/mL, R=1/5; c) 
[DEX]=40 mg/mL, R=1/4; d) [DEX]=40 mg/mL, R=1/2. 
 
Table III.12 PSD data in terms of volume of particles (CDEX: DEX 













2 10 1/5 0.3 0.7 1.3 
4 20 1/5 0.3 0.7 1.2 
10 40 1/4 0.7 2.3 3.6 
20 40 1/2 0.6 1.6 2.7 
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As in the previous study using the mixture water:ethanol (70:30 v/v), it 
can be observed an effect of R on particle size. In particular, fixed DEX 
concentration in water, increasing R (hence, increasing GPB concentration) 
smaller particles were produced. 
 
 
Characterization of powders 
Solid state analyses performed revealed that a homogeneous dispersion of 
GPB was produced in all SAA powders. Thermograms (figure not reported) 
did not show the endothermic peak at about 196°C shown in Figure III.23, 
due to the fusion of crystalline structure, but only the glass transitions of the 
carriers used. Therefore, GPB coprecipitates were amorphous. Furthermore, 
FTIR spectra (figure not reported) demonstrated that no chemical 




To demonstrate the absence of recrystallization phenomenona, the 
morphology of the produced coprecipitates GPB-PVP and GPB-DEX was 
observed for 4 months by scanning electron microscope, as requested by 
Cerbios Pharma. Examples of the morphology of the coprecipitates at 
different time of storage are reported in Figure III.30.  
FESEM images showed that all SAA powder did not change morphology 
with time and no aggregation of particles was observed. These results were 
confirmed by DSC analyses: the thermograms did not present the melting 




   
 
   
Figure III.30 FESEM images of coprecipitates after 4 months; a) 
GPB/PVP=1/5; using [DEX]=40 mg/mL in water:ethanol (70:30 v/v) b), 




Comparison of the investigated systems 
The best results were obtained using DEX as carrier, producing perfect 
and spherical particles. Furthermore, using the mixture water:ethanol (70:30 
v/v) as solvent, the system allowed to produce larger and perfect particles 
using GPB/DEX weight ratios up to R=1/2 (corresponding to a weight 
percentage of GPB of 33.3%), whereas a starting coalescence was evinced 
using water. The differences between water and water:ethanol systems were 
to assign to the different surface tension (droplet diameter), solvents 
evaporation rate (ethanol is more volatile than water) and solvents solubility 
in SC-CO2. These characteristics can influence particle production and size, 
as demonstrated by the results. 
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III.7 Conclusions on drugs proposed by Cerbios Pharma 
All these compounds were previously unsuccessfully tested using 
conventional techniques by other research groups. On the contrary, SAA 
demonstrated to be effective in overcoming these limitations and reaching 
the specific targets requested by the company. BRI, FUL and NAP were 
micronized alone, whereas DAS and GPB were dispersed in carrier matrices 
producing coprecipitates. 
In particular, BRI crystalline particles, in form of agglomerates, were 
produced using ethanol as solvent, with a particle size d90 < 1 µm and with 
non detectable residual solvents, as requested by the customers. 
Unfortunately, the low solubility did not allow to obtain a good productivity 
(mL of solute injected per minute), useful in a large-scale production 
perspective.  
FUL micronization in acetone was really successful; amorphous sub-
microparticles with d50 ranging between 0.4 and 0.7 µm were obtained, by 
reaching the desired targets. Furthermore, SAA FUL particles showed a 4-
fold faster dissolution rate compared to the untreated FUL, demonstrating 
the improvement of bioavailability. 
The experimentation on NAP in ethanol was fundamental in order to 
validate SAA industrial plant and obtain SwissMedic authorization for GMP 
(Good Manufacturing Practice) production on January 2017.  
The production of a SAA solid dispersion of DAS in a matrix consisted 
of PVP was obtained and confirmed by EDX analyses, demonstrating that 
DAS was intimately mixed in each particle at nanometric level, forming 
microspheres.  
GPB was a very difficult compound to be processed due to the fast 
crystallization rate and the high tendency to agglomerate. The production of 
composite systems using the two different matrices investigated (dextran and 
PVP) demonstrated to be able to promote the stabilization of the drug on 
time, by preventing the typical GPB behavior to agglomerate.  
 
For each optimized product, different batches were produced for further 
















About 40% of novel drugs on the market is classified as poorly water-
soluble, according to the Biopharmaceutics Classification System (Lipinski 
et al., 2001, Bhakay et al., 2018). Among the several approaches mentioned 
in the Introduction section, particle size reduction approaches to form stable 
sub-microparticles and nanoparticles have emerged to enhance the 
bioavailability of poorly water-soluble compounds. Indeed, these particles 
have larger specific surface areas promoting greater interactions with the 
solvent and, hence, higher dissolution rates. However, micro and 
nanoparticles of drug may be affected by aggregation or recrystallization 
phenomena and are difficult to handle in an industrial perspective. For this 
reason, the current strategy is the production of composite systems with 
improved pharmacokinetic behavior and bioavailability (Junyaprasert and 
Morakul, 2015, Savjani et al., 2012, Khadka et al., 2014). As mentioned in 
the state of the art, conventional methods are not always suitable or feasible 
and may show some drawbacks, whereas SC-CO2-based processes can be 
used as an alternative to traditional techniques to overcome these limitations 
(Cocero et al., 2009, Campardelli et al., 2015). The aim of this part of work 
was to test the applicability of SAA process in the production of 
coprecipitates able to improve dissolution rates and, hence, the 
bioavailability of different type of active principles. In particular, 
investigations and studies were performed on some compounds of natural 
origin with attested pharmacological properties (curcumin, luteolin, 
palmitoylethanolamide) and a drug (nifedipine). Three carriers were used in 





Polyvinylpyrrolidone (PVP, Mw: 10,000), dextran from Leuconostoc 
mesenteroides (DEX, average MW 43,000), curcumin (CUR, purity 99%), 
nifedipine (NIF, purity), fluorescein isothiocyanate (FITC isomer I, purity 
90%), ethanol (EtOH, purity 99.9%), acetone (Ac, purity 99.8%) were 
supplied by Sigma Aldrich (Italy). Hydroxypropyl-β-cyclodextrin (HPβCD, 
97%) was provided by Acros Organic (Belgium), luteolin (LUT) and 
palmitoylethanolamide (PEA) were provided by Epitech Group SpA (Italy). 
Carbon dioxide (CO2, 99.9%) was purchased by Morlando Group (Italy) and 
nitrogen (N2, 99%) by SOL (Italy). All materials were used as received. 
 
IV.2 PEA stabilization 
PEA is an endogenous fatty acid amide, belonging to the class of nuclear 
factor agonists. It has been studied extensively for its anti-inflammatory and 
neuroprotective action (Skaper et al., 2014, Petrosino et al., 2016). It has 
recently been demonstrated that PEA exerts neuroprotection in central 
nervous system pathologies and it significantly reduces inflammatory 
secondary events associated with spinal cord injury (Andresen et al., 2016). 
However, the lipidic nature of the molecule and its large particle size in the 
native state produce limitations in terms of solubilization in aqueous systems 
and, consequently, reduce its bioavailability. Indeed, native PEA shows a 
morphology characterized by large flat crystals (Reverchon et al., 2015). The 
production of particles with micrometric size can overcome the problems 
related to the low bioavailability; indeed, the dissolution rate of a drug can 
be enhanced by the increase of exposed surface area (Schifilliti et al., 2014, 
Andresen et al., 2016, Impellizzeri et al., 2014, Impellizzeri et al., 2015). In 
previous studies (Reverchon et al., 2015) some SCF techniques were tested 
in the attempt of reducing PEA particle size and crystallization. The work 
was only partly successful because PEA shows very fast crystallization rates, 
interfering with the micronization processes. PEA was also micronized by 
SAA technique; the best results in terms of powder morphology were 
obtained using ethanol and isopropanol as liquid solvent; but, irregular 
particles were produced in the micrometric range, due to PEA tendency to 
crystallize forming flat particles (Reverchon et al., 2015). Therefore, in this 
work (Adami et al., 2019) in collaboration with the Italian company Epitech 
Group, PEA coprecipitation experiments were carried using PVP and LUT, 
with the aim to reduce PEA tendency to crystallize during SAA 
micronization and to obtain micrometric composite particles with a regular 
(spherical) morphology. 
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IV.2.1 Experimental results 
SAA coprecipitation experiments PEA/PVP 
The first part of PEA coprecipitation experiments were performed using 
PVP, selected for its capacity to act as crystallization controller of active 
principles (Jain and Banga, 2010, Lee et al., 2013, Sekikawa et al., 1978). 
SAA operating conditions were: total concentration in ethanol 10 or 20 
mg/mL, 40°C; gas to liquid ratio (mass based, GLR) 2, injection pressure 
and temperature of about 80 bar and 80°C in the saturator, precipitation 
temperature 65 or 70°C. These conditions were optimized in a previous 
paper in which SAA precipitation of PEA alone was attempted (Reverchon 
et al., 2015). In this work, PEA/PVP weight ratios (R) 1:3, 1:5 and 1:8 w/w 
were proposed. In Table IV.1, the operating conditions for coprecipitation 
experiments are summarized. Each experiment was performed in triplicate. 
 
Table IV.1 Operating conditions used for PEA-PVP coprecipitation 










PEA 10 7.82 65 
PEA:PVP 1:8 20 6.64 70 
PEA:PVP 1:5 20 7.47 70 
PEA:PVP 1:3 20 8.19 65 
 
 
It is already known that a GLR=2 avoids the precipitation of PEA in the 
saturator by antisolvent effect (Reverchon et al., 2015). Moreover, previous 
studies on SAA process showed that decreasing the concentration of the 
starting solution, smaller droplets/particles were obtained (Liparoti et al., 
2015). The first coprecipitation experiments were performed using the 1:3 
w/w PEA/PVP ratio. Figure IV.1a reports a SEM image of the particles 
obtained; the precipitate was formed by irregular, large particles and the 
presence of flat particles was also evident, that confirms the typical tendency 
of PEA to crystallize with this morphology. This fact demonstrates that at 
this PEA/PVP ratio, PVP was not able to block the tendency to fast 




   
 
 
Figure IV.1 FESEM images of SAA powders produced at different weight 
ratios (R=PEA/PVP w/w): a) R=1/3; b) R=1/5 and c) R=1/8. 
 
Therefore, PVP content was increased to 1:5 wt/wt. In Figure IV.1b, a 
SEM image is reported of the composite particles obtained by SAA using 
this composition ratio. They show a quasi-spherical morphology; but, they 
are still coalescent and not well separated, probably due to PEA incipient 
crystallization. However, the morphology obtained in this experiment 
represents an improvement with respect to the one observed in the previous 
tests. When SAA tests at PEA/PVP ratio 1:8 w/w were performed, particles 
like the ones reported in Figure IV.1c were obtained. In this case, FESEM 
image shows perfectly spherical particles with no coalescence, in which PEA 
has been efficiently blocked, producing a coprecipitate. PSD of 
coprecipitated PEA/PVP 1:8 w/w was investigated calculating particle 
diameter from FESEM photomicrographs. PEA/PVP particles showed a 
relatively narrow distribution, with d10=0.23 µm; d50=0.40 µm; d90=0.84 µm. 
 
IV.2.2 Characterization of coprecipitates PEA-PVP 
XRPD analysis (Figure IV.2) showed that untreated PEA has a crystalline 
structure, with well-defined peaks; SAA micronized PEA using ethanol as 
solvent shows a different crystalline structure. The coprecipitates PEA/PVP 
1:8 and 1:5 w/w do not show the characteristic peaks of PEA. 
Coprecipitation of pharmaceutical compounds using SAA technique 
59 
 
Figure IV.2 XRPD spectra: comparison among SAA coprecipitates PEA-
PVP, PEA micronized by SAA and PEA untreated. 
 
A detail of XPRD of coprecipitates PEA/PVP 1:8 and 1:5 w/w (figure not 
shown) reports the characteristic peak halos of PVP whereas PEA peaks are 
almost disappeared, except than one at 2θ=22° that is more evident for 
PEA/PVP 1:5 w/w ratio. Therefore, we can state PEA in these coprecipitates 
has an amorphous structure. 
 
Loading efficiency tests 
To verify the effective coprecipitation of the two compounds, loading 
measurements were performed. HPLC analyses carried out on SAA 
coprecipitates showed the presence of 11.1% and 16.7% of PEA for 
PEA/PVP 1:8 and 1:5 w/w respectively, with very high loading efficiency 
for all the samples, close to 100%. 
 
SAA coprecipitation experiments PEA/LUT 
LUT alone when micronized by SAA, starting from a solution of 20 
mg/mL in ethanol, at 81°C and 93 bar in the saturator and 65°C in the 
precipitator, has a partially irregular morphology, as shown in the FESEM 
photomicrograph reported in Figure IV.3, with the formation of spherical 
particles covered by small needles. This result means that, during spherical 
droplet evaporation, small LUT acicular crystals are formed on particle 
surface, due to LUT recrystallization. Nevertheless, the original spherical 




Figure IV.3 FESEM image of LUT micronized by SAA at 81°C and 93 bar 
in the saturator, 65°C in the precipitator. 
 
Therefore, differently from PVP, whose microparticles produced by SAA 
are perfectly spherical, luteolin precipitates are relatively less regular. 
However, it has been reported that the pharmacological association PEA-
LUT shows better results than PEA alone and it is currently on the market as 
Glìalia® (produced by Epitech Group Spa, Saccolongo, Italy). Therefore, a 
series of coprecipitation experiments was performed by SAA to try to 
produce PEA-LUT nanostructured coprecipitates. 
Coprecipitation experiments were carried using PEA-LUT weight ratios 
10:1, 8:1, 6:1 w/w, solubilizing both compounds in ethanol. SAA operating 
conditions were: total concentration in ethanol 10 or 20 mg/mL, gas to liquid 
ratio 2, saturator temperature 80°C, precipitation temperature between 55 
and 65°C. In Table IV.2, SAA operating conditions, used in this set of 
experiment, are summarized. 
A FESEM photomicrograph of the coprecipitates PEA/LUT 10:1 w/w is 
reported in Figure IV.4.  
 
Table IV.2 Compositions and operating conditions used to perform PEA-
LUT coprecipitation experiments. (C: total concentration; QCO2: CO2 flow 











LUT 20 7.82 93 65 
PEA:LUT 10:1 10 6.75 93 65 
PEA:LUT   8:1 10 7.13 80 60 
PEA:LUT   6:1 10 7.13 80 55 
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Figure IV.4 FESEM image of SAA PEA-LUT coprecipitate, produced at 
PEA/LUT=10:1 (w:w) ratio. 
 
A large improvement of the morphology with respect to pure LUT and 
PEA can be noted; indeed, spherical particles are produced in which the flat 
crystals characteristic of PEA are no more visible, no acircular crystals are 
present and particle coalescence is practically absent. However, the 
microparticles are not perfectly spherical: holes and cavities can be 
observed: similar morphologies have been previously observed when the 
start of a crystallization process superimposed to droplet (amorphous) drying 
(Reverchon et al., 2005, Martin et al., 2013, Adami et al., 2012). 
Increasing the amount of luteolin (8:1, 6:1 w/w), keeping constant the 
total concentration of solutes in ethanol, only small modifications of particle 
morphology were observed with no more morphological improvements. 
Therefore, we assumed that the best results in terms of particle morphology 
were obtained using the highest PEA/LUT ratio (10:1 w/w) and analysed in 
details these coprecipitates. The particles show a sharp PSD with a d50 of 
0.97 µm; i.e., submicronic particles have been successfully produced. 
A possible explanation of the success of PEA/LUT coprecipitation is the 
influence of two scientific aspects: luteolin very efficiently inhibits PEA 
crystallization process, favourably interacting with it and the use of a lower 
temperature in the precipitator reduces crystallization rate of precipitates. 
PEA/LUT 10:1 w/w reproducibility tests were repeated 7 times using the 
same starting batch; practically the same results in terms of coprecipitate 
morphology and PSDs were obtained. 
 
IV.2.3 Characterization of coprecipitates PEA-LUT 





Figure IV.5 XRPD spectra: comparison among a) LUT, untreated and 
micronized by SAA and b) SAA coprecipitates PEA-LUT and untreated PEA. 
 
It is possible to note that LUT micronized by SAA mainly shows the 
halos typical of the amorphous structures, confirming FESEM images 
observations, whereas the untreated compound shows a crystalline structure. 
These spectra have been used as subtraction reference for the measurement 
of the crystalline degree of coprecipitates. XRPD analyses showed that PEA 
in SAA coprecipitates 10:1 w/w has a crystalline degree of 43% when 
compared to the untreated sample. 
The infrared (IR) spectrum of PEA/LUT coprecipitates showed 
significant changes when compared to the spectra of LUT and PEA alone, as 
shown in Figure IV.6, where a detail of these spectra in the range 2500-3700 
cm-1 is reported.  
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Figure IV.6 FTIR spectra in the 3700-2500 cm-1 range: comparison among 
SAA PEA-LUT coprecipitate (10:1 w:w), untreated LUT and pure PEA. 
 
 
The coprecipitates show the presence of hydrogen bonding between the 
two compounds that have a significant influence on the peak shape and 
intensities in the region of the IR spectrum evidenced. They caused peak 
broadening and shifts in absorption to lower frequencies. IR traces indicated 
that there is a smoother band at 3297 cm-1, compared with PEA spectrum; 
furthermore, a band broadening is present at 3200 cm-1. These two changes 
can be explained by the breakdown of the intermolecular hydrogen bonding 
of LUT and the creation of new hydrogen bonds between PEA and LUT 
(Corredor et al., 2009). The interaction between the two compounds 
produces also the shift of the PEA peak located at 3093 cm-1, to higher 
frequencies. In addition, the absorption band at 1284 cm-1 in PEA is shifted 
to 1269 cm-1 in PEA/LUT spectrum, due to another interaction between the 
compounds. These intermolecular bonds and the steric hindrance restrict the 
molecular mobility of PEA molecules and provide stability to the system 
(Baghel et al., 2016). As reported in the literarure, molecules capable of 
specifically interacting with an active principle in a dispersion, such as 
through hydrogen bonding, can inhibit crystallization (Newman et al., 2012). 
These results substantially confirm the previous observation that LUT 
efficiency in the partial blocking PEA crystallization should be related to 
interactions between the two compounds (Lin et al., 2008, Di Capua et al., 




Figure IV.7 DSC thermograms related to PEA, LUT and SAA PEA-LUT 
coprecipitates. 
 
It is possible to note that PEA-LUT coprecipitated by SAA show a 
different thermal behavior compared to the untreated materials. In particular, 
untreated LUT thermogram shows no peaks, indicating that it is amorphous 
and untreated PEA thermogram shows two melting peaks at 80°C and 
100°C, indicating that two crystalline forms are present in the molecule. The 
thermograms of PEA-LUT coprecipitates show a single melting peak at 
temperatures between 95°C and 100°C that suggests the presence of a single 
PEA crystalline form. 
The analyses of ethanol residues showed that for all the powders 
produced by SAA, they are far below the limits stated by US Pharmacopea 
(5000 ppm for ethanol) (Levy and Nelson, 1961), and are even below the 
ones in the starting (untreated) material in the case of LUT, due to solvent 
extraction during SAA processing (see Table IV.3). 
 
Table IV.3 Solvent residues in the tested materials. 
 
Sample ppm Ethanol 
PEA untreated 2 
LUT untreated 435 
PEA/LUT 10:1 
coprecipitated by SAA 
87 
 
Loading efficiency tests 
HPLC analyses on the sample PEA/LUT 10:1 w/w, confirms the 
efficiency of SAA process in producing coprecipitates, showing the presence 
of 90.5% of PEA, with a loading efficiency of 99.6%. 
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Stability tests 
Stability tests on the coprecipitates PEA/LUT 10:1 w/w SAA processed, 
have been carried for 23 days, aimed at studying the variation of morphology 
and PSD of the coprecipitates with time, as required by Epitech Group SpA. 
The sample was stored in dark and dry conditions, keeping the powder under 
nitrogen; then, SEM analyses were repeated at different times. An example 
of the morphology of the coprecipitates after 10 days of storage is reported 
in Figure IV.8. FESEM photomicrograph shows that the powder did not 
change morphology with time and no aggregation of particles took place. 
The same morphology was also observed after 4 months of storage, in a long 
stability test performed at the end of this study. In Table IV.4 the major 
characteristics of particles PSD with time are reported. They show very 
similar characteristic dimensions for d10 and d50; only d90 shows a non-
negligible increase at the longest storage times. 
 
 
Figure IV.8 FESEM image of PEA-LUT particles (10:1 w/w) coprecipitated 
by SAA after 10 days of storage. 
 
Table IV.4 Stability analysis of SAA coprecipitates of PEA/LUT 10:1 w/w 










0 0.4 1.1 12.6 
3 0.6 1.4 11.9 
7 0.6 1.3 10.1 
10 0.6 1.2 11.5 
16 0.6 1.3 14.4 




IV.2.4 Conclusions on PEA-PVP and PEA-LUT systems 
This work demonstrated that the solid dispersions obtained by SAA 
coprecipitation allow to efficiently produce PEA-PVP and PEA-LUT 
submicroparticles. PEA showed the tendency to precipitate separately from 
PVP and the control of morphology was incomplete at lower PVP contents; 
however, increasing PVP content, stable dispersions were obtained for 
PEA/PVP 1:8 w/w ratio. Spherical particles were obtained without the 
production of PEA independent crystals and with a PEA loading very similar 
to the starting formulation value. 
The coprecipitation of PEA-LUT also produced spherical submicrometric 
particles. LUT was efficient in controlling the tendency of PEA to crystallize 
even at very low LUT contents. This result can be explained by the fact that 
PEA-LUT interactions are obtained. The ratio PEA/LUT that produces the 
best control of morphology is 10:1 w/w. 
The most relevant difference between the two series of results proposed 
in this work is the different sensitivity of PEA at the two guest compounds. 
PEA/PVP 1:8 w/w gives good results in terms of morphology and loading 
efficiency; however, PEA/LUT 10:1 w/w is an exceptional result: very small 
quantities of LUT stabilize the coprecipitates; i.e., they are sufficient to 
modify the crystallization behavior of PEA, using a quantity of the guest 
compound 80 times smaller than in the case of PVP. The explanation is that 
PEA-LUT is not a simple coprecipitate and PEA-LUT chemical interactions 
control the result of the precipitation. 
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IV.3 Improvement of CUR bioavailability 
CUR is contained in large quantities in the roots of Curcuma longa; it 
possesses well-known antioxidant, antimicrobial, anti-inflammatory and 
anticancer properties (Bansal et al., 2011, Wilken et al., 2011, 
Chattopadhyay et al., 2004). However, it has a very low solubility in water 
based systems and, consequently, it shows a poor bioavailability, that 
represents a great limitation to its use as a powerful pharmaceutical agent. 
Moreover, CUR is relatively unstable in aqueous solution and undergoes 
rapid hydrolytic degradation that severely reduces its bioavailability (Shen 
and Ji, 2012, Paradkar et al., 2004). 
Martins et al. (Martins et al., 2013) used spray-drying to prepare 
microparticles of Curcuma longa extract plus PVP and colloidal silicon 
dioxide. CUR-PVP microparticles were generally larger than 5 µm with a 
maximum yield of 53%. Comparison of the dissolution profiles of these 
microparticles with starting materials and residual solvent analysis were not 
reported. Paradkar et al. (Paradkar et al., 2004) used the same technique to 
produce microspheres of CUR in PVP, obtaining irregular and spherical 
particles of 3-10 μm. Solid dispersions of CUR at different PVP ratios were 
also prepared. Dissolution studies on CUR and its physical mixtures in 0.1 N 
HCl (pH 1.2) showed negligible release of CUR (0.25%) after 90 min. 
During the same time microspheres release up to 1.5% CUR for the 1/10 
ratio. Farazuddin et al. (Farazuddin et al., 2014) proposed the encapsulation 
of CUR in PLGA microparticles to increase its bioavailability and facilitate 
slow release kinetics. Microparticles were prepared using an oil-in-water 
emulsion plus solvent evaporation technique. PLGA microparticles showed 
17% release of CUR in 48 hours, which increased slowly with time. Khan et 
al. (Khan and Rathod, 2014) prepared CUR alone nanoparticles via solvent-
nonsolvent nanoprecipitation using a spinning disc reactor. CUR particle 
diameters were in the range 180-220 nm, using PVP as stabilizer. They 
showed a decrease of crystallinity and displayed larger water dissolution 
rates than pure CUR. It was observed a complete dissolution in about 50 
minutes in water, whereas the starting material in the same time dissolved at 
no more than 5%. Krausz et al. (Krausz et al., 2015) dissolved CUR and 
chitosan in methanol with PEG400 and tetramethyl orthosilicate-HCl 
inducing polymerization. The resulting gel was dried and processed by ball 
milling cycles to produce uniform particles. They obtained particles with a 
mean diameter around 220 nm containing CUR at 1% embedded in a porous 
lattice. An incomplete release (around 80%) of CUR was obtained in 24 
hours. CUR loaded in dextran sulphate and chitosan nanoparticles was 
prepared by simple coarcevation method by Anitha et al.(Anitha et al., 
2011). These particles had a spherical morphology with an average size 
around 200 nm. Drug entrapment efficiency was around 74%. In vitro drug 
release studies showed a burst release in the first 3 h, followed by a release 
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of CUR over a period of one week; about 70% of drug was released in this 
time. 
In addition, SCFs based techniques were attempted to produce curcumin 
delivery systems. For example, Xie et al. (Xie et al., 2015) used SAS process 
with a coaxial injector and hexafluoroisopropanol as the solvent, to form a 
silk fibroin plus 0.5-1% CUR solution. These authors produced nanoparticles 
generally smaller than 100 nm. They obtained low drug loading and 
encapsulation efficiencies of 12% ± 0.62 and 36% ± 1.9, respectively. In 
vitro studies in phosphate buffer saline solution showed that 75% of CUR 
was released from silk-fibroin in about 200 hours. Nanoparticles produced 
by SAS are formed by nucleation and growth; therefore, the composite 
nanoparticles can be produced by homogeneous nucleation and/or chemical 
interactions between the compounds to be coprecipitated. This mechanism 
can explain the low encapsulation efficiencies they obtained (Reverchon and 
De Marco, 2011). Zabihi et al. (Zabihi et al., 2014) produced CUR 
nanoparticles coated by poly(lactic-co-glycolic acid) (PLGA) using a 
fluidization assisted supercritical anti-solvent process. PLGA solution was 
sprayed into supercritical CO2 medium, in which CUR nanoparticles were 
fluidized by ultrasonic vibration. The loading of particles was enhanced by 
increasing ultrasound power and fluidizing potential. High anti-solvent flow 
rate also improved the loading efficiency and size distribution. PLGA-CUR 
particles were obtained with the average size of 40 nm at the ultrasonic 
power of 350 W. However, the CUR loading never exceeded 38%. No burst 
release was observed and after 600 minutes only 31.3% of CUR was 
released. Pedro et al. (Pedro et al., 2016) used PGSS to process 
[tristearin/soy phosphatidylcholine]/[CUR/DMSO] mixtures. Various 
lipid/CUR mixtures were processed. SEM analyses showed that the particles 
were large and presented an irregular shape in all formulations proposed. For 
example, mean particle size was between 20 μm and 70 μm. CUR loading 
ranged between 30 and 87 drug/lipid w/w and strongly decreased, increasing 
CUR content in the initial mixture. Dissolution studies were not proposed. 
Therefore, according to the literature, until now the problem of CUR 
dissolution rate enhancement has not been resolved. In this work (Adami et 
al., 2017a), for the first time SAA process was proposed for the production 
of a biocompatible drug delivery system based on PVP loaded with CUR. 
Appropriate SAA process parameters and conditions were studied and the 
effect of polymer/drug ratio on the co-precipitate characteristics is 
investigated. The precipitates were analyzed in terms of morphology, solid 
state and loading efficiency. In-vitro release studies were performed to 
measure the increase of CUR release rate. 
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IV.3.1 Experimental results 
Trying to take advantage of these previous experiences (Liparoti et al., 
2013, Liparoti et al., 2015), the process conditions used in this study were: 
saturator pressures ranging between 93 and 99 bar and temperature fixed at 
80°C; these conditions assure large solubility of CO2 in the liquid solution 
formed by ethanol and CUR. The temperature of the precipitation vessel was 
fixed at 80°C at a pressure of about 1.50 bar. Different gas-to liquid ratio 
(GLR: mass ratio between CO2 and liquid solution) were investigated: 0.8, 
1.3 and 1.8. Considering these GLR values in the framework of the high-
pressure phase equilibria diagram CO2-ethanol at 80°C, the operating points 
fall into the two-phase gas-liquid region, as shown in Figure IV.9. The 
polymer was dissolved in ethanol at a concentration of 10 mg/mL and 
several drug/polymer weight ratios (R) were investigated, as summarized in 
Table IV.5.  
 
 
Figure IV.9 Operative points in the phase equilibrium diagram CO2-ethanol 
at 80°C. 
 









PVPC1 1/8 11.25 1.8 
PVPC2 1/6 11.66  
PVPC3 1/4 12.50  
PVPC4 1/2 15.00  
PVPC5 1/8 11.25 1.3 
PVPC6 1/8 11.25 0.8 
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The particles produced in these experiments consisted of spherical and/or 
spherical collapsed submicrospheres, as shown in Figure IV.10, where 
examples of FESEM images at different R are reported. 
 
   
 
   
Figure IV.10 FESEM images (Mag=20 KX) of CUR/PVP microparticles, 
obtained by SAA at different mass ratios R: a) 1/8, b) 1/6, c) 1/4, d) 1/2. 
 
The collapse of microparticles may be due to the fragility of the solid 
structure formed and can be correlated to the presence of CUR, since PVP 
alone particles formed by SAA did not show this characteristic (Adami et al., 
2017b). The collapse of particles is particularly evident as R increases, 
confirming that can be correlated to the increase of CUR content. Similar 
results have sometimes been previously observed in SAA produced 
microparticles (Adami et al., 2017b, Della Porta et al., 2010), but also in 
some cases of spray drying, that shows some similitaries with the SAA 
process (Vicente et al., 2013). In both processes, the evaporation of the 
droplets involves mass and heat transfer mechanisms, influenced by the 
drying temperature and the solute concentration. During drying, the 
precipitation of the solid starts from the droplet surface and the thin layer 
formed can be fragile, depending on the material. If solvent evaporation is 
fast, due to the high temperature in the precipitator, particles can collapse 
(Vicente et al., 2013).  
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PSDs in term of number of particles calculated from FESEM images are 
reported in Figure IV.11, where the curves obtained at different 
drug/polymer ratios are compared. Table IV.6 also summarizes PSDs data 
obtained, in term of number of particles and particle volume. For all 
CUR/PVP mass ratios studied, the mean particle size ranged between 0.24 
and 0.38 µm and a very moderate increase of the mean diameter was 
observed increasing the amount of CUR. Probably, the presence of CUR 
implies an increase of viscosity in the starting solution, the generation of 
larger droplets and an overall result of enlargement of particle size. This 
effect is more evident for R= 1/2 and 1/4; whereas, no large differences can 
be noted for coprecipitates at 1/6 and 1/8. This result is expected for SAA, 
where parameters such as viscosity and density of the solution can influence 
the atomization process. Volumetric PSDs data in Table IV.6 confirm that 
the mean particle size is larger when the distribution is calculated in terms of 
particle volume: these differences are mainly due to the formation of few 
larger particles that have a relevant impact on the volumetric distribution. 
 
 
Figure IV.11 PSDs in terms of particles number of CUR/PVP particles at 
different drug/polymer weight ratios. 
 
Table IV.6 PSDs data based on number and volume of CUR-PVP particles. 
 













R=1/8 0.13 0.24 0.51 0.24 0.54 0.94 
R=1/6 0.12 0.22 0.48 0.26 0.53 0.95 
R=1/4 0.18 0.31 0.63 0.34 0.64 1.06 




GLR depends on the amount of CO2 dissolved in the saturator, increasing 
the GLR there is an increase of CO2 content in the liquid system forming the 
expanded liquid, smaller droplets are formed in the spray and consequently 




Table IV.7 PSDs data based on the volume of CUR/PVP particles at 








GLR=1.8 0.24 0.54 0.94 
GLR=1.3 0.24 0.54 0.97 
GLR=0.8 0.62 1.43 2.3 
 
 
IV.3.2 Characterization of coprecipitates 
XRPD analyses of all coprecipitates and pure CUR and PVP are reported 
in Figure IV.12. Untreated drug is crystalline and PVP is amorphous. SAA 
particles show only the characteristic peak halos of PVP while CUR peaks 
are not detectable; therefore, CUR in coprecipitates is amorphous. The drug 
is homogeneously dispersed at nanolevel in PVP matrix; therefore, a 
nanodispersion of CUR in SAA microparticles can be hypothesized. This 
result can be also explained by the particle formation mechanism in SAA 
process: each particle is the result of the drying of a droplet containing 
dissolved PVP and CUR; as a consequence, a homogeneous solid mixture of 
the two compounds is expected in the solid particle. 
These results are confirmed by DSC analyses, shown in Figure IV.13. 
CUR alone is crystalline and its fusion temperature is at 174°C, whereas 
PVP is completely amorphous with a glass transition temperature around 
155°C. According to the literature, when only one glass transition 
temperature, Tg, is observed, a one-phase solid powder is obtained (Aid et 
al., 2017). In the thermograms of SAA coprecipitates, the peak related to 
CUR fusion is not present, and the profiles are very similar to the one of 
PVP. Therefore, all SAA particles are in an amouphous state, and a 
homogenous CUR dispersion in PVP matrix are obtained by SAA process. 
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Figure IV.12 XRPD related to the PVP and CUR untreated and all 
coprecipitates produced by SAA. 
 
 
Figure IV.13 DSC analysis related to the PVP and CUR untreated and all 
coprecipitates produced by SAA. 
 
The FTIR analyses (Figure IV.14) showed that no chemical bonds were 
formed between CUR and PVP during the coprecipitation. It can be 
observed, indeed, that the characteristic peaks of CUR (1000-750 cm-1) are 






Figure IV.14 FTIR analyses of raw material and SAA coprecipitates. 
 
Loading efficiencies and dissolution tests 
A relevant information is the loading efficiency of the process that also 
indicates if coprecipitation was successful. The UV-vis analyses showed 
CUR loading efficiencies larger than 94% for all drug/polymer weight ratios 
studied, up to a maximum of 100%. These high values of loading efficiency 
correspond to high contents of CUR in SAA coprecipitates: for example, for 
the particles produced at R=1/2, it was demonstrated the presence of 32.5% 
of CUR, with a loading efficiency of 97%. 
To test the effectiveness of CUR/PVP coprecipitates in improving the 
dissolution rate of the drug, experiments in PBS at pH 6.5 and 7.4, were 
performed; standard deviations were about 1.2% for SAA coprecipitates. 
These different values of pH are similar to those in a tumoral tissue and 
blood system, respectively. Figure IV.15 shows the dissolution profiles of 
SAA coprecipitates with respect to a physical mixture at pH 6.5. 
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Figure IV.15 Dissolution profiles of CUR in PBS at 37 °C and pH 6.5. 
 
Decreasing drug/polymer mass ratio, larger drug release rates are 
obtained; probably a more efficient dispersion of CUR in the polymeric 
matrix can be obtained and this fact allows the improvement of dissolution 
rate, observed in this study. These results are consistent with the literature: 
by reducing the particle size and the cristallinity behavior of curcumin, an 
enhanced dissolution rate resulted (DiNunzio et al., 2008). The physical 
mixture of the raw materials was realized using R=1/8; i.e., the most 
favorable ratio from the point of view of release rate, used in this study. It 
releases 100% of CUR in about 23 hours. All SAA coprecipitates show a 
faster release and the coprecipitates produced at R=1/8 show a total 
dissolution time of about 5.5 hours, that is about 4.5 times faster than the one 
of the physical mixture. Figure IV.15 also presents an insert with the 
enlargement of the first 20 minutes of CUR release, that cannot be 
appreciated in the overall diagram. During these first minutes, large 
quantities of CUR are released. 
The dissolution tests were repeated at pH 7.4 (Figure IV.16), to study the 





Figure IV.16 Dissolution profiles of CUR in PBS at 37 °C and pH 7.4. 
 
In these experiments we excluded R=1/2 that demonstrated in the 
previous analysis to be the less favorable value from the release rate point of 
view, and, on the basis of the results obtained for the pH 6.5, we did not 
repeat the dissolution test on the physical mixture. Standard deviations of 
these curves were about 1.5% for SAA coprecipitates. 
The results of the in vitro release of the particles obtained at CUR/PVP 
weight ratios of 1/8 and 1/6 and 1/4 show similar qualitative profiles as at 
pH 6.5. However, dissolution times are largely smaller. The full release of 
CUR occurs in a shorter time for all three coprecipitates. For example, for 
the coprecipitates at R=1/8 the total dissolution time is about 5.5 h at pH 6.5; 
but, it is 3.8 h at pH 7.4. Also at the higher pH values, the coprecipitates with 
a CUR/PVP weight ratio at 1/8 remain the most favorable from the point of 
view of release rate. In the literature, it is reported that a pH increase 
produces an opposite trend on CUR dissolution rates (Patra and Sleem, 2013, 
Rahman et al., 2009); i.e., dissolution rate decreases when pH increases. An 
explanation of our results could be the presence of PVP. Probably 
dissolution rate of PVP increases when the pH of the medium changes from 
acidic to mildly basic and can influence the dissolution rate of CUR. This 
phenomenon has been already observed in the literature and ti is due to the 
increase of PVP swelling at mildly basic pH; this fact can improve the 
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IV.3.3 Conclusions on CUR-PVP system 
SAA process demonstrated to be very efficient in the entrapment (up to 
100%) of CUR in a polymeric hydrosoluble matrix in which CUR is 
dispersed at nanometric level. The dissolution rate of CUR from SAA 
produced particles was successfully enhanced, when compared to the 
physical mixture, as confirmed by in vitro release results. CUR release is 4.5 
times faster for the 1/8 mass ratio with respect to CUR/PVP physical 
mixture. This result is very relevant from a pharmaceutical point of view, 
since an enhancement of CUR bioavailability is expected. Furthermore, 
drug/polymer ratio revealed to be an effective controlling parameter for drug 
release and the amorphous state of the powders produced by SAA process 
leads to a faster dissolution of the active principle. 
 
 
IV.4 Improvement of LUT bioavailability 
Flavonoids are naturally occurring polyphenolic compounds found in 
several kind of fruits, vegetables and medicinal plants (Lotito and Frei, 2004, 
Zheng and Wang, 2001). Apart from their physiological roles in the plants, 
flavonoids are relevant for human health because of their pharmacological 
properties, e.g. antiviral, antibacterial, anti-inflammatory, vasodilatory, anti-
ischemic and anticancer (Procházková et al., 2011). They may block 
proliferation of tumor cells, including metastatis and angiogenesis, by 
inhibiting kinase, reducing transcription factors, regulating cell cycle and 
inducing apoptotic cell death (Neuhouser, 2004, Sulaiman, 2015). Luteolin 
(LUT) is one of the most common flavonoids present in plants, usually used 
in Chinese traditional medicine to treat a wide variety of diseases, such as 
hypertension, inflammatory disorders and cancer (Sulaiman, 2015). 
However, its instability, poor bioavailability and hydrophobicity restricts its 
clinical applications.  
Several conventional micronization processes were used to improve LUT 
dissolution rate: spray drying, jet milling, coacervation, solvent evaporation. 
Dang et al. (Dang et al., 2014) prepared solid lipid nanoparticles (SLN) of 
LUT-soybean lecithin by hot-microemulsion technique at laboratory scale, 
melting lecithin at 75°C. They obtained nanoparticles with an entrapment 
efficiency of about 75%, that were tested in vitro and in vivo on rats, 
demonstrating an increase of LUT bioavailability of about 4.9 times with 
respect to LUT suspension in water. Khan et al. (Khan et al., 2014) prepared 
a laboratory recipe in which LUT was complexed with phospholipids, 
forming nanoparticles. They demonstrated that a faster dissolution rate of 
complexed LUT was possible, up to about 2.5 times than pure LUT in water. 
The LUT complex was also successfully tested in animal studies. Puhl et al. 
(Puhl et al., 2012) prepared LUT+polymer particles (polycaprolactone (PCL) 
Chapter IV 
78 
and poly(lactic-co-glycolic acid) (PLGA)) by nanoprecipitation at small 
laboratory scale using, as the organic phase, oils like oleic acid and isodecyl 
oleate, and obtained high encapsulation efficiencies (larger than 97%). This 
result is surprising, since, in nanoprecipitation, particles formation is driven 
by nucleation and growth and only a wrapping activity of the polymer can 
justify the formation of composite micro/nanoparticles instead of two 
separate precipitates. The success was possible due to the fact that very small 
quantities of LUT were used with respect to polymer content; they used 75 
mg of polymer against 1.25 mg of LUT: it means a ratio drug/polymer of 
1/60 w/w. 
Summarizing, the works found in the literature were successful in 
demonstrating the feasibility of LUT bioavailability increase when 
coprecipitated and produced at submicro scale. However, reliable, large 
scale applicable processes have not yet been tested for LUT coprecipitation. 
Therefore, in this work (Di Capua et al., 2017b) the applicability of SAA 
process for the production of systems LUT-PVP to produce composite 
particles with improved bioavailability and stability, is studied.  
 
IV.4.1 Experimental results 
First, LUT alone was micronized by SAA to evaluate its processability. 
The process conditions selected were: 4 mg/mL LUT in ethanol, at 80°C and 
95 bar in the saturator and 80°C in the precipitator. The CO2 flow rate was 
set at 7.8 g/min and the solvent flow rate was set at 5.4 mL/min, to obtain a 
gas-to liquid ratio (GLR: mass ratio between CO2 and liquid solution) in the 
saturator of 1.8. These process conditions were selected to assure a good 
solubility of CO2 in ethanol. The particles obtained showed an irregular 
morphology, as in the FESEM photomicrograph reported in Figure IV.17, 
with the formation of spherical particles from which small needles emerge. 
 
 
Figure IV.17 FESEM image (Mag= 35 KX) of SAA LUT particles. 
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These results indicate that LUT has a very fast crystallization kinetics 
and, during the late steps of droplets evaporation, it starts to crystallize. This 
particular tendency has been previously observed for other SAA processed 
materials (Martin et al., 2013, Adami et al., 2012). Each microsphere 
evidences the superposition of amorphous solidification and crystallization 
processes; therefore, LUT was not a good candidate for SAA micronization 
but for coprecipitation. The process conditions selected for coprecipitation 
experiments, were the same used for SAA experiments performed using 
LUT alone. LUT/PVP weight ratios 1/8, 1/6 and 1/4 w/w were selected to 
study the influence of this parameter on LUT release rate, using a constant 
concentration of polymer (10 mg/mL). In Table IV.8, the ratios and 
concentrations of LUT/PVP used in selected coprecipitation experiments are 
summarized. Examples of FESEM images of LUT/PVP 1/8 and 1/4 (w/w) 
samples are reported in Figure IV.18.  
 
 
Table IV.8 Ratios and concentrations of LUT and PVP used for SAA 
experiments. (Cpol: PVP concentration; C: total concentration; R=LUT/PVP 



























PVPL02 1/6 10 11.7 0.23 (±0.11) 
PVPL03 1/4 10 12.5 0.22 (±0.09) 
 
 
   
Figure IV.18 FESEM images (Mag=30 KX) of LUT/PVP microparticles 





These particles consist of spherical and/or collapsed submicrospheres. 
This morphology has been sometimes previously observed in SAA 
processing and can be due to the fragility of the solid structure (Liparoti et 
al., 2012, Adami et al., 2017a, Adami et al., 2017b). SAA particles are 
collapsed in a more evident manner as R increases. Since SAA shows many 
similarities with spray drying, particles collapse can be explained referring to 
this latter process. The theory of particle formation in spray drying (Vicente 
et al., 2013, Eslamian et al., 2009) claims that the particle morphology is 
influenced by drying time, shell flexibility and evaporation rate. When a 
dilute solution is processed, during drying, a thin layer of solid is formed. 
This shell can be fragile or flexible and, if the drying temperature is high, the 
solvent evaporation will be very fast and particles can deflate. This theory 
can also explain the morphology of LUT-PVP SAA produced particles. 
Figure IV.19 reports PSDs, in terms of number of particles calculated from 
FESEM images, where the curves obtained at different LUT/PVP ratios are 
compared. The mean size of the coprecipitates depends on LUT/PVP weight 
ratio (R): their mean diameter increases as R decreases. Submicroparticles 
were consistently obtained; the largest PSD covers the range from 0.1 to 
about 1.2 µm. 
 
 
Figure IV.19 PSDs of LUT/PVP composite particles produced by SAA at 
different drug/polymer weight ratios. 
 
IV.4.2 Characterization of particles 
XRPD analysis of coprecipitates and of pure LUT and PVP is reported in 
Figure IV.20. The analyses revealed that unprocessed LUT has a crystalline 
structure; whereas, untreated PVP shows the typical halos of an amorphous 
polymer. LUT processed by SAA, instead, shows only two enlarged peaks, 
probably due to a partial LUT re-crystallization during droplets evaporation. 
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This fact could explain the presence of the small needles, as seen in Figure 
IV.17. The diffractograms of all SAA coprecipitates show only PVP halos, 
whereas LUT peaks are not present: all coprecipitates show an amorphous 
structure. This result can be explained by a homogeneous dispersion of LUT 
in the polymer matrix (Aid et al., 2017). 
FT-IR analyses were performed to identify possible interactions between 
LUT and PVP in the composite particles. In Figure IV.21, FT-IR spectra of 
unprocessed LUT and PVP, SAA coprecipitates and physical mixture are 
reported in the range 1750-500 cm-1. 
 
 








PVP spectrum shows a characteristic absorption band at 1653 cm-1, 
corresponding to the stretching vibration of C=O groups, a C-H stretching 
vibration at 2875 cm-1 and a –OH stretching vibration at 3469 cm-1. The 
spectrum of untreated LUT shows characteristic absorption bands at 1656 
cm-1 that suggests the stretching vibration of carbonyl group, at 1166 cm-1 
related to C-O-C stretching vibration and at 1266 cm-1 related to phenolic 
hydroxyl groups bend. The spectrum of the physical mixture LUT/PVP 
shows the superimposition of the characteristic bands of LUT and PVP. All 
SAA coprecipitates show the presence of hydrogen bonding between the two 
compounds that have a significant influence on peak shape and intensities. 
The interaction between the two compounds produces the shift of the LUT 
peak located at 1036 cm-1 to lower frequencies. Also, the absorption peak at 
1377 cm-1 in PVP spectrum is shifted to 1371 and 1361 cm-1 in LUT/PVP 
spectrum, respectively for R=1/8 and R=1/4, due to another interaction 
between drug and polymer. Furthermore, there are two peaks broadening 
towards 1600 and 1260 cm-1 in the composite particles spectra, more evident 
at R=1/4. These two changes in LUT/PVP spectrum can be explained by the 
breakdown of the intermolecular hydrogen bonding of LUT and the creation 
of new hydrogen bonds between PVP and LUT. Therefore, higher R values 
lead to more hydrogen bonds and to more marked shifts of characteristic 
peaks of LUT.  
 
DSC analyses (Figure IV.22) were performed to determine the changes in 
thermal behavior of drug and polymer in the coprecipitates LUT-PVP. These 
thermograms confirmed that untreated LUT is crystalline and its fusion 
temperature is 340°C. Furthermore, LUT is a hygroscopic compound, as 
proved by the broad endothermic peak ranging from 90-100°C. Unprocessed 
PVP shows a broad endothermic peak ranging between 50-130°C, due to the 
loss of water; as previously demonstrated, it is an amorphous polymer. SAA 
processed LUT-PVP particles do not present any crystalline peak and their 
DSC thermograms are very similar to the one of PVP. According to the 
literature, when only one glass transition temperature, Tg, is observed, a one-
phase solid powder is obtained (Aid et al., 2017). 
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Figure IV.22 DSC analyses of untreated materials and SAA coprecipitates. 
 
Summarizing, all solid state analyses suggest that drug is homogeneously 
dispersed in the PVP matrix, since each particle is the result of the drying of 
a droplet containing LUT and PVP. The success of SAA coprecipitation in 
inhibiting the formation of crystals is the mutual influence of two factors: a 
favorable interaction between drug and carrier, and the use of low 
temperatures in the precipitator that reduce crystallization rates of 
precipitates. In particular, the interactions drug-carrier play a role in 
stabilizing the composite particles, due to the hydrogen bonding and the 
steric hindrance that restrict the molecular mobility of LUT molecules. 
Therefore, the ability of PVP to inhibit crystallization can be linked to its Tg 
and its capacity to interact with the drug (Baghel et al., 2016). 
 
LUT loading efficiency and dissolution tests 
The loading efficiency of LUT in the SAA particles was measured by 
UV-vis analyses and was over 99% for all weight ratios: an effective loading 
ranging between 11.1% (for R=1/8) and 20% (for R=1/4) of LUT with 
respect to the mass of polymer in the SAA particles, is obtained. This result 
is not surprising, since the mechanism of SAA microparticles formation is 
atomization of the solution and droplets drying; therefore, the components of 
the starting solution tend to remain together in the final particles. This result 
is particularly relevant since practically all LUT is entrapped in the final 
product; perhaps, the interactions LUT-PVP, evidenced in the previous 
analysis, play a role in further stabilizing the composite particles. Therefore, 
all analytical indications converge towards the conclusion that coprecipitated 
submicroparticles LUT-PVP were efficiently produced. Dissolution tests 
were performed to evaluate the improvement of the dissolution rate of LUT 




Figure IV.23 Dissolution profiles of LUT in PBS at 37°C and pH 7.4. 
 
It is possible to observe that untreated LUT and the physical mixture at 
R=1/4 show a complete dissolution time in about 70 and 57 hours, 
respectively. The coprecipitate produced at R=1/8 w/w totally dissolves in 
17 hours; whereas, the one produced at R=1/4 w/w completely dissolves in 
about 8 hours: 9 times faster than untreated LUT. 
The dissolution rate of SAA produced microparticles increases with the 
increase of drug/polymer weight ratio and all SAA coprecipitates show a 
faster release than the ones of untreated LUT. This result confirms that drug 
bioavailability is influenced by several factors, like reduction of particle size, 
morphology and solid state of material (Adami et al., 2017a, Martín and 
Cocero, 2008). Increasing the drug/polymer weight ratio, larger drug release 
rates are obtained. This trend seems unusual when compared to other 
coprecipitated systems tested by SAA, in which the dissolution rate increases 
when the relative quantity of polymer decreases (Adami et al., 2017a). This 
behavior was expected also in this case, since PVP is highly water soluble 
and at higher polymer contents, smaller LUT nanoparticles should be formed 
inside the coprecipitate. Several parameters usually influence drug release 
from coprecipitates. Our hypothesis, to explain the trend of LUT-PVP 
dissolution behavior, is that the main role is taken by the interactions 
between the two compounds that reduce the dissolution rate of PVP and, 
consequently, the release rate of LUT is slower in the liquid medium. These 
results were expected since the reduced sizes of LUT that is uniformly 
dispersed in PVP microparticles, as demonstrated by the solid state analyses. 
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IV.4.3 Conclusions on LUT-PVP system 
This work showed that it is possible to improve LUT dissolution rate and 
bioavailability preparing by SAA process LUT-PVP submicroparticles: the 
corresponding dissolution rate was up to 9 times faster than untreated drug. 
Dissolution time was reduced from the scale of days to only several hours.  
An unexpected result was that small quantities of PVP were enough to 
obtain excellent results for coprecipitation and for the increase of release 
rate. The formation of bonds LUT-PVP gaves an account of the apparently 
anomalous trend of the drug release rate curves, showing that LUT release 
rate increased reducing the PVP percentage used in the coprecipitate, up to 
the largest drug/polymer ratio tested in this work (R=1/4 w/w). 
 
 
IV.5 Fluorescent microspheres based on DEX, FITC and LUT 
Polysaccharide-based microparticles are used as loading or conjugating 
imaging and therapeutic agents (Saravanakumar et al., 2012, Swierczewska 
et al., 2016), to provide a faster, less invasive and accurate way to obtain 
information about the state of biological systems, to locate tumors and to 
track drug delivery, its biodistribution and efficacy in the body. DEX is a 
polysaccharide synthesized from sucrose by lactic-acid bacteria (as 
Leuconostoc mesenteroides and Streptococcus mutans) (Wasiak et al., 2016). 
It is a very simple substance since it is a combination of glucose molecules; 
but, it is widely used in the medical field for several aspects: reduction of 
blood viscosity, prevention of blood clots. Fluorescein-isothiocyanate-
dextran (FITC-DEX) (de Belder and Granath, 1973) allows to study the 
permeability changes of cells using an electron microscope (Thorball, 1981) 
and used to evidence cellular damages (Dvorak et al., 1988) and to monitor 
and guide the surgical resection of tumors in vivo (Piquer et al., 2014). 
Furthermore, DEX is FDA approved and its application as drug delivery 
system is used to improve bioavailability of poorly water soluble compounds 
and to increase the half-life of therapeutic substances (Mehvar, 2000). 
Among the several applications, the production of targeted delivery systems 
consisting in DEX and anticancer drug (for example doxorubicin and 
paclitaxel) for solid tumor therapy are the most relevant (Wasiak et al., 2016, 
Sagnella et al., 2014). The combination of the potential of DEX as drug 
delivery agent for anticancer drugs and of DEX-FITC as probe for 
permeability studies can lead to the production of a fluorescent carrier, to 
detect the drug transport in in vitro and in vivo. The addition of FITC to a 
system carrier+active principle allows to follow the distribution of the 
fluorescent materials and to track the drug delivery inside the cells (Feng et 
al., 2010).  
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In the last decades, researchers are increasingly focusing on the 
development of formulations based on natural compounds found in 
vegetables, fruits and plant extracts that have several pharmacological 
properties: antioxidant, anti-inflammatory, antiseptic, antibiotic (Amin et al., 
2009). Compounds of natural origin can lead to new, innovative therapeutic 
agents for cancer, since they may benefit in cancer prevention and promote 
human health without recognizable side effects. Therefore, recent studies are 
shifting their attention from chemically synthetic drugs to natural ones 
(Amin et al., 2009). As previous reported, LUT is a flavon that exists in 
many types of vegetables (broccoli, onion leaves, carrots peppers); it 
exhibits a wide variety of pharmacological properties ranging from anti-
inflammation to anticancer effects. Researchers have shown that LUT has 
antitumor activities in several types of cancer, such as lung cancer, head and 
neck cancer, prostate, breast, colon, liver and skin cancer (Sulaiman, 2015).  
The aim of this work (Di Capua et al., 2017a) was to develop for the first 
time by SAA a fluorescent system that acts as a carrier for an active 
molecule and, at the same time, as a probe to identify the distribution and 
permeability of drug in cells. Two different approaches are used to produce 
fluorescent DEX. The first one consists of dissolving DEX and FITC in a 
solution that is processed by SAA. The second method is based on a labeling 
technique that leads to the production of a DEX chemical conjugated to 
FITC as described in details in Chapter II, then micronized by SAA to 
produce microparticles. To confirm that there is no interference of FTIC on 
the system carrier-drug and to study the effectiveness of this fluorescent 
system, LUT was chosen as model drug. 
 
IV.5.1 Experimental results 
In this work, a mixture water:ethanol was used as liquid solvent, because 
LUT is a poorly water soluble compound, whereas DEX is soluble in 
aqueous solutions. Solubility of LUT and DEX was measured in different 
water/ethanol solutions; these tests indicated that DEX did not dissolve in 
aqueous mixtures containing more than ~35% (v/v) of ethanol (Antoniou et 
al., 2010). The best compromise was a mixture water:ethanol (70:30 v/v). 
 
Production of LUT/DEX+FITC microparticles 
DEX+FITC (0.01 mg/mL) micronization was performed at the following 
process conditions: mixture water:ethanol (70:30 v/v), injection pressure 92 
bar, saturator temperature 85°C and a precipitator temperature 100°C. The 
CO2 mass flow rate was set at 7.3 g/min and the one of liquid solvent at 4 
mL/min, to obtain a mass flow ratio (GLR, gas to liquid ratio) of 1.8. The 
effect of the concentration of DEX in water:ethanol (70:30 v/v) mixtures 
from 5 to 20 mg/mL was studied. SAA processing was successful; an 
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example of FESEM image of DEX+FITC (DF) particles and the PSDs in 
terms of particle percentages are reported in Figure IV.24. 
Spherical and non-coalescing microparticles were obtained, in the 
submicrometric range. When a concentration of 8 mg/mL was used, well 
separated microparticles with a mean diameter of about 0.4 µm were 
obtained, as shown in Figure IV.24a. Comparing the PSDs of the 
microparticles obtained at 5, 8 and 20 mg/mL, it was observed that, 
increasing the concentration, the mean diameter increased and the PSDs 
enlarged (Figure IV.24b). PSDs value related to these three different 
concentrations are summarized in Table IV.9.  
 
    
Figure IV.24 a) FESEM image of DF particles at concentration of 8 
mg/mL; b) PSDs of DF particles obtained at different DEX concentration. 
 
Table IV.9 Composition and PSD data of LUT/DEX microparticles 
produced by SAA (CFITC: FITC concentration; Ctot: total concentration; 
CDEX: carrier concentration; CLUT: LUT concentration; R= LUT/DEX w/w, 
wLUT= LUT weight, wDEX = DEX weight; DF: DEX+FITC; DF*: DEX 
















DF01 0.01 - 5 - 0.11 0.16 0.77 
DF02 0.01 - 8 - 0.22 0.34 0.81 
DF03 0.01 - 20 - 0.25 0.44 0.90 
DF* labeled - 20 - 0.24 0.42 0.88 
DLF01 0.01 1/8 10 1.25 0.27 0.41 0.76 
DLF02 0.01 1/8 8 1.00 0.21 0.32 0.68 
DLF03 0.01 1/8 5 0.70 0.12 0.20 0.41 
DLF04 0.01 1/10 8 0.80 0.24 0.35 0.77 
DLF05 0.01 1/6 8 1.33 0.20 0.23 0.63 
DFL* labeled 1/6 8 1.33 0.19 0.24 0.64 
Chapter IV 
88 
This behavior is commonly observed in SAA, since increasing the solute 
concentration, the viscosity of solution increases and larger droplets are 
formed at the exit of the injector, with the consequent production of larger 
particles. 
SAA experiments on LUT alone, using water:ethanol as solvent, were not 
successful: LUT precipitated as irregular particles (figure not reported). LUT 
shows a fast crystallization rate; probably, using a water:ethanol as solvent 
and a temperature of 100°C, the crystallization and agglomeration of LUT 
was very fast. A similar result was obtained in a previous work using pure 
ethanol (Di Capua et al., 2017b). Coprecipitation experiments were 
performed dissolving DEX, FITC and LUT in the water:ethanol mixture, at 
LUT/DEX weight ratio R=1/8 (w/w) and at three different polymer 
concentrations: 5, 8 and 10 mg/mL. In all cases, spherical and well-separated 
microparticles were produced; an exemplificative FESEM image is reported 
in Figure IV.25a. PSDs are reported and compared in Figure IV.25b. 
 
    
Figure IV.25 FESEM images of LUT/DEX+FITC coprecipitates at R=1/8 
w/w and DEX concentration of 10 mg/mL; PSDs of LUT/DEX R=1/8 w/w 
coprecipitates obtained at different DEX concentration. 
 
It is possible to observe that, according to the previous results on DEX 
alone, decreasing DEX concentration from 10 to 5 mg/mL, the mean 
diameter of particles reduces from 0.4 to 0.2 μm. 
Coprecipitated microparticles produced at DEX concentration of 8 
mg/mL (R=1/8) showed a sharp PSD and a mean diameter 0.3 μm, that can 
satisfy the desired target of producing micro/nanoparticles for biomedical 
applications. Therefore, this concentration was used for all the further 
experiments in this work. Three different LUT/DEX mass ratios (1/6, 1/8 
and 1/10) at DEX concentration of 8 mg/mL (and FITC concentration of 
0.01 mg/mL) were also selected to perform SAA tests. In Table IV.9, 
concentration and PSD values are summarized. Examples of FESEM images 
of LUT/DEX samples are shown in Figure IV.26. 
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Figure IV.26 FESEM images of coprecipitates produced at a) R=1/6 
(DLF05), b) R=1/6 (DFL*, using DEX labeled FITC). 
 
Again, SAA produced particles are spherical and well separated and the 
mean size is influenced by the drug-polymer weight ratio (R): when R is 
increased, the mean size of particles slightly decreases, as shown in Figure 
IV.27. SAA micronization tests were also performed using a DEX labeled 
with FITC (DF*) in a mixture of water:ethanol at 20 mg/mL. The particles 
produced were perfectly spherical and comparable to those obtained in the 
case of DEX not labeled with FITC. The PSD values are reported in Table 
IV.9. Then, a mixture containing DEX-FITC conjugate and LUT at R=1/6 
(test DFL*) weight ratio was processed producing spherical and well-
separated particles, as shown in Figure IV.26b. The PSD of DFL* particles 
is perfectly comparable to that of DLF05 (Figure IV.27): this fact means that 
chemical conjugation between DEX and FITC does not influence particle 
size and morphology. 
 
 
Figure IV.27 PSDs of LUT/DEX micronized by SAA, in terms of number of 




Fluorescence microscope and FITC content 
FM analyses of SAA processed coprecipitates were performed to study 
FITC dispersion in the powders and to verify the applicability of SAA 
microparticles as polymeric probe. Some exemplificative FM images are 
reported in Figure IV.28, where the blue fluorescence indicates the presence 
of FITC. The analyses indicated a homogenous FITC distribution into the 
polysaccharide matrix for all SAA coprecipitates. To visualize the 
fluorescence of SAA powders, an ultraviolet lamp was used. SAA 
coprecipitates containing DEX, LUT and FITC are yellow; when these 
powders are struck by ultraviolet rays, they produce a bright fluorescence. 
An exemplificative photograph of this behavior is reported in Figure IV.29. 
 
    
Figure IV.28 FM images related to a) R=1/6 DLF05; b) R=1/6 DFL*, test 
using DEX labeled with FITC. 
 
    
Figure IV.29 a) SAA powder under visible light; b) SAA powder under UV 
lamp. 
 
To obtain quantitative information about the FITC amount in the 
produced powders, UV-vis analyses were performed. All SAA coprecipitates 
obtained using non-linked FITC showed a FITC loading efficiency ranging 
between 60 and 80%. Using the same analytical technique on the 
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coprecipitate DFL* produced, instead, using DEX labeled FITC, it was 
possible to confirm that all FITC labeled DEX before SAA test is present 
after the process: therefore SAA process does not influence chemical 
conjugation between FITC and DEX. 
 
IV.5.2 Characterization of particles 
XRPD analyses were carried out to study the crystallization behavior of 
LUT/DEX; the patterns related to the untreated compounds and SAA 
coprecipitates are shown in Figure IV.30. Untreated DEX and DEX labeled 
FITC are amorphous, as shown by the single halo present in their spectrum. 
Untreated LUT is crystalline, also in the physical mixture (R=1/6), with the 
characteristic peaks of the drug. For all SAA coprecipitates, the spectra are 
similar to the one of DEX, alone showing the halo typical of the 
polysaccharide, it means that all coprecipitated powders are amorphous.  
 
 
Figure IV.30 XRPD spectra: comparison among untreated compound and 
microspheres produced by SAA; *test using DEX labeled FITC+LUT 
(DFL*). 
 
DSC analyses were performed on untreated drug and polymer and on 
SAA coprecipitates, to determine the changes in the thermal behavior of 
LUT and DEX in SAA powders. In Figure IV.31, some spectra are reported. 
LUT thermogram exhibited the profile of a crystalline compound with an 
endothermic peak at 340°C, due to a fusion phenomenon; unprocessed DEX 
shows a large endothermic peak between 50 and 150°C, due to the 
elimination of water. A glass transition of DEX is observed around 220°C 
that indicates no crystalline DEX are present and confirms the amorphous 
structure of the polymer, seen in X-Ray patterns. DEX degradation is noted 
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around 320°C, where a broad endothermic peak is present (Stenekes et al., 
2001, Amin et al., 2015). DEX processed with FITC by SAA has a smaller 
endothermic peak compared to that of untreated DEX and shifted to 305°C, 
probably due to some changes in polysaccharide chains during the 
atomization process. The physical mixture shows two endothermic peaks at 
275 and 312°C, indicating that the drug-polymer mixture generates some 
changes in the thermal behavior. In the thermograms of coprecipitates, the 
same loss of water noted for untreated DEX is observed, furthermore the 
endothermic peaks of DEX and LUT are both present, but shifted to lower 
temperatures and have smaller intensities. It is relevant to note that the 
intensity of the peak related to LUT increases when R increases. The shift of 
these two peaks, associated to the endothermic phenomenon of the loaded 
LUT and of DEX, could be related to the formation of chemical complex 
between the drug and the polysaccharide. 
 
 
Figure IV.31 DSC thermographs related to DEX, LUT and SAA 
coprecipitates; DF: DEX+FITC; * test using DEX labeled FITC (DFL*). 
 
 
This hypothesis is confirmed by FTIR analyses, performed to get 
information about the presence of some specific interactions between the 
drug and the polysaccharide. The spectra for unprocessed materials and SAA 
coprecipitates are shown in Figure IV.32, in the wavenumber range of 
interest (where the characteristic peaks are present). DEX spectrum shows a 
band in the region of 3400 cm-1 that is related to –OH stretching vibration of 
the of the polysaccharide. The band in the region of 2920 cm-1 is attributed 
to C–H stretching vibration and the band in the region of 1642 cm-1 is due to 
carboxyl group. The absorption peak at 906 cm-1 indicates the existence of α-
glycosidic bond. Peaks at 1151 cm-1 are due to vibrations of C–O–C bond 
and glycosidic bridge; the band at 1100 and 1044 cm-1 are due to the C-O 
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bond of glucose (Purama et al., 2009). The spectrum related to physical 
mixture of DEX and FITC (not reported) perfectly overlaps that of DEX. 
Untreated LUT spectrum shows: a broad peak at 3420 cm-1 that is attributed 
to the stretching vibration of the hydroxyl group (-OH); characteristic 
absorption bands at 1656 cm-1, related to the stretching vibration of carbonyl 
group, at 1266 cm-1, due to the bending of the phenolic hydroxyl groups, and 
at 1166 cm-1, related to C-O-C stretching vibration (Lin et al., 2008). In all 
SAA coprecipitates spectra, DEX characteristic bands are confirmed. 
However, some changes with respect to the LUT spectrum are present. For 
example, it is possible to note some adsorption bands at 1656, 1610 and 945 
cm-1 that confirm the presence of LUT in the microparticles; these peaks are 
shifted to lower frequencies compared to those of LUT spectrum; this result 
can be explained by an interaction between the drug and the polysaccharide. 
The smoother peak at (1538-1490 cm-1), compared with LUT spectrum 
(1541-1477 cm-1), reveals another interaction between the two compounds. 
In FTIR studies peak shape and intensities have a great importance to 
understand which kind of interactions is created between compounds. Our 
hypothesis is that DEX and LUT interact each other, leading to the creation 
of new hydrogen bonds between the drug and the polysaccharide; probably 
these interactions could be related to the carbonyl or a hydroxyl group in 
DEX molecule and a –OH group in LUT molecule. This kind of interactions 
has been already observed for LUT-PVP coprecipitated by SAA (Di Capua 
et al., 2017b). These interactions are more evident as higher R values (higher 
LUT content) are considered. The same considerations can be extended for 
the coprecipitate DFL*, where the chemical conjugation DEX-FITC is not 
easily visible, since FITC is labeled on DEX attacking a –OH bond. 
As already observed in previous works, the hydrogen bonding and the 
steric hindrance between the two compounds can allow to restrict the 
molecular mobility of LUT molecules and to provide stability to the system 






Figure IV.32 FTIR spectra of untreated compounds and SAA coprecipitates; 
*test using DEX labeled FITC (DFL*). 
 
LUT loading and dissolution tests 
The amount of LUT for each LUT/DEX weight ratio was measured by 
UV-vis spectroscopy. The loading efficiency ranged between 98.7% and 
100%, with LUT content ranging between 8.9% (for R=1/10) and 14.3% (for 
R=1/6) with respect to the mass of polymer. All the active principle 
processed is practically loaded in the polysaccharide matrix, as it frequently 
occurs during SAA particles formation (Adami et al., 2017a, Di Capua et al., 
2017b), due to the droplets drying mechanism. 
To verify the improvement of LUT dissolution rate when loaded in SAA 
microparticles, LUT release behavior was monitored using a dialysis bag in 
PBS pH 7.4, following the recommendation of US Pharmacopeia. The 
analyses were performed on the untreated compounds (physical mixture of 
DEX, LUT and FITC) and SAA coprecipitates in triplicates. The curves 
practically overlapped, for this reason, standard deviation reported in the 
diagram in Figure IV.33 is very small. 
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Figure IV.33 Release profiles of LUT in PBS at pH 7.4 and 37°C; * test 
using DEX labeled FITC (DFL*). 
 
The dissolution profiles related to the physical mixture and some SAA 
coprecipitates are compared by plotting the percentage of released LUT as a 
function of time. The physical mixture of untreated compounds (R=1/6), 
completely dissolved in 72 hours (3 days). The release of LUT from DEX 
coprecipitates was faster at all R values and was controlled by LUT/DEX 
ratio. The coprecipitates produced at R=1/10 and 1/8 totally dissolved in 12 
and 10 hours respectively; whereas, the one produced at R=1/6 achieve the 
fastest release: the 100% release in about 6 hours. Therefore, in this case the 
dissolution rate of LUT is about 12 times faster than the one of physical 
mixture. The same result was obtained for the coprecipitate (R=1/6*) 
produced using DEX labeled FITC: the dissolution curves overlapped (see 
Figure IV.33). This result confirms that the presence of FITC in the 
coprecipitates does not influence their overall behavior. Increasing the 
drug/polymer ratio, LUT content increases and leads to a larger drug release 
rate; this result is uncommon for SAA coprecipitates (Adami et al., 2017a, 
Liparoti et al., 2013), where the dissolution rate of the drug increases by 
increasing the relative amount of polymer. However, a similar result was 
obtained in a previous work (Di Capua et al., 2017b), where LUT was 
coprecipitated with PVP. Besides the diameter of microparticles, another 
relevant aspect that influences the dissolution rate is related to chemical 
interactions between the compounds, that can control the drug release from 
the polymeric matrix. In case of LUT/DEX coprecipitates, the presence of 
these interactions, evidenced in the FTIR spectra, decreases the dissolution 
rate of DEX and, as a result, LUT release is slower (Di Capua et al., 2017b). 
The effect of LUT is in some way similar to the influence of the charge 
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distribution in weak polyelectrolytes on the formation of hydrogen bond 
(Mella et al., 2015). 
 
IV.5.3 Conclusions on LUT-DEX-FITC system 
Complex multifunctional coprecipitates were successfully produced by 
SAA: microparticles with a mean diameter down to 350 nm were produced, 
formed by DEX, LUT and FITC. The free fluorescent material was 
encapsulated with efficiencies up to 80% and did not influence the overall 
behavior of the powders. SAA process did not affect also the chemical 
conjugation between DEX and FITC. The best results were obtained in 
correspondence of the largest drug/polymer weight ratio tested (R=1/6) with 
an increase of LUT dissolution rate up to 12 times with respect to the 
physical mixture. 
A possible perspective of this work might be to investigate the potential 




IV.6 Improvement of NIF bioavailability 
Nifedipine (NIF) is a 1,4-dihydropyridine calcium channel blocking 
activity with a high photosensitivity and poor solubility in water resulting in 
low and irregular bioavailability. It is indeed a Class II drug in accordance 
with Biopharmaceutics Classification System (BCS) (Khadka et al., 2014). 
When a drug is administered orally, as in the case of NIF, it has to dissolve 
in intestinal fluids, permeate the gut membrane and reach the blood system 
(Baghel et al., 2016). Bioavailability of poorly water soluble drugs that 
undergo dissolution rate-limited gastrointestinal absorption can be improved 
using chemical strategies, such as complexation (Brewster and Loftsson, 
2007, Adeoye et al., 2018, Taupitz et al., 2013) and salt formations, and 
physical ones, such as micronization and drug dispersions in carrier matrix 
(Kogermann et al., 2013). Most of the literature on the improvement of NIF 
bioavailability is based on the production of solid dispersions, for example 
using polyethylene glycol (Emara et al., 2002), mannitol (Zajc et al., 2005), 
poly(vinyl caprolactam-co-vinyl acetate-co-ethylene glycol) (Soulairol et al., 
2015), hydroxypropylmethylcellulose (HPMC) (Cilurzo et al., 2002), 
Eudragit and mesoporous silica from rice husks (Sriamornsak et al., 2016, 
Weerapol et al., 2017) as carriers. β-cyclodextrin, 2-hydroxypropyl-β-
cyclodextrin (HPβCD) (Jagdale et al., 2012, Beig et al., 2013) are instead 
used frequently to produce complexes with NIF.  
Solid dispersions of NIF and mannitol at different concentrations were 
prepared by hot melt method (Zajc et al., 2005); however, no regular 
particles are produced but only crystalline agglomerates up to 200 µm. 
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Soularoil et al (Soulairol et al., 2015) prepared solid dispersions of NIF and 
poly(vinyl caprolactam-co-vinyl acetate-co-ethylene glycol) using spray 
drying technique by dissolving the compounds in ethanol in different weight 
ratios. Irregular and amorphous particles were produced with average 
particle size between 0.8 and 1.7 µm. No interactions between drug and 
polymer were created and an improved dissolution rate compared to original 
NIF was obtained. Cilurzo et al. (Cilurzo et al., 2002) used the same 
technique to prepare NIF-HPMC in different weight ratios using methylene 
chloride:ethanol 90/10 v/v as solvent; however, no particles are showed in 
the work and the organic solvent used is classified as a Class 2 solvent 
(Schlosser et al., 2015, Pacheco et al., 2016) that should be limited in 
pharmaceutical products because of their inherent toxicity. Vippagunta et al. 
(Vippagunta et al., 2002) dispersed NIF (33.3% w/w) in a polymer matrix 
consisting of Pluronic F68 (33.3% w/w) and Gelucire (33.3% w/w) using 
melt method at 70°C. No results in terms of morphology are reported in this 
work; solid state analyses demonstrated that NIF is crystalline in the 
produced particles. Solid dispersions of NIF in Eudragit and mesoporous 
silica from rice husks were investigated by Sriamornsak et al. (Sriamornsak 
et al., 2016) and Weerapol et al. (Weerapol et al., 2017) by dissolving the 
compounds in different weight ratios and with some adsorbents in methylene 
chloride (Class 2); then, the solvent was removed by evaporation. No 
particles but agglomerates were formed in all cases studied. Summarizing, 
the works found in the literature were in part successful in demonstrating the 
improvement of NIF dissolution rate; however, the conventional techniques 
show the well-known drawbacks, such as the use of heavy and toxic organic 
solvents (as methylene chloride) with residual solvents in the produced 
powders, thermal degradation due to high temperatures used, difficulty in 
controlling recrystallization and particle size distribution.  
The aim of this work was the production of solid dispersions of NIF using 
HPβCD as carrier by SAA coprecipitation process, in order to improve NIF 
bioavailability avoiding the use of heavy solvents and the complexation 
steps. HPβCD was successfully precipitated by SAA in previous works, 
using water (Reverchon and Antonacci, 2006b) and a water:ethanol (30:70 
v/v) mixture as solvent (Di Capua et al., 2018), obtaining in both cases 
regular and spherical particles. The coprecipitation experiments for the 
production of NIF-HPβCD particles were performed using ethanol as solvent 
in which NIF and HPβCD are both soluble; however, until now neither of 
them were processed in ethanol by SAA. 
 
IV.6.1 Experimental results 
Preliminary studies were performed processing NIF alone to verify the 
feasibility of SAA process for this drug, investigating three different 
solvents: acetone, methanol and ethanol, since NIF is very soluble in these 
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solvents. Acetone-NIF solutions with concentrations ranging between 10 and 
40 mg/mL were tested by SAA operating the saturator at 75 bar and 40°C 
and the precipitator at 1 bar and 30°C, with a GLR of 3.5. These operative 
conditions were optimized to assure the evaporation of the solvent using two 
vacuum pumps (DVP mod. ZA100P) operating downstream the precipitator 
(Liparoti et al., 2012). Examples of morphologies obtained are shown in 
Figure IV.34. 
 
    
Figure IV.34. FESEM images of NIF micronized by SAA technique, using 
acetone as solvent at: a) 10 mg/mL, b) 40 mg/mL. 
As it is possible to observe, non-regular particles were formed but a 
partial spherical structure is present using low NIF concentration (Figure 
IV.34a). Increasing the amount of NIF dissolved in acetone, instead, some 
agglomerates were produced (Figure IV.34b). Other SAA tests were 
performed using methanol and ethanol: the results were unsatisfactory. 
 
SAA coprecipitation experiments NIF-HPβCD 
NIF coprecipitation experiments were performed using HPβCD, a water 
soluble cyclodextrin selected for its capacity to act as crystallization 
controller of active principles and to improve the bioavailability of some 
active compounds (Di Capua et al., 2017a). The coprecipitation experiments 
were performed in ethanol that was the best compromise since the carrier 
was not soluble in acetone and the drug was not soluble in water. SAA 
operating conditions were: HPβCD concentration in ethanol 10 mg/mL; gas 
to liquid ratio 1.8 (mass based, defined as GLR), injection pressure of about 
80-83 bar, saturator temperature 80°C and precipitation temperature 80°C. 
These conditions were optimized in a set of experiments. 
A first set of SAA tests was carried out to test HPβCD alone in ethanol. 
These experiments were performed operating at a solute concentration of 10 
mg/mL and at the operating conditions previously reported. HPβCD 
precipitated in form of non-coalescing with shrinkage cavities (Figure 
IV.35). 
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Figure IV.35. FESEM image of HPβCD micronized by SAA technique. 
 
This morphology was sometimes observed in the SAA particles (Di 
Capua et al., 2017b, Martin et al., 2013) and can be due to the fragility of the 
solid structure during the drying in the precipitator. This result can be related 
to a series of aspects, such as drying time, shell flexibility, evaporation rate, 
as described and evidenced by the theory of particle formation in spray 
drying (Eslamian et al., 2009), since this process shows many similarities 
with the SAA technique. When a dilute solution is processed, during drying 
a thin layer of solid is formed. This shell can be fragile or flexible and, if the 
drying temperature is high, the solvent evaporation will be very fast and 
particles can deflate. 
In this work, NIF/HPβCD weight ratios 1:2, 1:3, 1:4 and 1:8 w/w were 
proposed. In Table IV.10, a list of some experiments, with the indication of 
particle size distribution values (in terms of volume of particles) are 
summarized. Each experiment was performed in duplicate. The effect of 
NIF/HPβCD weight ratio (R, w/w) on morphology, mean size and particle 
size distribution was investigated. The influence of R on SAA NIF/HPβCD 
particles morphology can be semi-qualitatively observed in Figure IV.36, 
where some examples of particles produced at different R are reported. 
 
Table IV.10 Composition and PSD data of NIF/HPβCD particles produced 
by SAA (R=NIF/HPβCD w/w; CNIF: NIF concentration; Ctot: total 


















#01 1/8 1.25 11.3 0.08 0.14 0.24 >100* 
#02 1/4 2.50 12.5 0.11 0.24 0.48 >100* 
#03 1/3 3.33 13.3 0.15 0.28 0.52 >100* 
#04 1/2 5.00 15.0 0.18 0.37 0.73 >100* 
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Figure IV.36. FESEM images of NIF-HPβCD precipitated, at different 
weight ratios R: a) 1/4, b) 1/2. 
The produced particles at R=1/8 w/w (figure not reported) showed a 
morphology similar to that of SAA HPβCD (reported in Figure IV.35). 
When R increases up to 1/2, more defined spherical particles were produced, 
as shown in Figure IV.36. A comparison of the volumetric PSDs at different 
R are shown in Figure IV.37 and summarized in Table IV.10. The mean size 
of the coprecipitates depended on NIF/HPβCD weight ratio (R): increasing 
the amount of NIF in the injected solution, the mean diameter of the particles 
increases and PSD enlarged. The presence of the drug in solution influenced 
the viscosity and the density of the starting solution, generating larger 
droplets and consequently larger microparticles, during the atomization 
(Adami et al., 2017a). 
 
 
Figure IV.37 Volumetric cumulative particle size distributions of 
NIF/HPβCD, at different weight ratios R. 
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IV.6.2 Characterization of particles 
In order to study the solid state of produced powders X-ray 
diffractometry and IR spectroscopy were performed on untreated compounds 
and SAA particles. X-Ray analyses are reported in Figure IV.38. 
 
 
Figure IV.38 X-Ray spectra of NIF/HPβCD: comparison among raw 
materials and SAA coprecipitated microspheres. 
 
The diffraction pattern of HPβCD shows two broad halos at 11° and 18°, 
thus confirming its amorphous structure. Pure NIF shows characteristic 
peaks at 8.2°, 10.5°, 11.9°, 14.9°, 17.1°C, 20°, 22.6°, 24.7° and 27.2°, 
distinctive of X-ray scattering from crystalline structure. In the diffractogram 
of NIF processed by SAA, not all of these peaks are confirmed, whereas new 
peaks are evidenced at 7.5°, 9.2° and 12.4°: this might to be related to the 
partial loss of crystalline degree or to a recrystallization of NIF in a new 
crystalline form, as described in literature (Chan et al., 2004). The physical 
mixture (R=1/4) shows the most important peaks related to NIF with low 
intensities. The diffractograms related to the SAA produced particles retain 
the pattern of the cyclodextrin with its typical two halos, confirming that the 
coprecipitated powders are amorphous. 
FT-IR spectroscopy allows studying the possible interactions between 
NIF and HPβCD in SAA particles. FT-IR spectra (in the range of 4000-500 
cm-1) of unprocessed NIF and cyclodextrin, and some SAA particles are 





Figure IV.39 FT-IR spectra of NIF/HPβCD: comparison among raw 
materials and SAA coprecipitated microspheres. 
 
The spectrum of untreated NIF indicates a characteristic absorption bands 
–NH stretching at 3330 cm-1 and the absorption bands at 3245.8 and 2996.5 
cm-1 can be assigned to the stretching vibrations of –CH aromatic. At 2844 
cm-1 is evidenced the band related to the stretching of the group –CH3; the 
characteristic band –C=O stretching vibration of ester group is present at 
1686.7 cm-1 whereas those of pyridine group at 1642.8 and 1618.5 cm-1. In 
NIF spectrum, –NH bending (1534 cm-1), -CH bending (1497.9 cm-1), -CN 
symmetrical bending (1309 cm-1), -CO stretching (1224.2 cm-1) are 
highlighted. In the range between 830 and 700 cm-1, -CN stretching of aryl-
nitro group and –CH bending of aromatic group are evidenced (Blajovan and 
Modra, 2013). The FT-IR spectrum of HPβCD indicates a prominent 
absorption bands between 3300 and 3500 cm-1 (for -OH stretching vibration) 
and at 2926 cm-1 (for C–H stretching vibration) and 1159.1 cm-1, 1086 cm-1 
(-CH, -CO stretching vibration) (Lin et al., 2010). In all SAA coprecipitates 
spectra, HPβCD characteristic bands are confirmed; furthermore, the major 
peaks related to NIF are also present in all SAA patterns, such as for 
example at 830 cm-1, 862 cm-1, 1497.9 cm-1, 1534 cm-1. Particularly, 
increasing R the peaks related to NIF characteristic bands are more defined 
and deeper in terms of intensity due to the presence of higher amounts of 
drug. No new or shifted peaks are evidenced in all SAA spectra; therefore, 
the absence of interactions created between carrier and drug is verified. 
 
Loading efficiencies and dissolution tests 
Qualitatively, SAA powders are light yellow in color that is a 
compromise between that of HPβCD (white) and NIF (dark yellow). 
Quantitatively, NIF content in SAA samples for each weight ratio was 
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measured by UV-vis analyses. Table IV.10 summarizes these results. All 
NIF/HPβCD particles show high loading efficiencies, higher than 100%. 
These high values are due to the loss of small quantity of HPβCD into the 
saturator, due to an anti-solvent effect. This result is not new, indeed, this 
effect was previously observed in SAA processing (Martin et al., 2013). 
Indeed, the addition of carbon dioxide can induce the precipitation of small 
quantities of cyclodextrin from the feed solution. 
 
In order to verify the improvement of NIF dissolution rate, dissolution 
tests were performed in PBS pH 7.4 to simulate blood conditions. The drug 
release was monitored by UV-vis spectrophotometer and replicated for each 
sample. Dissolution tests were performed on untreated NIF and SAA 
coprecipitates (Figure IV.40). The untreated NIF dissolved completely in 
about 110 hours (more than 4 days), due to its poor solubility in water. The 
analyses on SAA coprecipitates revealed that the powders of NIF-HPβCD 
show a faster release than raw NIF for all weight ratios tested. The best 
result was obtained for the coprecipitate produced at R=1/8 that shows a 
total dissolution time around 3 times lower than the untreated NIF. The 
powders produced at R=1/4 and at R=1/2 dissolved completely in about 
twice times faster than raw drug. Furthermore, the dissolution rate was 
controlled by NIF/HPβCD ratio: decreasing drug/cyclodextrin mass ratio, 











This result is common for SAA coprecipitates produced at fixed carrier 
concentration: the dissolution rate of the drug increases by increasing the 
relative quantity of carrier. The drug bioavailability is indeed influenced by 
several aspects, as explained in literature: particle size, solid state, chemical 
interactions between compounds (Adami et al., 2017a, Di Capua et al., 
2017a, Di Capua et al., 2017b, Adami et al., 2017b). These results are 
consistent with the literature: by reducing the particle size and the efficient 
dispersion of NIF in the cyclodextrin, an enhanced dissolution rate resulted 
(DiNunzio et al., 2008).  
 
IV.6.3 Conclusions on HPβCD-NIF system 
SAA process demonstrated to be very efficient in the entrapment (up to 
100%) of NIF in the cyclodextrin selected as carrier, obtaining more regular 
and spherical particles by increasing NIF weight percentage in the solution 
injected. The dissolution rate of NIF related to the SAA produced particles 
was successfully enhanced up to 3 times faster for the 1/8 weight ratio when 
compared with the physical mixture. Furthermore, NIF/HPβCD mass ratio 
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Nowadays, a significant interest in incorporating several kinds of 
micronutrients into functional food and beverage products to benefit human 
health and wellness through diet. These bioactive compounds include 
vitamins, polyphenols, antioxidants, carotenoids, flavors, prebiotics; most of 
them are essential for human wellbeing (such as vitamins), whereas other 
substances derived from food sources provide health benefits in addition to 
their diet (nutraceuticals) (Joye et al., 2014, Handford et al., 2014). These 
compounds are usually labile molecules, highly affected by light, oxygen, 
heat; they cannot be incorporated into commercial food products in their 
pure form due to their low solubility in oil and/or water and to their easy 
physical and chemical degradation during food processing, transport or 
preparation. Therefore, the microencapsulation can be useful tool to improve 
the delivery of bioactive compounds into food (Joye et al., 2014, Champagne 
and Fustier, 2007) and overcome all limitations. Different delivery systems 
may be based on food grade biopolymers that include polyelectrolyte 
complexes, polymer particles and hydrogel particles. 
The aim of this part of work was to test for the first time the applicability 
of SAA process in the incorporation of bioactive compounds in polymeric 
matrices able to stabilize and protect the bioactive compound from 
environmental conditions and to enhance their bioavailability (Di Capua et 
al., 2018, Joye and McClements, 2013, Champagne and Fustier, 2007). In 
particular, investigations and studies were performed on beta-carotene and 
an ethanolic extract from propolis. Two carriers were used in these 





Polyvinylpyrrolidone (PVP, Mw: 10,000), ethanol (EtOH, purity 99.9%), 
acetone (Ac, purity 99.8%), Trolox and 2,2-Diphenyl-1-picrylhydrazyl 
(DPPH), β-carotene (BC, purity >93%) were supplied by Sigma Aldrich 
(Italy). Acros Organic (Belgium) provided Hydroxypropyl-β-cyclodextrin 
(HPβCD, 97%). A propolis sample is an ethanolic extract of propolis (EEP) 
and was purchased from a local beekeeper from the center of Chile; 
specifically located in northern part of the Valparaiso region, and was 
collected from the beehive in 2015. Sodium carbonate, Gallic Acid and 
Folin-Ciocalteu reagent were purchased from Merck Millipore (Darmstadt, 
Germany). Carbon dioxide (CO2, 99.9%) was purchased by Morland Group 




V.2 Stabilization and protection of Chilean propolis 
Propolis is a natural resinous mixture collected by honeybees from plant 
resins, leaves, buds and barks. Propolis mainly consists of resin, vegetable 
balsam, essential oils, waxes, pollen; it appears as a hard and fragile material 
at room temperature and it becomes gummy and very sticky when heated. 
The composition of propolis depends on the geographic origin and from the 
vegetation of the area in which bees live and feed (Wagh, 2013). Therefore, 
different kinds of propolis are present all over the world, from Venezuela, 
Brazil, Chile, Bulgaria, Italy, Argentina, Egypt, etc; each propolis is 
chemically different and has specific properties and applications (Russo et 
al., 2004). For thousands of years, it has been largely used in traditional 
medicine: researchers demonstrated the great pharmacological potential of 
propolis in many fields: it can be used as antimicrobial, anti-inflammatory, 
antiviral, antioxidant, antibacterial, antiseptic, antibiotic and anti-
carcinogenic; it is used also in cosmetic and food industries (Wagh, 2013, 
Russo et al., 2004, Krol et al., 2013, Khurshid et al., 2017). The major 
properties of propolis have to be attributed to its polyphenol content.  
Several procedures have been used to extract the bioactive components of 
propolis and to remove compounds such as waxes and hive detritus, using 
conventional techniques, such as maceration, ultrasonic extraction, 
microwave assisted extraction (Trusheva et al., 2007) and supercritical fluid 
extraction and fractionation (Machado et al., 2015, Paviani et al., 2012, 
Biscaia and Ferreira, 2009, De Zordi et al., 2014). The application of 
propolis extracts as a food ingredient or in the cosmetic and pharmaceutical 
industries is limited by their strong and unpleasant taste and aroma, and 
alcohol residues in the case of conventional extraction techniques. Propolis 
encapsulation can be an option to overcome these negative aspects, 
succeeding at the same time to protect bioactivity against oxidation of active 
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compounds. Encapsulation and dispersion in a water soluble matrix allow to 
increase propolis bioavailability in pharmaceutical formulations (Bruschi et 
al., 2003). Some several conventional processes have been proposed for this 
purpose: spray drying (Bruschi et al., 2003, Busch et al., 2017), 
emulsion/evaporation solvent (de Souza Ferreira et al., 2014), coacervation 
(Nori et al., 2011), inclusion complexation (Kalogeropoulos et al., 2009, 
Rocha et al., 2012), nanoprecipitation (do Nascimento et al., 2016). 
Busch et al. (2017) (Busch et al., 2017) encapsulated an Argentine 
alcohol free propolis in different maltodextrin matrices using spray drying, 
with production yields around 65%. The spray dried powders showed 
deformed spherical shape, due to the shrinkage of the particles during the 
drying process, with an encapsulation degree of quercetin and cinnamic acid 
of 40%. A high antioxidant activity was achieved, with a polyphenol 
encapsulation of around 89%. Kalogeropoulos et al. (Kalogeropoulos et al., 
2009) proposed the inclusion of propolis ethanol extract in β-cyclodextrin 
(βCD) cavity by sonication of propolis suspensions in aqueous solution 
containing βCD, followed by filtration and freeze-drying. Encapsulation 
efficiencies of flavonoids were around 4 and 10%, whereas encapsulation 
yield of polyphenols ranges between 3 and 20%. The inclusion complex of 
Brazilian propolis with HPβCD was prepared by Rocha et al. (Rocha et al., 
2012). Amorphous complexes were obtained with low antioxidant activity 
compared to the extract, due to the loss of phenolic compounds that were not 
encapsulated in the HPβCD. Do Nascimento et al. (do Nascimento et al., 
2016) developed polymeric nanoparticles loaded with Brazilian propolis 
extract with a combination of poly-ε-caprolactone and pluronic using 
nanoprecipitation method. Produced dried particles were irregular and 
coalescent, with size ranging between 200 and 960 nm. The mean 
encapsulation efficiency of flavonoids was 75% and the DPPH studies 
demonstrated a high antioxidant activity. 
SCF based techniques have been proposed as a successful alternative to 
conventional processes in several fields, such as extraction and fractionation 
(Machado et al., 2015, Paviani et al., 2012, Biscaia and Ferreira, 2009, De 
Zordi et al., 2014, Catchpole et al., 2004) and micronization/encapsulation 
(Wu et al., 2009) of propolis. SC-CO2 extraction of propolis tincture has 
been used by Catchpole et al. (Catchpole et al., 2004) to obtain flavonoids 
and essential oils fraction and to remove high molecular weight components 
by antisolvent precipitation. The process was optimized at laboratory and 
pilot scale, demonstrating a successful scale up and obtaining a flavonoid 
concentration in the ethanolic extract around 25-30%. The best results for 
extraction were obtained using ethanol as co-solvent (Machado et al., 2015) 
(or by supercritical antisolvent fractionation (Catchpole et al., 2004). Wu et 
al. (Wu et al., 2009) and Yang et al. (Yang et al., 2014) adopted SAS process 
to micronize propolis and to encapsulate it in polyethylene glycol, 
respectively. They obtained sticky irregular particles. Therefore, the 
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coprecipitation was substantially unsuccessful. No analyses on total 
polyphenol content were performed. In conclusion, the works found in the 
literature demonstrated the feasibility of propolis processing by SC-CO2, but 
irregular morphologies and agglomerates were produced that can hinder the 
practical (industrial) application of the products in the case of coprecipitates. 
Therefore, in this work (Di Capua et al., 2018) in collaboration with 
Chilean Institute of Fraunhofer, propolis coprecipitation was attempted by 
SAA to assess the feasibility and efficiency of the process to load and protect 
phenolic compounds contained in a propolis ethanolic extract. Experiments 
were carried using HPβCD and PVP as carriers, with the aim to obtain 
micrometric particles, to prevent oxidation and to improve its bioavailability.  
 
 
V.2.1 Experimental results 
The propolis solution used for the experiments was a mother tincture of 
water:ethanol 30:70 (v/v) that is the typical preservation technique for 
propolis in the Chilean area. HPβCD and PVP were used as carrier; they are 
selected based on their suitable chemical and physical properties, including 
good solubility in the water:ethanol 30:70 (v/v) solution used in this work, 
possible protection ability, possible enhancement of the bioavailability of 
bioactive compounds (Kanaze et al., 2010, Jun et al., 2007). 
These two carriers were successfully precipitated by SAA in previous 
works: HPβCD from water (Reverchon and Antonacci, 2006) and PVP from 
ethanol, water, and mixtures of water/acetone (Liparoti et al., 2015); but, 
they were never processed in a water:ethanol 30:70 (v/v) solution that is 
required in this case since the starting material is present in this solution. 
Therefore, a first set of experiments was performed testing each carrier 
alone, using a solute concentration of 20 mg/mL for each carrier. To assure 
large solubility of CO2 in the liquid solution (Adami et al., 2017a, Di Capua 
et al., 2017b, Liparoti et al., 2013), the process conditions used were: 
pressure of about 90 bar and temperature of 80°C in the saturator, 
temperature of 90°C in the precipitation vessel; CO2 mass flow rate was set 
at 9 g/min and the one of liquid solvent at 5 g/min, to obtain a mass flow 
ratio (GLR, gas to liquid ratio) of 1.8. HPβCD and PVP precipitated in form 
of non-coalescing, regular spheres (Figure V.1). 
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Figure V.1 FESEM images related to a) HPβCD and b) PVP, micronized by 
SAA alone at 20 mg/mL in water:ethanol 30:70 (v/v) solution. 
 
A simple representation of the whole process of coprecipitation and SAA 
precipitator with the aim to give an overview of the whole experimental 
procedure is reported in Figure V.2. 
 
 
Figure V.2 A simple representation of the whole process and SAA 
precipitator. 
 
Table V.1 reports a list of the coprecipitation experiments performed to 
study the effect of the total concentration and of the EEP/carrier mass ratio 
(R, w/w) for both carriers investigated, with the indications of 
concentration, and PSD values (in terms of number of particles) expressed as 







Table V.1 Composition and PSDs data of EEP-carrier microparticles 
produced by SAA (R=EPP/carrier w/w; Ctot: total concentration; CEEP: EEP 

















   HPβCD     
#01 1/2 30 10 20 --- --- --- 
#02 1/3  7 23 0.21 0.37 1.03 
#03 1/5  5 25 0.20 0.28 0.80 
#04 1/8  3 27 0.14 0.20 0.71 
#05 1/5 60 10 50 0.27 0.44 1.31 
   PVP     
#06 1/2 30 10 20 --- --- --- 
#07 1/3  7 23 0.34 0.50 1.26 
#08 1/5  5 25 0.32 0.43 1.11 
#09 1/8  3 27 0.16 0.23 0.50 
#10 1/5 60 10 50 0.28 0.41 1.23 
 
 
Effect of EEP/carrier (R, w/w) 
For each carrier, the effect of EEP/carrier ratio (R, w/w) on morphology, 
mean size and particle size distribution was investigated at a total 
concentration of 30 mg/mL in solution. The influence of R on SAA EEP-
HPβCD particles morphology can be semi-qualitatively observed in Figure 
V.3, in which some FESEM images obtained at different R are reported. 
When R=1/2 was processed, coalescing microparticles were observed 
(Figure V.3a); therefore, the powder could not be characterized in terms of 
PSD. At the ratio R 1/3 (image not reported) and at the same operating 
process conditions, particles were still partly coalescing. When R was 
decreased down to 1/5 and 1/8, well defined spherical particles were 
produced; Figure V.3b reports, for example a FESEM image of the particles 
obtained at R=1/5. 
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Figure V.3 FESEM images related to SAA test a) #01 (R=1/2), b) #03 
(R=1/5). 
 
A comparison of the PSDs on the basis of number of particles at different 
R are shown in Figure V.4. Increasing the amount of EEP in the injected 
solution, the mean diameter of the particles increases and PSD enlarges 
(Figure V.4 and Table V.1). A possible explanation of the effect of R on 
particle size and distribution can be related to the increase of viscosity of the 
starting solution due to a higher concentration of EEP. Since viscosity is a 
cohesive force, its increase tends to produce larger droplets and consequently 
larger microparticles, during the atomization. 
 
 
Figure V.4 Comparison of PSDs related to EEP-HPβCD particles 







Also PVP was tested, with EEP/PVP mass ratios ranging between 1/2 and 
1/8 at a fixed total concentration of 30 mg/mL. Using PVP as carrier, in the 
case of R=1/2 coalescing microparticles were obtained; consequently, it was 
not possible to evaluate the PSD. Operating at the same operating conditions 
and decreasing R down to 1/3 or lower, well separated and spherical 
particles were produced, as shown in Figure V.5, where FESEM images are 
reported, for R=1/3 and R=1/8, respectively. Lower amounts of PVP 
compared to HPβCD are necessary to obtain regular particles. 
 
   
Figure V.5 FESEM images related to SAA test a) #07 (R=1/3 w/w), b) #09 
(R=1/8 w/w). 
 
PSDs are summarized in Figure V.6 and Table V.1. Also for EEP-PVP 
system, increasing the percentage of EEP in the injected solution, the mean 
diameter of the particles increases and PSD enlarges. Also in this case, 
increasing R, the viscosity of the solution injected increases and larger 
particles are obtained. Looking at the overall results (Table V.1), the effect 
of R on the PS is more pronounced in the system EEP-PVP compared to 
EEP-HPβCD and EEP-PVP particles are slightly larger than those produced 
using HPβCD as carrier at each R tested.  
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Figure V.6 Comparison of PSDs related to EEP-PVP particles precipitated 
at a concentration of 30 mg/mL (tests #07, #08, #09). 
 
Effect of total concentration 
The effect of the total concentration in water:ethanol was investigated for 
both systems at R=1/5, varying the overall concentration (EEP+carrier) 
from 30 to 60 mg/mL (Table V.1). The PSDs in terms of number of particle 
percentage at different concentrations show very similar mean diameters for 
both carriers. However, if the PSD is remeasured in terms of volumetric 
cumulative, the comparison between the results at different concentration are 
more emphasized. Using an overall concentration of 30 mg/mL for the 
system EEP-HPβCD (test #03) and EEP-PVP (test #08), spherical 
microparticles are produced, with a mean diameter in terms of volumetric 
cumulative of about 1 μm and 1.4 μm, respectively. Increasing the 
concentration to 60 mg/mL (test #05 and #10), regular microparticles were 
still obtained, but larger particles were obtained with a mean size of about 
1.7 μm and 1.8 μm. This behavior is commonly observed in SAA powders, 
since increasing the solute concentration, the viscosity of the injected 
solution increases and larger droplets are formed at the exit of the nozzle, 
with the consequent formation of larger microspheres. 
Particles of EEP-PVP are larger than those produced in the case of EEP-
HPβCD; whereas the effect of the overall concentration on PSD is less 






V.2.2 Characterization of particles 
Differential Scanning Calorimetry (DSC) and X-Ray analyses were 
performed on unprocessed materials and on SAA processed EEP-carrier, to 
evaluate potential changes in the thermal and the crystallization behavior of 
EEP and the carriers in the coprecipitates, respectively. DSC thermograms of 
both system are reported in Figure V.7. DSC thermogram of the unprocessed 
EEP show different endothermic phenomena at temperatures of 85, 95, 102 
and 125°C (do Nascimento et al., 2016). Broad endothermic peaks ranging 
between 85 and 102°C are due to the water loss, whereas the other 
endothermic peaks can be related to the melting of phenolic compounds 
(several compounds) that are present in the EEP. DSC of untreated HPβCD 
reveals that the carrier is amorphous with a broad endothermic peak ranging 
from 40 to 100°C, related to water loss. Thermal decomposition occurs after 
300°C. As already reported in previous works, PVP is an amorphous and 
hygroscopic polymer. The thermal profiles of SAA EEP-HPβCD ans SAA 
EEP-PVP particles are close to that of pure HPβCD and PVP, respectively: 
these curves reveal only the broad endothermic peak associated with the 
release of water from the samples. The absence of melting peaks suggests 
that EEP-HPβCD and EEP-PVP coprecipitates are in an amorphous and 
homogeneous solid state (Aid et al., 2017).  





Figure V.7 DSC analyses of a) HPβCD, EEP and EEP-HPβCD 
coprecipitates b) PVP, EEP and EEP-PVP coprecipitates. 
 
 
A further supporting indication was obtained from the powder X-Ray 






Figure V.8 XPRD related to a) HPβCD and EEP-HPβCD coprecipitates b) 
PVP and EEP-PVP coprecipitates. 
 
Pure EEP was not tested by this technique because of its status: EEP is in 
form of concentrated slurry and becomes very sticky when heated. Untreated 
HPβCD shows an amorphous structure: in the pattern, two broad peaks 
around 11.7° and 18.8° are identified. SAA EEP-HPβCD coprecipitates have 
only the broad peaks related to the carrier: this fact suggests that propolis is 
finely dispersed in the HPβCD matrix. A similar result was observed in 
Figure V.8b for EEP-PVP produced microparticles: also in this case, a 
homogeneous dispersion of the EEP in polymer matrix was obtained.  
Summarizing, all solid state analyses suggest that EEP is homogeneously 
dispersed in the two matrices used for coprecipitation tests. The success of 
SAA coprecipitation in inhibiting the formation of crystals is due to the use 
of low temperatures in the precipitator, that reduce crystallization rates of 
precipitates, and the production of a one-phase dispersion (Aid et al., 2017) 
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EEP-carrier, related to the glass transition temperatures of PVP and HPβCD 
(Baghel et al., 2016). 
 
V.2.3 Antioxidant activity 
The antioxidant activity of coprecipitates obtained by SAA was studied 
using as reference the total concentration of polyphenols (expressed in mg of 
Gallic Acid Equivalents (GAE) per gram of powder) and DPPH free radical 
scavenging activity, as described in Chapter II (equation (2)). DPPH assay is 
widely used to measure the ability of the particles to act as free radical 
scavengers; this method is fast, easy and reliable since it does not require a 
special reaction and device. All results are summarized in Table V.2. 
 
 
Table V.2 Antioxidant activity of propolis coprecipitates: total polyphenol 
content; scavenging activity (IC50) by DPPH method (R: EEP/carrier w/w; 
















#01 1/2 33.3 66.7 99.7±6.3 100.0 17.2±2.8 
#02 1/3 25.0 75.0 71.2±7.3 98.6 19.0±1.3 
#03 1/5 16.7 83.3 47.6±7.2 98.4 38.8±0.3 
#04 1/8 11.1 88.9 32.0±7.2 98.7 56.6±0.3 
PVP 
#06 1/2 33.3 66.7 91.3±6.0 93.6 17.3±1.0 
#07 1/3 25.0 75.0 68.4±7.7 96.0 25.2±0.4 
#08 1/5 16.7 83.3 43.0±7.8 87.9 30.2±1.0 
#09 1/8 11.1 88.9 29.3±8.1 90.2 67.2±0.3 
 
 
Total polyphenol content increases in SAA particles as the amount of 
EEP in the starting solution, that corresponds to a higher EEP-to-carrier 
mass ratio increases. Polyphenol-rich particles are obtained for both carrier 
used and their loading efficiency is calculated as the percentage of total 
polyphenol in the dried powder compared to the total polyphenol in EEP 
(Table V.2). Total polyphenol content reaches values around 100 and 96.0% 
for HPβCD coprecipitates and for PVP coprecipitates, respectively, 
therefore, the encapsulation efficiency in SAA particles is very high, 
confirming that the SAA coprecipitation mechanism, based on droplet 
drying, allows the effective coprecipitation and preservation of the active 
principles contained in the native EEP. SAA demonstrated to be an 
alternative technique to overcome the results obtained using conventional 
processes. The homogeneous dispersion of EEP in the two matrices made by 
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SAA process, indeed, improve the quality of powders obtaining an highest 
polyphenol loading efficiency up to 30 times larger than those reported in 
literature by Kalogeropoulos et al. (Kalogeropoulos et al., 2009). 
In Table V.2, DPPH results are summarized and expressed as the half 
maximum inhibitory concentration of DPPH radicals (IC50), in µg/mL. The 
antioxidant activity obviously increases with EEP content in the starting 
solution. Results suggest that there are no significant differences in the 
inhibition of radicals by the particles obtained with both carriers. The IC50 
values of free radical scavenging activity ranged between 56.6 and 17.2 
µg/mL for HPβCD and 67.2 and 17.3 µg/mL for PVP; whereas, the IC50 of 
EEP alone is 17.1 µg/mL. A lower IC50 means a higher free radical 
scavenging activity of the compounds. For both systems studied, the best 
results were obtained in the case of EEP-carrier at R=1/2 w/w (tests #01 and 
#06), where IC50 values are close to the one of EEP alone. The homogeneous 
dispersion of EEP in the two matrixes provides the retention of polyphenols 
in the coprecipitates and both HPβCD and PVP are good carriers to preserve 
the antioxidant properties. They can inhibit the crystallization and reduce the 
chemical degradation rate of the active ingredient, since the areas of EEP 
exposed to the external environment are reduced in SAA particles, thereby 
contributing to increase the shelf life of the loaded EEP. It is known in 
literature, that the entrapment in a matrix allows to stabilize the active 
compounds because the carrier acts as a physical barrier for oxygen and 
small molecules inhibiting chemical and enzymatic degradation; 
consequently, the shelf life of the loaded products could be prolonged (Wang 
et al., 2009, Reksamunandar et al., 2017, Machado et al., 2018). In case of 
EEP, the oxidation prevention is demonstrated by the IC50 values for both 
studied systems, that show that in case of coprecipitates produced at R=1/2 
and R=1/5 the antioxidant activity is preserved. Therefore, the 
coprecipitation of EEP-carrier and the size reduction may allow to maintain 
a good quality of the scavenging activity of untreated EEP (Meneses et al., 
2015): this fact could be an interesting added value for the production of 
nutraceutical and functional products.  
 
V.2.4 Conclusions on EEP solid dispersions 
SAA technique revealed to be a good alternative to conventional 
processes for EEP-carriers coprecipitation. In this study, SAA was 
successfully used to load and protect bioactive compounds, such as 
polyphenols in an ethanolic extract of propolis, using two carriers: HPβCD 
and PVP. Not all the mass ratios EEP/carrier were suitable for successful 
coprecipitation of non-coalescing microparticles, but starting from R=1/5 for 
EEP-HPβCD and R=1/3 for EEP-PVP the process is successful. The product 
obtained was a dry powder formed by microparticles containing up to 100% 
of the total polyphenol content present in the EEP and with a preserved 
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antioxidant power due to the homogeneous EEP dispersion in the used 
carriers.  
As a result, the polyphenol-rich particles produced using SAA could be 
very promising, as a source of natural antioxidants, and for food supplies. 
Indeed the suggested carriers allow improving the handling of the product 




V.3 Stabilization and protection of beta-carotene 
BC is one of the most common and abundant carotenes in nature; it is a 
strongly orange-colored pigment (Fiedor and Burda, 2014, Gul et al., 2015) 
and is the major carotenoid in human diet. It has several biological activities, 
like high antioxidant activity and high pro-vitamin A activity. Clinical 
studies demonstrated that BC may reduce the risk of some chronic diseases, 
such as lung cancer, cardiovascular and heart diseases, colorectal adenomas 
and can protect against cutaneous photodamage (Grune et al., 2010, Fiedor 
and Burda, 2014, Goralczyk, 2009). The application of BC to food systems, 
nutraceutical products is limited because of its poor water solubility, low 
bioavailability, lipophilic and crystalline nature and instability in presence of 
light, heat and oxygen (Fiedor and Burda, 2014, Gul et al., 2015). Since 
carotenoid particles alone with a very small size are more sensitive to 
degradation, its incorporation in polymeric matrices can represent a suitable 
method to stabilize and protect it from environmental conditions 
(Champagne and Fustier, 2007, Di Capua et al., 2018). 
Traditional approaches used to try to incorporate BC are spray drying 
(Loksuwan, 2007, Coronel-Aguilera and San Martín-González, 2015) and 
emulsion/solvent evaporation (Tan and Nakajima, 2005). For examples, 
using spray drying, BC were loaded in carriers, such as starch, tapioca starch 
and native starch and Arabic gum, obtaining particles with irregular 
morphologies, wide particle size distributions and BC content ranging 
between 47 and 82%, depending on the carrier. Moreover, no studies on 
dissolution rates of encapsulated BC were performed, to verify the 
enhancement of bioavailability. Analyses on BC antioxidant activity were 
not performed (Loksuwan, 2007, Coronel-Aguilera and San Martín-
González, 2015). The application of SC-CO2 techniques to the precipitation 
of BC alone and to the production of formulations based on BC and 
biopolymers, using SAS technique (Cocero et al., 2009, Mattea et al., 2009) 
and SAILA (Campardelli et al., 2012) was already studied. For example De 
Paz et al. (de Paz et al., 2012) studied a system formed by BC and poly-(Ɛ-
caprolactones), using SAS technique. Produced particles were irregular and 
agglomerated, with very low BC content. BC has been coprecipitated with 
poly(3-hydroxybutirate-co-hydroxyvalerate) (Priamo et al., 2011, Franceschi 
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et al., 2008) or polyethylene glycol (He et al., 2007) by SAS, with loading 
efficiencies lower than 50% and irregular particle shapes. Prosapio et al. 
(Prosapio et al., 2015) proposed SAS to prepare coprecipitates of BC and 
PVP from an acetone:ethanol (70:30 v/v) mixture. Spherical and amorphous 
microparticles in the range 1-2.4 μm were obtained; dissolution analyses 
showed a vitamin dissolution rate 10 times faster than untreated BC. 
Therefore, in this study (Di Capua et al., 2019) in collaboration with the 
Laboratory of Mechanics, Modeling & Clean Processes of University of 
Marseille, BC coprecipitation experiments were carried using PVP, aimed at 
reducing BC tendency to crystallize, obtaining micrometric particles with 
spherical morphology and enhanced BC bioavailability. Two liquid solutions 
were used, ethanol and acetone:ethanol (70:30 v/v), to compare their 
performance in giving coprecipitates.  
 
 
V.3.1 Experimental results 
In previous studies, PVP was precipitated by SAA using ethanol, water, 
and water:acetone mixtures (Liparoti et al., 2013, Liparoti et al., 2015, 
Adami et al., 2017a); but, it was never processed using acetone:ethanol 
(70:30 v/v) mixtures. Therefore, first experiments were performed to test 
SAA polymer behavior in ethanol as reference point and in acetone:ethanol 
(#06) at a concentration of 10 mg/mL. SAA operating conditions were: GLR 
1.8, injection pressure of about 85 bar, saturator and precipitation vessel 
temperature 80°C; they were based on previous SAA studies (Adami et al., 
2017a, Di Capua et al., 2017b, Di Capua et al., 2018). PVP precipitated in 
form of spherical, separated microparticles from both solvents; in Figure 
V.9, two SEM images are reported that, qualitatively, confirm this statement. 
However, using the mixture acetone:ethanol, smaller PVP particles were 
obtained. In Table V.3, PSDs values, expressed in percentiles as d10, d50 and 
d90, are summarized. 
BC alone processed by SAA, at high concentrations, showed a marked 
antisolvent effect in the saturator producing an undesired precipitation. For 
this reason in the SAA coprecipitation experiments only a low BC 
concentration (0.5 mg/mL) was used. 
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Figure V.9 FESEM images of PVP precipitated from a) ethanol and b) 
acetone/ethanol 70/30 (v/v) (#06). 
 
Table V.3 Composition and PSD data of BC-PVP SAA particles 
(R=BC/polymer w/w; Ctot: total concentration; CPVP: PVP concentration). 
 
    Test 










      d90 
   (μm) 
ethanol 
#01 - 10 10 0.37 0.78 1.18 
#02 1/4 2 2.5 0.20 0.42 0.70 
#03 1/6 3 3.5 0.22 0.49 0.83 
#04 1/10 5 5.5 0.36 0.70 1.18 
#05 1/20 10 10.5 0.43 0.84 1.33 
acetone/ethanol 70/30 (v/v) 
#06 - 10 10 0.25 0.53 0.85 
#07 1/4 2 2.5 0.16 0.28 0.42 
#08 1/6 3 3.5 0.19 0.39 0.63 
#09 1/10 5 5.5 0.25 0.43 0.69 
#10 1/20 10 10.5 0.25 0.48 0.80 
 
 
SAA coprecipitation experiments BC-PVP using ethanol 
Keeping constant BC amount in ethanol (0.5 mg/mL) and varying the 
polymer concentration, a set of experiments was performed, to study the 
effect of BC/PVP weight ratio (R); in particular, R=1/4, 1/6, 1/10 and 1/20 
wt/wt were investigated (Table V.3). A SAA test using R=1/2 was also 
performed, but, it is not reported since particles produced showed a partially 
coalescent morphology. All produced powders showed an homogeneous 
orange color (Figure V.10a), intermediate between that of PVP (white) and 
BC (deep orange). The amount of powder obtained for all coprecipitation 
experiments ranges between about 70 and 80% of all solutes injected since 
part of the material produced was difficult to recover from the internal 
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surfaces of the precipitator. An example of SEM image of coprecipitated 
BC-PVP particles is reported in Figure V.10b. 
Spherical microparticles with a homogeneous morphology were 
produced. A significant increase in particle size was observed when the total 
concentration moved from 2.5 to 10.5 mg/mL, with d50 varying between 0.42 
and 0.84 µm (Table V.3). A graphical comparison between volumetric 
cumulative particle size distributions of BC-PVP microspheres obtained 
from ethanol is reported in Figure V.11. All particles were smaller than 
about 1.6 µm and a decrease of d50 was observed when R increased. 
 
    
Figure V.10 a) Picture of the filter covered by coprecipitated powder; SEM 
image of BC-PVP precipitated from ethanol at R=1/6 (#03). 
 
 
Figure V.11 Volumetric cumulative PSD of BC-PVP in ethanol, at different 
weight ratios R (w/w). 
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BC/PVP coprecipitation experiments using acetone:ethanol 70/30 v/v 
A second set of experiments was performed dissolving BC and PVP in a 
mixture of acetone:ethanol (70:30 v/v). Concentrations and BC/PVP weight 
ratios used in these SAA tests are summarized in Table V.3 and the 
operating conditions were the same of the previous set of experiments. 
Homogeneous and orange powders were produced also in this case. 
Spherical and well-defined microparticles were obtained, as shown, for 
example, in the SEM image reported Figure V.12a in the case of R=1/20. 
When R increased, particles produced were smaller and morphologies 
obtained were less regular (Figure V.12b). Volumetric PSDs were compared 
and shown in Figure V.13: all particles were smaller than about 1.1 µm and, 
also in this case, a decrease of d50 was observed when R increased. 
 
   
Figure V.12 FESEM images of BC-PVP precipitated from acetone/ethanol 
70/30 (v/v) at different R, a) 1/20 and b) 1/6 (#08). 
 
 
Figure V.13 Volumetric cumulative particle size distribution of BC-PVP in 




Summarizing, the particles obtained using ethanol are more regular and 
larger than those produced using the mixture acetone:ethanol (70:30 v/v). As 
a general comment, SAA particles obtained in this work showed a markedly 
more regular morphology compared to those obtained by spray drying and 
SAS technique (Prosapio et al., 2015, Franceschi et al., 2008, Priamo et al., 
2011), also using BC/PVP weight ratios up to 1/4. The production of more 
regular morphologies and the absence of aggregates can be an indication of a 
successful coprecipitation process. Until now, only Prosapio et al. (Prosapio 
et al., 2015) obtained reasonably microparticles, using SAS technique and 
BC/PVP lower than 1/10 w/w. Generally speaking, SAS coprecipitation is 
frequently not successful since at nanoparticles level the two compounds 
(polymer+active principle) tend to precipitate separately. 
 
V.3.2 Characterization of BC-PVP coprecipitates  
DSC analyses were performed on untreated compounds, physical mixture 
BC/PVP and SAA processed BC-PVP, to study the changes in the thermal 
behavior of the active principle and polymer in the coprecipitates. In Figure 
V.14 the thermograms related to two coprecipitates (produced at R=1/6 and 
1/20) and raw materials are reported. Raw BC shows a broad endothermic 
peak ranging between 50 and 100°C, due to the evaporation of bond water, 
and a second endothermic peak at about 170°C, due to the fusion of 
crystalline structure. Unprocessed PVP shows only the removal of water 
between 50 and 130°C; the physical mixture (at R=1/6) shows both the 
polymer and BC peaks (the intensity of this last peak is lower than that of 
raw BC). In thermograms of all SAA processed BC-PVP, obtained both in 
ethanol and in the mixture, the melting peak of BC is not present, indicating 
that the BC entrapped in the microspheres is in an amorphous state. The 
thermograms of SAA coprecipitates are very similar to the one of PVP. 
According to the literature, when only one glass transition temperature, Tg, is 
observed, a one-phase solid powder is obtained and the production of a 
homogeneous dispersion is produced (Aid et al., 2017). 
These results were confirmed by X-Ray analyses that give informations 
about the solid state of materials (Figure V.15). 
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Figure V.14 DSC thermograms of BC-PVP: comparison among raw 
materials and SAA coprecipitates. 
 
 
Figure V.15 X-Ray spectra of BC/PVP: comparison among raw materials 
and SAA coprecipitated microspheres. 
 
Untreated BC has a spectrum typical of crystalline form, whereas PVP 
shows the halos typical of amorphous form. As an example, in Figure V.15, 
the spectra of coprecipitates produced at R=1/6 and R=1/20, obtained in 
ethanol and in the mixture acetone:ethanol, are reported and showed the 
same behavior. The patterns of these coprecipitated powders show a 
complete amorphous solid state, with no characteristic BC peak. 
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FT-IR analyses were performed to identify possible interactions between 
the active principle and the polymer in the coprecipitates. FT-IR spectra (in 
the range of 4000-500 cm-1) of unprocessed BC and PVP, SAA processed 
BC-PVP coprecipitates, obtained in ethanol and in the mixture 
acetone:ethanol at R=1/6 and R=1/20, as an example, are reported in Figure 
V.16. In the spectrum of BC, the broad peak at 3411 cm-1 represents the 
presence of –OH stretching of the hydroxyl group. The peaks at 2929 and 
2869 cm-1 are related to the CH2 asymmetry and symmetric stretching, 
respectively. The most intense peak in the spectrum is the one at about 1000 
cm-1, that is the trans-conjugated-alkenes CH out of the plane deformation 
mode (Yi et al., 2015). In the FT-IR spectrum of PVP, the broad peak in the 
range of 3550-3200 cm-1 is related to the OH stretching of the hydroxyl 
group. The sharp peak at 1656 cm-1 indicates the presence of carbonyl group, 
whereas the peak at 1291 and 1440 cm-1 are due to the stretching of amide 
group and C-H deformation of CH2 group, respectively (Laot et al., 1999). 
FT-IR spectra of all coprecipitates show the same behavior: the peaks related 
to the active principle are present, but not very marked. No shifts or 
broadening of peaks related to BC and PVP are present in these spectra and 
this suggests that no new bonds are formed between BC and PVP. 
 
 
Figure V.16 FT-IR spectra: comparison among raw materials and SAA 
coprecipitated microspheres. 
 
Loading efficiencies and dissolution tests 
Qualitatively, BC presence in SAA produced microparticles is easy to 
demonstrate, since powders are orange, as already reported (Figure V.10a). 
Quantitatively, BC content in SAA powders for each BC/PVP weight ratio 
was measured using an UV-vis spectrophotometer, to ascertain the effective 
presence and the quantity of this compound in coprecipitates. BC content in 
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SAA powders can give an indication about the success of coprecipitation 
process. The loading efficiency, expressed as the amount of BC in SAA 
powder vs its amount in the starting solution, ranged between about 73% and 
93% for BC-PVP coprecipitates obtained in ethanol and between about 63 
and 94% for BC-PVP coprecipitates obtained from the acetone:ethanol 
mixture, as summarized in Table V.4.  
 
Table V.4 BC loading efficiency in SAA coprecipitates; antioxidant activity 






















- - 9.4 730.2±1.5 
 Ethanol 
#02 1/4 20.0 18.5 92.6 10.5 901.2±1.0 
#03 1/6 14.3 10.7 75.0 11.3 963.2±1.2 
#04 1/10 9.0 6.6 73.2 14.6 1194.8±0.8 
#05 1/20 4.7 3.4 73.2 20.8 1741.1±1.3 
 acetone/ethanol 70/30 (v/v) 
#08 1/6 14.3 13.5 94.4 8.2 623.0±0.9 
#09 1/10 9.0 5.7 63.4 9.6 752.3±1.0 
#10 1/20 4.7 3.1 66.0 15.9 1305.8±1.6 
 
 
During SAA tests, very small quantities of BC precipitated in the 
saturator; therefore, loading efficiencies lower than in previous studies were 
obtained (Adami et al., 2017a, Di Capua et al., 2017b). In particular, loading 
efficiencies decrease with the increasing amount of polymer; probably, when 
PVP at large concentrations was used a larger antisolvent effect, though at a 
limited value, could be added in the saturator, reducing BC content also. 
However, these values are much higher than those reported in the literature, 
where BC loading efficiencies obtained, for example using SAS technique, 
are lower than 50% (Franceschi et al., 2008, Priamo et al., 2011). 
To verify the improvement of BC bioavailability when loaded in PVP 
matrix, dissolution tests were performed using a dialysis bag in PBS pH 7.4, 
simulating conditions of the small intestine. The dissolution profiles, 
obtained fixed an equivalent amount of BC (5 ppm) for each BC/PVP weight 
ratio, for particles obtained from ethanol and the mixture acetone:ethanol 






Figure V.17 Release profiles of BC in PBS at 37°C and pH 7.4: BC-PVP 
particles obtained using a) EtOH and b) Ac:EtOH (70:30 v/v) as solvent. 
 
The physical mixture of the raw materials was prepared at R=1/6; it 
released 100% of BC in about 100 hours (more than 4 days), due to its poor 
solubility in water. The analyses on SAA coprecipitates confirmed that the 
powders of BC-PVP show a faster release than physical mixture. In Figure 
V.17a, the coprecipitate at R=1/6 shows a total dissolution time of about 4.5 
hours, that is about 22 times faster than the one of the physical mixture, 
overcoming the best results (10 times) found in literature (Prosapio et al., 
2015). The coprecipitates produced using ethanol at R=1/10 and 1/20 totally 
dissolved in 6 and 15 hours, respectively. Furthermore, the release was 
controlled by BC/PVP weight ratio: increasing R, larger drug release rates 
were obtained. This trend is unusual when compared to other coprecipitated 
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systems tested by SAA, in which the dissolution rate increases when R 
decreases (Adami et al., 2017a). However, in those cases, particles were 
produced keeping constant polymer concentration in the liquid and changing 
active principle concentration and the produced particle size increased with 
R (Adami et al., 2017a). In this work, instead, particles are produced fixing 
BC concentration and varying PVP concentration and particle size decreases 
with R. As a general comment, the dissolution behavior of coprecipitates is 
affected by several parameters: interactions between compounds, particle 
size, solid state. Our hypothesis to explain the trend of BC-PVP dissolution 
behavior, is that the main role is taken by particle size: smaller particles are 
produced at higher R and, consequently, larger surface areas are available for 
dissolution in the aqueous medium and faster dissolution rates are obtained. 
In the dissolution curves related to particles obtained using the mixture 
acetone:ethanol, particularly in the case of higher BC/PVP weight ratios, the 
release profiles showed different behaviors from those obtained using 
ethanol (Figure V.17b). This fact might be due, again, to the differences of 
the two liquid solutions injected in SAA apparatus and more specifically to 
the different drying/solidification rates of droplets in SAA precipitator. 
Droplets drying is, indeed, a fundamental step during SAA process that can 
influence the distribution of the active compound in the carrier. Parameters 
including temperature, initial droplet size, droplet number density influence 
particle formation (Eslamian et al., 2009, Mezhericher et al., 2007, Wang et 
al., 2005). Furthermore, a very fast evaporation of the solvent may affect the 
dispersion of the active principle in the carrier that can be more concentrated 
on particle surface. Only the coprecipitate at R=1/20 (Figure V.17b) showed 
a dissolution curve similar to those obtained using the ethanolic system, with 
a 4-fold faster dissolution rate compared to the physical mixture. The most 
intriguing results are that BC dissolution rate largely depends not only by 
BC/PVP ratio, but also on the solvent/solvent mixture used. A possible 
explanation of this result can be found looking at the precipitation 
mechanism that forms microparticles. SAA microparticles are formed from 
liquid droplets and their subsequent transformation in microparticles by 
solvent evaporation. Different solvent/solvent mixtures are characterized by 
different surface tension (droplet diameter), solvents evaporation rate 
(acetone is more volatile than ethanol) and solvents solubility in SC-CO2. 
These last two characteristics can produce different particle arrangements at 
nanometric level that, in turn, can induce different BC release rates. 
 
V.3.3 Antioxidant activity 
In the works found in the literature and reported in the Introduction 
(section V.3) , none of authors proposed the study of BC antioxidant activity 
before and after the process; however, to demonstrate the preservation of this 
feature is fundamental. Antioxidant activity of untreated BC was measured 
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using DPPH assay, as described in Materials and Methods. The scavenging 
activity related to the untreated BC is 9.4%. Analyses on SAA coprecipitates 
showed a general enhancement of the inhibition capacity with respect to BC. 
The SA (%) values found in ethanol were between 10.5 and 20.8% for BC-
PVP particles obtained using ethanol and between 8.2 and 15.9% for BC-
PVP particles obtained using acetone:ethanol (Table V.4). A higher SA 
value indicates a higher free radical scavenging activity of the compounds 
dissolved: this means that a lower concentration is required to quench DPPH 
radical. The antioxidant capacity of SAA powders were also expressed in 
terms of Trolox equivalent (TE) by gram of powder, where higher value 
means higher antioxidant power. The values found for each sample were 
reported in Table V.4. The results indicate that SAA coprecipitates show a 
good preservation of BC antioxidant power. The highest SA values were 
achieved for samples produced at R=1/20: the coprecipitate #05 (obtained 
using ethanol) shows a SA of 20.8% and the coprecipitate #10 (obtained 
using acetone:ethanol) a SA of 15.9%. As reported in literature (Desai and 
Jin Park, 2005, Reksamunandar et al., 2017), the dispersion of an active 
compound in polymeric matrices may provide a better preservation of the 
active ingredient creating a barrier with the external environment.  
Furthermore, all SAA formulations showed larger SA compared to 
untreated BC. This unexpected result might be due to several issues. Some 
researchers demonstrated that reduced size of a pure active principle can 
improve free radical scavenging activity, due to the enhanced dissolution 
rate of the compound (Kakran et al., 2012, Meneses et al., 2015). 
Furthermore, another aspect to be considered, to explain the enhanced 
antioxidant activity of complex systems, is the chemical structure of the 
compounds in the formulations. Both compounds are good hydrogen and 
electron donors and contribute to the quenching of DPPH radical. As a 
support to this hypothesis, both BC and PVP have many protons in their 
structures that can reduce DPPH radical in solution. 
 
V.3.4 Conclusions on BC-PVP system 
Coprecipitates formed by PVP and BC were successfully produced using 
SAA technique: microparticles with loading efficiencies up to 94% and an 
enhanced BC dissolution rate up to 22 times with respect to the physical 
mixture largely overcoming the best result in the literature (10 times using 
SAS technique) (Prosapio et al., 2015). 
An unexpected result was that very small quantities of PVP were enough 
to improve BC release rate and protect it from chemical degradation. 
Another interesting result is that changing the organic solvent, and leaving 
all the other processed conditions unmodified, different arrangements can be 
obtained inside the microparticles (at nanometric level) that can largely 
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VI.1 Saffron petals as sources of antioxidants 
Interest in natural antioxidants is increasing due to concerns by 
consumers over safety of synthetic antioxidants that may potentially cause 
health problems (Carocho et al., 2015, Wojcik et al., 2010). Antioxidants are 
mainly used in food to prevent off-flavors by oxidation of fats; however, 
they play a role also in the prevention and treatment of several chronic 
diseases, such as asthma, cardiovascular problems and cancer (Sardas, 
2003). Due to their highly profitable properties, the extraction of these 
antioxidant compounds from plants and flowers and their incorporation in 
our diet as nutraceutical ingredients is growing. 
Crocus Sativus, most known as saffron, is a perpetual plant used to 
produce the typical spice in our kitchens. Only stigmas (the red part of the 
flower) are collected, dried and used as a culinary spice; whereas, the 
remaining part of saffron flowers is considered as a waste (Righi et al., 
2015). Floral bio-residues are the major by-product (around 90% of total 
weight of saffron) composed by tepals, stamens and styles. Mechanization of 
flower collection and spice production have led to an increase of productive 
capacity, expanding also the amount of waste materials (Serrano-Díaz et al., 
2013). These floral bioresidues are rich of carotenoid derivates (such as 
crocetin, crocin and lutein diesters), carbohydrates (glucose, fructose, 
mannitol), monoterpenoids (picrocrocin, crocusatins), flavonoids and their 
glycoside derivates and anthocyanins (Serrano-Díaz et al., 2013, Tuberoso et 
al., 2016). These substances can be used in food, pharmaceutical and/or 
cosmetic industries due to their natural colorant, antioxidant and therapeutic 
properties (Ahmad et al., 2018). Flavonoids in saffron flowers are mainly 
represented by kaempferol and quercetin and their glycosides (Hadizadeh et 
al., 2010, Righi et al., 2015, Tuberoso et al., 2016, Zeka et al., 2015, 
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Termentzi and Kokkalou, 2008), with kaempferol 3-O-sophoroside being the 
most abundant (around 84%) (Zeka et al., 2015, Babaei et al., 2014). 
Researchers have demonstrated that saffron petal extracts show biological, 
antioxidant, antifungal and antiradical activities, cytotoxic effect and metal 
chelant properties (Tuberoso et al., 2016). They may induce malignant cell 
death, slow skin aging by inhibiting a variety of enzymes that degrade the 
extracellular matrix, prevent arteriosclerosis and heart diseases (Hadizadeh 
et al., 2010). The major properties of saffron flower extracts have to be 
attributed to its kaempferol content (Tuberoso et al., 2016). 
Some procedures have been used to extract bioactive components from 
saffron petals, such as maceration, ultrasound assisted extraction (Ahmad et 
al., 2018, Khazaei et al., 2016, Lotfi et al., 2015) and, more recently, using 
supercritical fluid processes (Ahmadian-Kouchaksaraie et al., 2016b, 
Ahmadian-Kouchaksaraie and Niazmand, 2017, Ahmadian-Kouchaksaraie et 
al., 2016a). Conventional methods are mainly based on a solid-liquid 
extraction using organic solvents, like ethanol, water, and mixtures 
water:ethanol (Zeka et al., 2015, Ahmadian-Kouchaksaraie et al., 2016b, 
Ahmadian-Kouchaksaraie and Niazmand, 2017, Khazaei et al., 2016). 
Ahamadian-Kouchaksaraie et al. (Ahmadian-Kouchaksaraie et al., 2016b, 
Ahmadian-Kouchaksaraie and Niazmand, 2017) investigated green 
extraction technologies, such as supercritical carbon dioxide and subcritical 
water extraction of antioxidants from saffron petals. These innovative 
technologies allowed increasing the extraction capacity both in phenolic 
compounds and anthocyanins compared to conventional extractions. In 
particular, using supercritical CO2 and subcritical water extraction the 
amount of flavonoids extracted was 2 and 3 times higher compared to 
conventional extraction results, respectively. 
Nevertheless, the effectiveness of these extracted bioactive compounds 
depends on preserving their stability against heat, light and oxygen (Ahmad 
et al., 2018, Machado et al., 2018, Guamán-Balcázar et al., 2019) and the 
bioactivity and bioavailability of active principles. Furthermore, the strong 
and unpleasant taste and aroma sometimes can limit the direct application of 
these extracted compounds in food products (Di Capua et al., 2018). The 
current challenge is to protect such promising molecules from deterioration 
and loss of their activity. The encapsulation of extracted compounds from 
saffron petals is still poorly investigated. In the literature, very few works 
have focused their attention on the encapsulation of saffron petal extracts. 
For example, Ahmad et al. (2018) loaded anthocyanins extracted from 
saffron petals using ethanol acidified at pH=2 in two different carrier: β-
glucan and β-cyclodextrin, using spray drying technique. In Figure VI.1, 
examples of particles produced by Ahmad et al. are reported (Ahmad et al., 
2018). 
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Figure VI.1 SEM images of samples produced using: SG) β-glucan and SC) 
β-cyclodextrin (Ahmad et al., 2018). 
 
As it is possible to observe, produced powders were irregular and 
coalescent agglomerates, difficult to be characterized in terms of particle 
size. Loading efficiencies were very low, ranging between 45 and 63%, 
respectively using β-glucan and β-cyclodextrin. Mahdavee Khazaei et al. 
(Mahdavee Khazaei et al., 2014) studied the microencapsulation of saffron 
petal's anthocyanins using maltodextrin and gum Arabic as carrier and the 
freeze drying as technique. Also in this case, powders produced consisted of 
very irregular and flat crystals; however, no results in terms of loading 
efficiencies were reported, whereas a stability study demonstrated a 
preservation of anthocyanins encapsulated. In recent years, the encapsulation 
by SC-CO2–based processes is demonstrated to be an efficient alternative for 
natural products preservation, due to the use of low temperatures, to reduce 
organic solvent consumption and to control PSD (Cocero et al., 2009). 
Several investigations have obtained successful results using PVP as carrier, 
for examples in the case of mango leaves (Guamán-Balcázar et al., 2019) 
and blackberry residues (Machado et al., 2018). Indeed, PVP is a common 
polymer, often used as carrier to enhance the dissolution rate of hydrophobic 
compounds; it is readily soluble in water, non-toxic, biocompatible and 
accepted by FDA (Kamada et al., 2000, Guamán-Balcázar et al., 2019). In 
this thesis work, SAA demonstrated to be effective in the production of 
coprecipitates in which bioactive compounds, such as propolis ethanolic 
extract and beta-carotene, were dispersed in PVP matrix (Di Capua et al., 
2018) preserving antioxidant power of the active compounds investigated.  
Therefore, the first aim of this work was to optimize extraction 
parameters (temperature, flower maceration time, solvent) in order to 
maximize the amount of kaempferol and quercetin glycosides extracted. 
Then, the optimized extracts were processed by SAA technique in order to 
stabilize these glycosides through their dispersion in PVP matrix. The 
objective was to produce stable particles able to preserve glycoside 
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antioxidant activity and to extend their shelf life. Analyses of solid state, 
morphology, PSD, glycosides content in the formulations and antioxidant 
activity analyses on time were performed, to assess the efficiency of SAA 
process on the production of glycoside-rich powders and on the preservation 
of floral bio-residues. 
 
Materials 
Polyvinylpyrrolidone (PVP, Mw: 10,000), ethanol (EtOH, purity 99.9%), 
2,2-Diphenyl-1-picrylhydrazyl (DPPH) and methanol (MetOH, purity 
>99.9%) were supplied by Sigma Aldrich. Crocus Sativus bulbs were from 
Holland; they were collected in Magnano in Riviera (Udine, Italy). The 
floral residues, obtained after the separation of the stigma, were stored in a 
dark, dry place, under vacuum conditions. Carbon dioxide (CO2, 99.9%) was 
purchased by Morland Group (Italy) and nitrogen (N2, 99%) by SOL (Italy). 
All materials were used as received. 
 
VI.1.1 Extraction from saffron petals 
The polyphenols extraction was obtained by conventional solid-liquid 
extraction from saffron petals (Figure VI.2), as described in literature with 
minor modifications (Ahmadian-Kouchaksaraie and Niazmand, 2017, 
Ahmadian-Kouchaksaraie et al., 2016a, Ahmadian-Kouchaksaraie et al., 
2016b, Zeka et al., 2015). 
 
 
Figure VI.2 Saffron petals. 
 
Saffron petals (2.5 g) were mixed with 75 mL of solvent; the extraction 
was carried under dark and continuous stirring (Ahmadian-Kouchaksaraie et 
al., 2016a). Four different solvents (pure ethanol, aqueous ethanol (59% v/v), 
ethanol acidified with HCl (pH=2), aqueous ethanol (59% v/v) acidified with 
HCl (pH=2) were investigated for extraction, at room temperature. 
Furthermore, different intervals of time extraction were investigated ranging 
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between 3 and 24 hours. After extraction, each sample was filtered through 
filter paper; 20 mL of each extract was then evaporated under vacuum at 
30°C. The dried extract was weighted to evaluate the extract concentration; 
then, each dried extract was dissolved in methanol and analyzed by HPLC to 
estimate the amount of glycosides of kaempferol and quercetin extracted. 
First, saffron petals extractions using ethanol and a mixture of water:ethanol 
(41:59 v/v) were performed. Examples of extracts produced varying the time 
of maceration and solvents are reported in Figure VI.3. 
 
a.   b.   c. 
     
Figure VI.3 Extracts obtained using ethanol as solvent at room temperature 
after a) 3 h; b) 6h; c) 24h. 
A gradient of color is easily observable in Figure VI.3, where ethanolic 
extracts at different time of flower maceration are reported. In particular, the 
extract obtained after 3 hours of extraction was clear yellow; however, 
increasing the time of infusion (6 and 24 h), the extracts were less clear and 
greenish. A similar trend is possible to note also in the case of extracts 
obtained using a mixture of water:ethanol (41:59 v/v), in Figure VI.4. 
As shown in Figure VI.4, extracts obtained in water:ethanol mixture were 
increasingly dark, varying the time of flower maceration between 3 and 24 
hours.  
 
A second set of extraction experiments was carried out using the same 
solvents (ethanol, water:ethanol 41:59 v/v) acidified with HCl at pH=2 
(Khazaei et al., 2016, Ahmad et al., 2018). Examples of extracts produced 








a.   b.   c. 
     
Figure VI.4 Extracts obtained using water:ethanol (41:59 v/v) as solvent at 
room temperature after a) 3 h; b) 6h; c) 24h. 
 
a.    b.  
                    
Figure VI.5 Extracts obtained at room temperature after 6 hours of flower 
maceration, using a) ethanol at pH=2; b) water:ethanol (41:59 v/v) at 
pH=2. 
 
As it is possible to observe in Figure VI.5a, the extract obtained in 
ethanol at pH=2 was opaque and yellow/greenish; it was really similar to the 
color obtained using the solvent not acidified (Figure VI.3b). The extract 
produced using the mixture water:ethanol (41:59 v/v) at pH=2, instead, was 
dark with shades of purple, as shown in Figure VI.5b. This particular color 
was due to the extraction of compounds like anthocyanins that are water-
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soluble pigments belonging to flavonoid family, used as food supplements 
(Ahmad et al., 2018, Khazaei et al., 2016, Mahdavee Khazaei et al., 2014). 
Another extraction parameter considered was the temperature. On the 
basis of literature (Ahmadian-Kouchaksaraie et al., 2016a), two different 
temperatures were investigated: 25 and 66°C. However, a real effect of 
temperature was not verified, indeed the results obtained at 25°C were 
similar to those at 66°C (not reported); hence, a lower temperature was 
preferred to avoid the degradation of active compounds in solution. 
 
Quantification of kaempferol and quercetin glycosides in extracts 
This study focused mainly in two antioxidant compounds: kaempferol 
and quercetin glycosides. These compounds were identified and quantified 
using HPLC analyses, as described in Chapter II. In Figure VI.6 and Figure 
VI.7, histograms represent the areas under the peaks identified in HPLC 
chromatograms as quercetin (elution time 2 min) and kaempferol (elution 
time 7 min) glycosides, for extracts obtained using ethanol and water:ethanol 
(41:59 v/v), respectively, varying the time of flower maceration. 
As it is possible to observe in Figure VI.6, the amount of kaempferol and 
quercetin glycosides in the extract obtained in ethanol increases as 
increasing the time of flower maceration. However, the increase of extracted 
compounds obtained from 6 to 24 hours was limited. Figure VI.7 shows the 
extraction capacity of mixture water:ethanol (41/59 v/v). 
 
 
Figure VI.6 Areas under peaks related to the glycosides of kaempferol and 
quercetin in the HPLC chromatograms of the extracts obtained in ethanol, at 






Figure VI.7 Areas under peaks related to the glycosides of kaempferol and 
quercetin in the HPLC chromatograms of the extracts obtained in 
water:ethanol (41:59 v/v), at 25°C and different times of flower maceration. 
 
 
The amount of extracted compounds was practically unchanged 
increasing the time of flower infusion up to 6 hours, whereas after 24 hours, 
HPLC analyses demonstrated a reduction of kaempferol and quercetin 
glycosides, due to a partial degradation of extracted compounds. However, 
the mixture water:ethanol (41:59 v/v) shows a highest extraction power in 
terms of kaempferol and quercetin glycosides compared to ethanol, as 
resulted by the comparison of the results summarized in Figure VI.6 and 
Figure VI.7. On the basis of results obtained both in ethanol and in the 
mixture water:ethanol, a flower maceration of 6 hours was the best 
compromise to perform extraction experiments, avoiding compounds 
degradation and obtaining a good amount of quercetin and kaempferol 
glycosides extracted. 
The results obtained using solvents acidified at pH=2 are summarized in 
histograms reported in Figure VI.8, where it is possible to observe the areas 
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   a.  b. 
 
Figure VI.8 Areas under peaks related to the glycosides of kaempferol and 
quercetin in the HPLC chromatograms of the extracts obtained in ethanol 
and water:ethanol (41:59 v/v) at pH=2 and 6 hours of flower maceration. 
 
By comparing the results obtained using acidified ethanol and pure 
ethanol, quercetin glycoside was practically extracted in the same quantity, 
whereas the amount of kaempferol glycoside increased at pH=2 (Figure 
VI.8a); a similar result is obtained also by Yi et al. (Yi et al., 2016) from 
Gynura medica. Using the mixture water:ethanol (41:59 v/v) at pH=2, 
instead, HPLC analyses demonstrated a reduction of both kaempferol and 
quercetin glycosides (Figure VI.8b). 
In Table VI.1 results of extractions performed at 6 hours of flowers 
maceration are summarized, in terms of total yield of extraction (expressed 
as mg of dried extract/g of saffron petals), total extract concentration (Cext) 
and kaempferol (CK) and quercetin (CQ) concentrations evaluated from 




Table VI.1 Extraction results obtained after 6 hours using ethanol and 
water:ethanol (41:59 v/v); (Cext: extract concentration; CK: kaempferol 
















EtOH 405.0 13.5 5.5 1.0 55.0 30.4 
EtOH 
(pH=2) 
344.7 11.5 7.4 0.6 36.1 27.0 
H2O:EtOH 723.0 24.1 12.4 4.6 76.8 35.1 
H2O:EtOH 
(pH=2) 
868.2 28.9 5.7 1.9 83.8 32.5 
 
From Table VI.1, it can be clearly noted that the higher levels of 
quercetin and kaempferol extracted were obtained using water:ethanol 
(41:59 v/v). After 6 hours, about 165 mg of kaempferol glycoside and 30 mg 
of quercetin glycoside per g of dried petals were extracted using ethanol, 
whereas, about 370 mg of kaempferol glycoside and 137 mg of quercetin 
glycoside per g of dried petals using water:ethanol (41:59 v/v). These results 
overcome the yields of extraction obtained, for examples, by Zeka et al. 
(Zeka et al., 2015) where 126 mg of kaempferol aglycone for g dried petals 
were extracted using methanol in 16 hours. In Table VI.1, antioxidant 
activities related to extracts (at t=0, i.e. time of preparation) are also 
reported; Scavenging Activity (SA) results were consistent with the total 
extract concentrations. It was observed, indeed, that SA related to aqueous 
extracts is higher than those evaluated for ethanol extracts; therefore, SA 
showed a strong dependence on the solvent used for the extraction. After 3 
months, the extracts stored in a dark and dry place were analyzed afresh; as 
detailed in Table VI.1, it was verified a SA reduction ranged between 27 and 
30% for ethanol extracts and between 32 and 35% for aqueous extracts. 
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Preparation of saffron petals extracts and polymer solutions 
Produced extracts were characterized by different concentrations, 
depending on the solvents used (Table VI.1). For the precipitation 
experiments, firstly extracts were processed as produced, dissolving PVP 
directly into the extracts, at different R=extract/PVP weigh ratios (1/3, 1/5). 
A second set of experiments were performed after extract dilution down to 2 
mg/mL and using the same extract/PVP weight ratios. 
 
 
VI.1.2 SAA coprecipitation experiments 
Identified the best extraction conditions, the produced extracts have been 
treated using SAA technique to produce particles consisting in a polymeric 
matrix (PVP) in which the active compounds extracted from the petals can 
be finely dispersed (Ahmad et al., 2018, Mahdavee Khazaei et al., 2014). 
PVP was already precipitated by SAA in form of spherical, separated 
microparticles, using ethanol, water, and water:acetone and acetone:ethanol 
mixtures (Liparoti et al., 2015, Liparoti et al., 2013, Di Capua et al., 2018, 
Adami et al., 2017a, Di Capua et al., 2019). Therefore, since PVP behavior 
in ethanol, and water:ethanol mixture was well known, SAA operating 
conditions were optimized in previous studies. For ethanol system, SAA 
process conditions were: GLR 1.8, injection pressure of about 80-83 bar, 
saturator and precipitation vessel temperature 80°C. For water:ethanol 
system, SAA process conditions were: GLR 1.8, injection pressure of about 
80-85 bar, saturator temperature of 80°C and precipitator temperature of 
90°C (Adami et al., 2017a).  
By using the produced extracts as they were obtained (total extract 
concentrations summarized in Table VI.1) in SAA coprecipitation tests, a 
clear coalescence was observed in the particles produced; moreover, for 
water:ethanol extracts at pH=2, irregular and non-uniform in color particles 
were obtained. Therefore, the best compromise was to decrease extract 
concentrations (2 and 4 mg/mL) to promote the production of regular and 
homogeneous particles. Table VI.2 reports a list of coprecipitation 
experiments, concentrations and PSD values (in terms of volume particles) 
expressed as d10, d50 and d90. Keeping constant extract concentration and 
varying polymer concentration, a set of experiments was performed for each 









Table VI.2 Composition and PSD data of extract-PVP particles produced 
by SAA (R=extract/PVP w/w; Cext: total extract concentration; CPVP: PVP 




















#ZAF01 1/5 10 2 80 80 0.20 0.42 0.67 
#ZAF02 1/3 6    0.19 0.33 0.55 
ethanol pH=2 
#ZAF03 1/5 10 2 80 80 0.16 0.29 0.51 
#ZAF04 1/3 6    0.13 0.24 0.44 
water:ethanol (41:59 v/v) 
#ZAF05 1/5 10 2 80 90 0.34 0.76 1.32 
#ZAF06 1/3 6    0.26 0.59 0.99 
water:ethanol (41:59 v/v) pH=2 
#ZAF08 1/5 10 2 80 90 0.38 0.76 1.20 
#ZAF09 1/3 6    0.25 0.56 1.00 
 
 
A picture of SAA powders and some examples of FESEM images related 
to particles produced from extracts based on ethanol with PVP are reported 
in Figure VI.9 and Figure VI.10. Qualitatively all SAA produced powders 
are homogeneously colored and resulted in a color intermediate between that 
of PVP (white) and processed extract. In particular, the powders produced 
from both ethanol extracts were clear yellow (Figure VI.9a, Figure VI.10a) 
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Figure VI.9 a) SAA powder obtained from EtOH extract with PVP; FESEM 
images related to SAA tests performed at b) R=1/5, c) R=1/3. 
     
 
 
Figure VI.10 a) SAA powders from EtOH extract at pH=2 with PVP; 




The particles produced were spherical and well separated at all R 
investigated. In Figure VI.11, a comparison of PSDs related to extract-PVP 
particles precipitated from ethanol extract (pink) and from ethanol extract at 
pH=2 (blue) at different R is reported (PSD values are reported also in Table 
VI.2). As it is possible to observe, there is an effect due to the presence of 
HCl on SAA particle size. Indeed, particles obtained from ethanol extracts at 
pH=2 resulted smaller than those produced without HCl. Moreover, an 
increase of d50 was observed when R decreased (hence, increasing PVP 
concentration) due to the higher viscosity of the solution injected, as 





Figure VI.11 Comparison of PSDs related to extract-PVP particles 
precipitated from ethanol extract (pink) and from ethanol extract at pH=2 
(blue) at different R (w/w). 
 
 
Also extracts based on the water:ethanol (41:59 v/v) were tested by SAA; 
exemplificative FESEM images with enlargement of 20 KX are proposed in 
Figure VI.12 and Figure VI.13. 




   
Figure VI.12 a) SAA powder from H2O:EtOH (41:59 v/v) extract with PVP; 
FESEM images of samples obtained at: b) R=1/5, c) R=1/3. 
 
     
 
 
Figure VI.13 a) SAA powder from H2O:EtOH (41:59 v/v) extract at pH=2 
with PVP; FESEM images of samples obtained at b) R=1/5, c) R=1/3. 
Chapter VI 
146 
As the photographs showed, the powders obtained from water:ethanol 
extracts (41:59 v/v) were clear brown in color (Figure VI.12); whereas, pink 
powders were collected when the extracts based on water:ethanol (41:59 v/v) 
at pH=2 were processed (Figure VI.13). However, when an extract 
concentration of 2 mg/mL was used for the coprecipitation tests, 
homogeneous powders consisted of spherical and well-defined particles 
were obtained regardless of the pH of solution injected (Figure VI.12b and c, 
Figure VI.13b and c). A SAA test was performed processing a higher 
concentration of extract (4 mg/mL) and using R=1/3: in this case, a partial 
coalescence was observed in SAA particles produced (figure not reported). 
In Table VI.2, PSD data are summarized: there is no effect related to the pH 
of the water:ethanol extract, but smaller particles were obtained increasing R 
(Di Capua et al., 2017a, Di Capua et al., 2018). Looking at overall results 
(Table VI.2), the particles produced using water:ethanol (41:59 v/v) extracts 
were larger and more perfectly spherical than those produced in ethanol. 
 
 
VI.1.3 Characterization of extract-PVP coprecipitates 
DSC (Figure VI.14) and X-Ray (Figure VI.15) analyses were performed 
to study the solid state and the crystallization behavior of extracts-PVP 
coprecipitates. 
In Figure VI.14, the thermograms related to coprecipitates produced at 
R=1/3 for each kind of extract and PVP are reported. In literature, 
kaempferol and quercetin glycosides show melting point around 276-278°C 
and 316°C, respectively (Har Bhajan and Bharati, 2014). In Figure VI.14, 
the unprocessed PVP shows only the removal of water between 50 and 
130°C, due to its amorphous nature. In thermograms of SAA processed 
extract-PVP particles reported, patterns similar to that of PVP can be 
observed, and no peaks are detectable. Therefore, a nanodispersion of 
extracted compounds in SAA particles can be hypothesized. These results 
were confirmed by X-Ray analyses; in Figure VI.15, the diffractograms 
related to the coprecipitates obtained from ethanol and water:ethanol at 
different extract/PVP weight ratios. 
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Figure VI.15 XPRD related to coprecipitates obtained from ethanol extract 
and from water:ethanol (41:59 v/v) with PVP, at different R (extract/PVP 
w/w). 
 
Untreated PVP shows the typical halos due to its amorphous structure: in 
the pattern, two broad peaks around 11.5° and 20.5° are identified. SAA 
extract-PVP coprecipitates show only the broad peaks related to the carrier, 
regardless of the extract type processed and the weight ratio R. These 
analyses suggested that extracted compounds were finely dispersed in the 
PVP matrix (Aid et al., 2017). This is a typical result for SAA coprecipitates 
when compared to other coprecipitated systems tested by SAA; for example, 
the homogeneous dispersion of the active principle in polymer matrix 
obtained in this work can be found also in the coprecipitates based on beta-
Chapter VI 
148 
carotene and PVP (Di Capua et al., 2019), propolis extract and PVP or 
hydroxypropyl-β-cyclodextrin (Di Capua et al., 2018), curcumin and PVP 
(Adami et al., 2017a), LUT and dextran (Di Capua et al., 2017a), 
dexamethasone and PVP (Liparoti et al., 2013). Similar results were 
obtained for the particles produced from extracts at pH=2. 
 
Loading efficiencies and antioxidant activity in SAA particles 
The loading efficiencies of quercetin and kaempferol glycosides in SAA 
powder were calculated using HPLC calibration curves; the resulted values 
are summarized in Table VI.3.  
 
Table VI.3 Loading efficiences of quercetin and kaempferol glycosides and 
antioxidant activity of powders (R: extract/PVP w/w; Cext: extract 
concentration; Q: quercetin glycoside; K: kaempferol glycoside; SA 

















#ZAF01 1/5 2 90.0 75.2 24.1 
#ZAF02 1/3  88.0 74.0 22.0 
ethanol pH=2 
#ZAF03 1/5 2 89.9 89.8 23.8 
#ZAF04 1/3  85.1 83.1 26.4 
water:ethanol (41:59 v/v) 
#ZAF05 1/5 2 ~100 ~100 7.9 
#ZAF06 1/3  ~100 ~100 1.4 
water:ethanol (41:59 v/v) pH=2 
#ZAF08 1/5 2 88.5 89.6 1.0 
#ZAF09 1/3  92.8 95.0 18.2 
 
 
Looking at the particles produced from ethanol extracts, quercetin 
loading efficiencies ranged between about 85% and 90%, whereas 
kaempferol loading efficiencies between about 74 and 90%. Also the 
particles obtained from water:ethanol extracts exhibited high loading 
efficiencies both for quercetin and kaempferol glycosides. In particular, 
particles precipitated from water:ethanol extracts showed loading 
efficiencies up to 100%. These results were very promising, mainly 
compared to encapsulation efficiencies found in literature ranging between 
45 and 63% (Ahmad et al., 2018).  
In Table VI.3, the antioxidant activities related to SAA powders (at t=0, 
i.e. time of powder preparation) were consistent with the corresponding 
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extracts. Indeed, the SA values related to powders obtained from aqueous 
extracts were higher than those measured from particles precipitated from 
ethanol extracts. However, the most relevant aspect to be considered was the 
SA reductions over time. After 3 months in a dry and dark place, it was 
verified a SA reduction ranged between 22 and 24% for powders produced 
from ethanol extracts and between 1 and 8% for powders produced from 
water:ethanol extracts (see Table VI.3). Values slightly higher were found 
for powders produced from the extracts at pH=2. An excellent result was 
obtained, since SA reductions were greatly reduced compared to the raw 
extracts results (see Table VI.1). Particularly, after 3 months, the SA values 
were practically confirmed for the coprecipitates produced from 
water:ethanol extracts, and reduced by 35% for raw saffron extracts. 
Therefore, the incorporation of these glycosides into PVP matrix allowed 
stabilizing the active compounds since the polymer acts as a barrier against 
oxygen and small molecules promoting the shelf life of the loaded products. 
In particular, PVP has been demonstrated a carrier recommendable to 
enhance precipitate stability and integrity mainly starting from water:ethanol 
extracts. This fact can be probably due to the larger particle diameters and 
the more regular morphologies obtained using water:ethanol extract that 
proved to be the best starting solution to prepare stable coprecipitated 
particles using SAA process. 
 
 
VI.1.4 Conclusions on extract-PVP systems 
The process proposed in this work was effective for the protection of 
valuable compounds obtained from saffron residues by solid-liquid 
extractions. SAA product obtained was a dry powder formed by particles 
containing up to 100% of compounds extracted, using a water:ethanol 
mixture (41:59 v/v). An excellent result is that small quantities of PVP are 
enough to preserve their antioxidant activity over time; these results could be 
used as evidence of the effective protection role of PVP. After three months, 
the values of scavenging activity were practically confirmed for SAA 
coprecipitates and reduced by 35% for raw saffron extracts 
Therefore, the SAA process was efficient in producing stable particles with 
remarkable antioxidant capacity, which can be applied in the food and 











The aim of this Ph.D. work was the development of new and stable 
formulations consisting of microparticles with improved bioavailability, 
using supercritical assisted processes for pharmaceutical and nutraceutical 
applications. The SAA process has revealed to be very efficient in the 
improvement of the bioavailability of several active principles, producing 
nano and microparticles of pure drugs and coprecipitates, as well as in the 
case some compounds to be difficulty processed by conventional methods. 
 
The SAA process was successfully applied both in pharmaceutical and 
nutraceutical fields, demonstrating to be attractive and available from an 
industrial point of view. 
 
In the framework of the pharmaceutical formulations, five drugs were 
investigated, as part of the agreement between Cerbios Pharma and the 
Department of Industrial Engineering (DIIN) of the University of Salerno. 
Differently from the conventional techniques, the SAA process was able to 
reach the specific targets requested by the Company. In particular, BRI, FUL 
and NAP were micronized alone, whereas DAS and GPB were dispersed in 
carrier matrices producing coprecipitates. This study eventually allowed 
obtaining the validation of the SAA industrial plant in the Cerbios Pharma 
facility of Lugano, and achieving the SwissMedic authorization for GMP 
production, on January 2017. 
 
Selected carriers (PVP, DEX and HPβCD) demonstrated to be very able 
to produce well-separated and amorphous microspheres with diameters 
lower than 1.8 µm and high active principle loading efficiences, up to 100% 
in most of the performed studies. In particular, they were very valuable in 
controlling the tendency of active principles to crystallize and agglomerate, 
by producing SAA particles stable over time. Dissolution tests confirmed 
that the produced composite particles showed drug dissolution rates much 
faster with respect to the corresponding physical mixtures, thus improving 
their bioavailability up to 12 times. In particular, the achieved results allow 
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concluding that the active principle/carrier weight ratio and the chemical 
interactions revealed to be controlling parameters for dissolution rate. 
Definitely, the particle size reduction and the production of amorphous 
composite systems demonstrated to be crucial in achieving the Ph.D. goals 
using the SAA technique. The SAA amorphous formulations have proved to 
be homogeneous dispersions of a drug in a carrier matrix since each particle 
is the result of the fast drying of a droplet containing the two compounds. 
These SAA composite systems show higher dissolution rates: the water-
soluble carrier fastly dissolves and releases the micronized drug molecules. 
The smaller drug particles show larger surface area to volume ratios thus 
obtaining higher interactions with the aqueous medium; whereas, the 
disordered arrangements, typical of an amorphous solid, lead to faster 
dissolutions since no energy is required to break up the crystal lattice. 
Therefore, the mutual influence of these two factors positively affects the 
final dissolution rates of the active principles. The success of the SAA 
technique in the stabilization of active principles is related to the ability to 
develop some one-phase amorphous solid dispersions, and to the interactions 
between active substance and carrier, mostly attributed to the formation of 
hydrogen bonding and the steric hindrance resulting from the kind of carrier 
structure. 
 
Finally, the SAA technique revealed to be a reliable alternative to 
conventional processes also in the unexplored field of nutraceuticals. For the 
first time, SAA composite systems based on the dispersion in different 
carriers of bioactive compounds, such as carotenoids, polyphenols and 
flavonoids, were successfully produced. Defined, spherical and amorphous 
particles with high loading efficiencies up to 94-100% and with preserved 
antioxidant activity were obtained. Particularly, the study on saffron petals, 
normally considered as industrial wastes, demonstrated that SAA produced 
particles, using PVP as carrier, were able to preserve the antioxidant power 
over time. After three months, the antioxidant activity was confirmed for the 
SAA coprecipitates and reduced by 35% for crude saffron extracts. As an 
overall result, the antioxidant-rich particles produced can be used as source 
of natural antioxidants and for food supplements. Moreover, the suggested 









ADAMI, R., DI CAPUA, A. & REVERCHON, E. 2017a. Supercritical 
Assisted Atomization for the production of curcumin-biopolymer 
microspheres. Powder Technology, 305, 455-461. 
ADAMI, R., LIPAROTI, S., DELLA PORTA, G., DEL GAUDIO, P. & 
REVERCHON, E. 2017b. Lincomycin hydrochloride loaded albumin 
microspheres for controlled drug release, produced by Supercritical 
Assisted Atomization. The Journal of Supercritical Fluids, 119, 203-
210. 
ADAMI, R., LIPAROTI, S., DI CAPUA, A., SCOGNAMIGLIO, M. & 
REVERCHON, E. 2019. Production of PEA composite microparticles 
with polyvinylpyrrolidone and luteolin using Supercritical Assisted 
Atomization. The Journal of Supercritical Fluids, 143, 82-89. 
ADAMI, R., LIPAROTI, S., IZZO, L., PAPPALARDO, D. & 
REVERCHON, E. 2012. PLA–PEG copolymers micronization by 
supercritical assisted atomization. The Journal of Supercritical Fluids, 
72, 15-21. 
ADAMI, R., LIPAROTI, S. & REVERCHON, E. 2011. A new supercritical 
assisted atomization configuration, for the micronization of 
thermolabile compounds. Chemical Engineering Journal, 173, 55-61. 
ADAMI, R., OSSEO, L. S. & REVERCHON, E. 2009. Micronization of 
lysozyme by supercritical assisted atomization. Biotechnol Bioeng, 104, 
1162-70. 
ADAMI, R. & REVERCHON, E. 2012. Composite polymer-Fe3O4 
microparticles for biomedical applications, produced by Supercritical 
Assisted Atomization. Powder Technology, 218, 102-108. 
ADAMI, R., SCHUSTER, J., LIPAROTI, S., REVERCHON, E., 
LEIPERTZ, A. & BRAEUER, A. 2013. A Raman spectroscopic 
method for the determination of high pressure vapour liquid equilibria. 
Fluid Phase Equilibria, 360, 265-273. 
ADEOYE, O., COSTA, C., CASIMIRO, T., AGUIAR-RICARDO, A. & 
CABRAL-MARQUES, H. 2018. Preparation of 
ibuprofen/hydroxypropyl-γ-cyclodextrin inclusion complexes using 
supercritical CO2-assisted spray drying. The Journal of Supercritical 
Fluids, 133, 479-485. 
AHMAD, M., ASHRAF, B., GANI, A. & GANI, A. 2018. 
Microencapsulation of saffron anthocyanins using beta glucan and beta 
cyclodextrin: Microcapsule characterization, release behaviour & 
antioxidant potential during in-vitro digestion. Int J Biol Macromol, 
109, 435-442. 
AHMADIAN-KOUCHAKSARAIE, Z. & NIAZMAND, R. 2017. 
Supercritical carbon dioxide extraction of antioxidants from Crocus 
References 
154 
sativus petals of saffron industry residues: Optimization using response 
surface methodology. The Journal of Supercritical Fluids, 121, 19-31. 
AHMADIAN-KOUCHAKSARAIE, Z., NIAZMAND, R. & NAJAF 
NAJAFI, M. 2016a. Optimization of extraction conditions of bioactive 
components from saffron petal using response surface method (RSM). 
JRIFST, 5, 39-54. 
AHMADIAN-KOUCHAKSARAIE, Z., NIAZMAND, R. & NAJAFI, M. N. 
2016b. Optimization of the subcritical water extraction of phenolic 
antioxidants from Crocus sativus petals of saffron industry residues: 
Box-Behnken design and principal component analysis. Innovative 
Food Science & Emerging Technologies, 36, 234-244. 
AID, S., EDDHAHAK, A., ORTEGA, Z., FROELICH, D. & 
TCHARKHTCHI, A. 2017. Experimental study of the miscibility of 
ABS/PC polymer blends and investigation of the processing effect. 
Journal of Applied Polymer Science, 134. 
ALIAKBARIAN, B., PAINI, M., ADAMI, R., PEREGO, P. & 
REVERCHON, E. 2017. Use of Supercritical Assisted Atomization to 
produce nanoparticles from olive pomace extract. Innovative Food 
Science & Emerging Technologies, 40, 2-9. 
ALONZO, D. E., ZHANG, G. G. Z., ZHOU, D., GAO, Y. & TAYLOR, L. 
S. 2010. Understanding the Behavior of Amorphous Pharmaceutical 
Systems during Dissolution. Pharmaceutical Research, 27, 608-618. 
ALSHAMSAN, A. 2014. Nanoprecipitation is more efficient than emulsion 
solvent evaporation method to encapsulate cucurbitacin I in PLGA 
nanoparticles. Saudi Pharm J, 22, 219-22. 
AMIN, A. R. M. R., KUCUK, O., KHURI, F. R. & SHIN, D. M. 2009. 
Perspectives for Cancer Prevention With Natural Compounds. Journal 
of Clinical Oncology, 27, 2712-2725. 
AMIN, M., HUSSAIN, M. A., SHAHWAR, D. & HUSSAIN, M. 2015. 
Thermal Analysis and Degradation Kinetics of Dextran and Highly 
Substituted Dextran Acetates. Journal of the Chemical Society of 
Pakistan, 37, 673-679. 
ANDRESEN, S. R., BING, J., HANSEN, R. M., BIERING-SØRENSEN, F., 
JOHANNESEN, I. L., HAGEN, E. M., RICE, A. S. C., NIELSEN, J. 
F., BACH, F. W. & FINNERUP, N. B. 2016. Ultramicronized 
palmitoylethanolamide in spinal cord injury neuropathic pain: a 
randomized, double-blind, placebo-controlled trial. PAIN, 157, 2097-
2103. 
ANITHA, A., DEEPAGAN, V. G., DIVYA RANI, V. V., MENON, D., 
NAIR, S. V. & JAYAKUMAR, R. 2011. Preparation, characterization, 
in vitro drug release and biological studies of curcumin loaded dextran 




ANTONIOU, E., THEMISTOU, E., SARKAR, B., TSIANOU, M. & 
ALEXANDRIDIS, P. 2010. Structure and dynamics of dextran in 
binary mixtures of a good and a bad solvent. Colloid and Polymer 
Science, 288, 1301-1312. 
AQUINO, R. P., AURIEMMA, G., MENCHERINI, T., RUSSO, P., 
PORTA, A., ADAMI, R., LIPAROTI, S., DELLA PORTA, G., 
REVERCHON, E. & DEL GAUDIO, P. 2013. Design and production 
of gentamicin/dextrans microparticles by supercritical assisted 
atomisation for the treatment of wound bacterial infections. Int J 
Pharm, 440, 188-94. 
BABAEI, A., ARSHAMI, J., HAGHPARAST, A. & DANESH 
MESGARAN, M. 2014. Effects of saffron (Crocus sativus) petal 
ethanolic extract on hematology, antibody response, and spleen 
histology in rats. Avicenna Journal of Phytomedicine, 4, 103-109. 
BAGHEL, S., CATHCART, H. & O'REILLY, N. J. 2016. Polymeric 
Amorphous Solid Dispersions: A Review of Amorphization, 
Crystallization, Stabilization, Solid-State Characterization, and 
Aqueous Solubilization of Biopharmaceutical Classification System 
Class II Drugs. Journal of Pharmaceutical Sciences, 105, 2527-2544. 
BALASUNDRAM, N., SUNDRAM, K. & SAMMAN, S. 2006. Phenolic 
compounds in plants and agri-industrial by-products: Antioxidant 
activity, occurrence, and potential uses. Food Chemistry, 99, 191-203. 
BALDINO, L., CARDEA, S., DE MARCO, I. & REVERCHON, E. 2014a. 
Chitosan scaffolds formation by a supercritical freeze extraction 
process. The Journal of Supercritical Fluids, 90, 27-34. 
BALDINO, L., CARDEA, S. & REVERCHON, E. 2014b. Supercritical 
assisted enzymatic membranes preparation, for active packaging 
applications. Journal of Membrane Science, 453, 409-418. 
BANSAL, S. S., GOEL, M., AQIL, F., VADHANAM, M. V. & GUPTA, R. 
C. 2011. Advanced drug delivery systems of curcumin for cancer 
chemoprevention. Cancer Prev Res (Phila), 4, 1158-71. 
BEIG, A., MILLER, J. M. & DAHAN, A. 2013. The interaction of 
nifedipine with selected cyclodextrins and the subsequent solubility-
permeability trade-off. Eur J Pharm Biopharm, 85, 1293-9. 
BETANCOURT, T., BROWN, B. & BRANNON-PEPPAS, L. 2007. 
Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: 
preparation, characterization and in vitro evaluation. Nanomedicine 
(Lond), 2, 219-32. 
BHAKAY, A., RAHMAN, M., DAVE, R. & BILGILI, E. 2018. 
Bioavailability Enhancement of Poorly Water-Soluble Drugs via 
Nanocomposites: Formulation–Processing Aspects and Challenges. 
Pharmaceutics, 10, 86. 
References 
156 
BISCAIA, D. & FERREIRA, S. R. S. 2009. Propolis extracts obtained by 
low pressure methods and supercritical fluid extraction. The Journal of 
Supercritical Fluids, 51, 17-23. 
BLAJOVAN, R. & MODRA, D. 2013. THE STUDY SYNTHESIS OF 
NIFEDIPINE-CALCIUM ANTAGONIST. New Frontiers in 
Chemistry, 22, 47. 
BRAND-WILLIAMS, W., CUVELIER, M. E. & BERSET, C. 1995. Use of 
a free radical method to evaluate antioxidant activity. LWT - Food 
Science and Technology, 28, 25-30. 
BREWSTER, M. E. & LOFTSSON, T. 2007. Cyclodextrins as 
pharmaceutical solubilizers. Adv Drug Deliv Rev, 59, 645-66. 
BRUSCHI, M. L., CARDOSO, M. L., LUCCHESI, M. B. & GREMIAO, M. 
P. 2003. Gelatin microparticles containing propolis obtained by spray-
drying technique: preparation and characterization. Int J Pharm, 264, 
45-55. 
BUSCH, V. M., PEREYRA-GONZALEZ, A., ŠEGATIN, N., 
SANTAGAPITA, P. R., POKLAR ULRIH, N. & BUERA, M. P. 2017. 
Propolis encapsulation by spray drying: Characterization and stability. 
LWT, 75, 227-235. 
CAI, M.-Q., GUAN, Y.-X., YAO, S.-J. & ZHU, Z.-Q. 2008. Supercritical 
fluid assisted atomization introduced by hydrodynamic cavitation mixer 
(SAA-HCM) for micronization of levofloxacin hydrochloride. The 
Journal of Supercritical Fluids, 43, 524-534. 
CAMPARDELLI, R., ADAMI, R. & REVERCHON, E. 2012. Preparation 
of Stable Aqueous Nanodispersions of β-Carotene by Supercritical 
Assisted Injection in a Liquid Antisolvent. Procedia Engineering, 42, 
1493-1501. 
CAMPARDELLI, R., BALDINO, L. & REVERCHON, E. 2015. 
Supercritical fluids applications in nanomedicine. The Journal of 
Supercritical Fluids, 101, 193-214. 
CAPUTO, G., LIPAROTI, S., ADAMI, R. & REVERCHON, E. 2012. Use 
of Supercritical CO2 and N2 as Dissolved Gases for the Atomization of 
Ethanol and Water. Industrial & Engineering Chemistry Research, 51, 
11803-11808. 
CAROCHO, M., MORALES, P. & FERREIRA, I. C. F. R. 2015. Natural 
food additives: Quo vadis? Trends in Food Science & Technology, 45, 
284-295. 
CATCHPOLE, O. J., GREY, J. B., MITCHELL, K. A. & LAN, J. S. 2004. 
Supercritical antisolvent fractionation of propolis tincture. The Journal 
of Supercritical Fluids, 29, 97-106. 
CHAMPAGNE, C. P. & FUSTIER, P. 2007. Microencapsulation for the 
improved delivery of bioactive compounds into foods. Current Opinion 
in Biotechnology, 18, 184-190. 
References 
157 
CHAN, K. L. A., FLEMING, O. S., KAZARIAN, S. G., VASSOU, D., 
CHRYSSIKOS, G. D. & GIONIS, V. 2004. Polymorphism and 
devitrification of nifedipine under controlled humidity: a combined FT-
Raman, IR and Raman microscopic investigation. Journal of Raman 
Spectroscopy, 35, 353-359. 
CHATTOPADHYAY, I., BISWAS, K., BANDYOPADHYAY, U. & 
BANERJEE, R. K. 2004. Turmeric and curcumin: Biological actions 
and medicinal applications. Current Science, 87, 44-53. 
CHEN, H., KHEMTONG, C., YANG, X., CHANG, X. & GAO, J. 2011. 
Nanonization strategies for poorly water-soluble drugs. Drug Discov 
Today, 16, 354-60. 
CHIOU, A. H.-J., CHENG, H.-C. & WANG, D.-P. 2006. Micronization and 
microencapsulation of felodipine by supercritical carbon dioxide. 
Journal of Microencapsulation, 23, 265-276. 
CHOW, S.-C. 2014. Bioavailability and Bioequivalence in Drug 
Development. Wiley interdisciplinary reviews. Computational statistics, 
6, 304-312. 
CILURZO, F., MINGHETTI, P., CASIRAGHI, A. & MONTANARI, L. 
2002. Characterization of nifedipine solid dispersions. Int J Pharm, 242, 
313-7. 
COCERO, M. J., MARTÍN, Á., MATTEA, F. & VARONA, S. 2009. 
Encapsulation and co-precipitation processes with supercritical fluids: 
Fundamentals and applications. The Journal of Supercritical Fluids, 47, 
546-555. 
CORONEL-AGUILERA, C. P. & SAN MARTÍN-GONZÁLEZ, M. F. 
2015. Encapsulation of spray dried β-carotene emulsion by fluidized 
bed coating technology. LWT - Food Science and Technology, 62, 187-
193. 
CORREDOR, C., TESLOVA, T., CAÑAMARES, M. V., CHEN, Z., 
ZHANG, J., LOMBARDI, J. R. & LEONA, M. 2009. Raman and 
surface-enhanced Raman spectra of chrysin, apigenin and luteolin. 
Vibrational Spectroscopy, 49, 190-195. 
DANG, H., MENG, M. H. W., ZHAO, H., IQBAL, J., DAI, R., DENG, Y. 
& LV, F. 2014. Luteolin-loaded solid lipid nanoparticles synthesis, 
characterization, & improvement of bioavailability, pharmacokinetics in 
vitro and vivo studies. Journal of Nanoparticle Research, 16, 2347. 
DE BELDER, A. N. & GRANATH, K. 1973. Preparation and properties of 
fluorescein-labelled dextrans. Carbohydrate Research, 30, 375-378. 
DE CICCO, F., REVERCHON, E., ADAMI, R., AURIEMMA, G., RUSSO, 
P., CALABRESE, E. C., PORTA, A., AQUINO, R. P. & DEL 
GAUDIO, P. 2014. In situ forming antibacterial dextran blend hydrogel 
for wound dressing: SAA technology vs. spray drying. Carbohydr 
Polym, 101, 1216-24. 
References 
158 
DE PAZ, E., MARTÍN, Á., DUARTE, C. M. M. & COCERO, M. J. 2012. 
Formulation of β-carotene with poly-(ε-caprolactones) by PGSS 
process. Powder Technology, 217, 77-83. 
DE SOUZA FERREIRA, S. B., DE ASSIS DIAS, B. R., OBREGON, C. S., 
GOMES, C. C., DE ARAUJO PEREIRA, R. R., RIBEIRO GODOY, J. 
S., ESTIVALET SVIDZINSKI, T. I. & BRUSCHI, M. L. 2014. 
Microparticles containing propolis and metronidazole: in vitro 
characterization, release study and antimicrobial activity against 
periodontal pathogens. Pharm Dev Technol, 19, 173-80. 
DE SOUZA SIMÕES, L., MADALENA, D. A., PINHEIRO, A. C., 
TEIXEIRA, J. A., VICENTE, A. A. & RAMOS, Ó. L. 2017. Micro- 
and nano bio-based delivery systems for food applications: In vitro 
behavior. Advances in Colloid and Interface Science, 243, 23-45. 
DE ZORDI, N., CORTESI, A., KIKIC, I., MONEGHINI, M., SOLINAS, 
D., INNOCENTI, G., PORTOLAN, A., BARATTO, G. & 
DALL’ACQUA, S. 2014. The supercritical carbon dioxide extraction of 
polyphenols from Propolis: A central composite design approach. The 
Journal of Supercritical Fluids, 95, 491-498. 
DELLA PORTA, G., ADAMI, R., DEL GAUDIO, P., PROTA, L., 
AQUINO, R. & REVERCHON, E. 2010. Albumin/gentamicin 
microspheres produced by supercritical assisted atomization: 
optimization of size, drug loading and release. J Pharm Sci, 99, 4720-9. 
DELLA PORTA, G., ERCOLINO, S. F., PARENTE, L. & REVERCHON, 
E. 2006. Corticosteroid Microparticles Produced by Supercritical-
Assisted Atomization: Process Optimization, Product Characterization, 
and “in Vitro” Performance. Journal of Pharmaceutical Sciences, 95, 
2062-2076. 
DESAI, K. G. H. & JIN PARK, H. 2005. Recent Developments in 
Microencapsulation of Food Ingredients. Drying Technology, 23, 1361-
1394. 
DI CAPUA, A., ADAMI, R., COSENZA, E., JALABER, V., CRAMPON, 
C., BADENS, E. & REVERCHON, E. 2019. β-Carotene/PVP 
microspheres produced by Supercritical Assisted Atomization. Powder 
Technology, 346 (2019), 228-236. 
DI CAPUA, A., ADAMI, R., IZZO, L. & REVERCHON, E. 2017a. 
Luteolin/dextran-FITC fluorescent microspheres produced by 
supercritical assisted atomization. The Journal of Supercritical Fluids, 
130, 97-104. 
DI CAPUA, A., ADAMI, R. & REVERCHON, E. 2017b. Production of 
Luteolin/Biopolymer Microspheres by Supercritical Assisted 
Atomization. Industrial & Engineering Chemistry Research, 56, 4334-
4340. 
DI CAPUA, A., BEJARANO, A., ADAMI, R. & REVERCHON, E. 2018. 
Preparation and characterization of Chilean propolis coprecipitates 
References 
159 
using Supercritical Assisted Atomization. Chemical Engineering 
Research and Design, 136, 776-785. 
DINUNZIO, J. C., MILLER, D. A., YANG, W., MCGINITY, J. W. & 
WILLIAMS, R. O. 2008. Amorphous Compositions Using 
Concentration Enhancing Polymers for Improved Bioavailability of 
Itraconazole. Molecular Pharmaceutics, 5, 968-980. 
DO NASCIMENTO, T. G., DA SILVA, P. F., AZEVEDO, L. F., DA 
ROCHA, L. G., DE MORAES PORTO, I. C., LIMA, E. M. T. F., 
BASILIO-JUNIOR, I. D., GRILLO, L. A., DORNELAS, C. B., 
FONSECA, E. J., DE JESUS OLIVEIRA, E., ZHANG, A. T. & 
WATSON, D. G. 2016. Polymeric Nanoparticles of Brazilian Red 
Propolis Extract: Preparation, Characterization, Antioxidant and 
Leishmanicidal Activity. Nanoscale Res Lett, 11, 301. 
DU, Z., TANG, C., GUAN, Y.-X., YAO, S.-J. & ZHU, Z.-Q. 2013. 
Bioactive insulin microparticles produced by supercritical fluid assisted 
atomization with an enhanced mixer. International Journal of 
Pharmaceutics, 454, 174-182. 
DVORAK, H. F., NAGY, J. A., DVORAK, J. T. & DVORAK, A. M. 1988. 
Identification and characterization of the blood vessels of solid tumors 
that are leaky to circulating macromolecules. The American Journal of 
Pathology, 133, 95-109. 
EMARA, L. H., BADR, R. M. & ELBARY, A. A. 2002. Improving the 
dissolution and bioavailability of nifedipine using solid dispersions and 
solubilizers. Drug Dev Ind Pharm, 28, 795-807. 
ESLAMIAN, M., AHMED, M. & ASHGRIZ, N. 2009. Modeling of 
Solution Droplet Evaporation and Particle Evolution in Droplet-to-
Particle Spray Methods. Drying Technology, 27, 3-13. 
FAHIM, T. K., ZAIDUL, I. S. M., ABU BAKAR, M. R., SALIM, U. M., 
AWANG, M. B., SAHENA, F., JALAL, K. C. A., SHARIF, K. M. & 
SOHRAB, M. H. 2014. Particle formation and micronization using non-
conventional techniques- review. Chemical Engineering and 
Processing: Process Intensification, 86, 47-52. 
FARAZUDDIN, M., DUA, B., ZIA, Q., KHAN, A. A., JOSHI, B. & 
OWAIS, M. 2014. Chemotherapeutic potential of curcumin-bearing 
microcells against hepatocellular carcinoma in model animals. Int J 
Nanomedicine, 9, 1139-52. 
FENG, X., LV, F., LIU, L., TANG, H., XING, C., YANG, Q. & WANG, S. 
2010. Conjugated polymer nanoparticles for drug delivery and imaging. 
ACS Appl Mater Interfaces, 2, 2429-35. 
FIEDOR, J. & BURDA, K. 2014. Potential Role of Carotenoids as 
Antioxidants in Human Health and Disease. Nutrients, 6, 466-488. 
FRANCESCHI, E., DE CESARO, A. M., FEITEN, M., FERREIRA, S. R. 
S., DARIVA, C., KUNITA, M. H., RUBIRA, A. F., MUNIZ, E. C., 
CORAZZA, M. L. & OLIVEIRA, J. V. 2008. Precipitation of β-
References 
160 
carotene and PHBV and co-precipitation from SEDS technique using 
supercritical CO2. The Journal of Supercritical Fluids, 47, 259-269. 
FU, Q., MA, M., LI, M., WANG, G., GUO, M., LI, J., HOU, Y. & FANG, 
M. 2017. Improvement of oral bioavailability for nisoldipine using 
nanocrystals. Powder Technology, 305, 757-763. 
GORALCZYK, R. 2009. Beta-carotene and lung cancer in smokers: review 
of hypotheses and status of research. Nutr Cancer, 61, 767-74. 
GRUNE, T., LIETZ, G., PALOU, A., ROSS, A. C., STAHL, W., TANG, G., 
THURNHAM, D., YIN, S. A. & BIESALSKI, H. K. 2010. Beta-
carotene is an important vitamin A source for humans. J Nutr, 140, 
2268s-2285s. 
GUAMÁN-BALCÁZAR, M. C., MONTES, A., PEREYRA, C. & 
MARTÍNEZ DE LA OSSA, E. 2019. Production of submicron particles 
of the antioxidants of mango leaves/PVP by supercritical antisolvent 
extraction process. The Journal of Supercritical Fluids, 143, 294-304. 
GUL, K., TAK, A., SINGH, A. K., SINGH, P., YOUSUF, B. & WANI, A. 
A. 2015. Chemistry, encapsulation, and health benefits of β-carotene - 
A review. Cogent Food & Agriculture, 1, 1018696. 
GUPTA, S., KESARLA, R. & OMRI, A. 2013. Formulation Strategies to 
Improve the Bioavailability of Poorly Absorbed Drugs with Special 
Emphasis on Self-Emulsifying Systems. ISRN Pharmaceutics, 2013, 16. 
HADIZADEH, F., KHALILI, N., HOSSEINZADEH, H. & KHAIR-
ALDINE, R. 2010. Kaempferol from Saffron Petals. Iranian Journal of 
Pharmaceutical Research, Volume 2, 251-252. 
HANCOCK, B. C. & PARKS, M. 2000. What is the True Solubility 
Advantage for Amorphous Pharmaceuticals? Pharmaceutical Research, 
17, 397-404. 
HANDFORD, C. E., DEAN, M., HENCHION, M., SPENCE, M., 
ELLIOTT, C. T. & CAMPBELL, K. 2014. Implications of 
nanotechnology for the agri-food industry: Opportunities, benefits and 
risks. Trends in Food Science & Technology, 40, 226-241. 
HAR BHAJAN, S. & BHARATI, K. A. 2014. 6 - Enumeration of dyes. In: 
HAR BHAJAN, S. & BHARATI, K. A. (eds.) Handbook of Natural 
Dyes and Pigments. Woodhead Publishing India. 
HE, W., SUO, Q., HONG, H., SHAN, A., LI, C., HUANG, Y., LI, Y. & 
ZHU, M. 2007. Production of natural carotene-dispersed polymer 
microparticles by SEDS-PA co-precipitation. Journal of Materials 
Science, 42, 3495-3501. 
HIJAZI, N., RODIER, E., LETOURNEAU, J.-J., LOUATI, H., SAUCEAU, 
M., LE MOIGNE, N., BENEZET, J.-C. & FAGES, J. 2014. Chitosan 
nanoparticles generation using CO2 assisted processes. The Journal of 
Supercritical Fluids, 95, 118-128. 
HOYER, H., SCHLOCKER, W., KRUM, K. & BERNKOP-SCHNÜRCH, 
A. 2008. Preparation and evaluation of microparticles from thiolated 
References 
161 
polymers via air jet milling. European Journal of Pharmaceutics and 
Biopharmaceutics, 69, 476-485. 
HUANG, Q., YU, H. & RU, Q. 2010. Bioavailability and Delivery of 
Nutraceuticals Using Nanotechnology. Journal of Food Science, 75, 
R50-R57. 
IMPELLIZZERI, D., BRUSCHETTA, G., CORDARO, M., CRUPI, R., 
SIRACUSA, R., ESPOSITO, E. & CUZZOCREA, S. 2014. 
Micronized/ultramicronized palmitoylethanolamide displays superior 
oral efficacy compared to nonmicronized palmitoylethanolamide in a rat 
model of inflammatory pain. J Neuroinflammation, 11, 136. 
IMPELLIZZERI, D., CAMPOLO, M., DI PAOLA, R., BRUSCHETTA, G., 
DE STEFANO, D., ESPOSITO, E. & CUZZOCREA, S. 2015. 
Ultramicronized palmitoylethanolamide reduces inflammation an a 
Th1-mediated model of colitis. European Journal of Inflammation, 13, 
14-31. 
ISHWARYA, S. P., ANANDHARAMAKRISHNAN, C. & STAPLEY, A. 
G. F. 2015. Spray-freeze-drying: A novel process for the drying of 
foods and bioproducts. Trends in Food Science & Technology, 41, 161-
181. 
JAGDALE, S. C., JADHAV, V. N., CHABUKSWAR, A. R. & 
KUCHEKAR, B. S. 2012. Solubility enhancement, physicochemical 
characterization and formulation of fast-dissolving tablet of nifedipine-
betacyclodextrin complexes. Brazilian Journal of Pharmaceutical 
Sciences, 48, 131-145. 
JAIN, P. & BANGA, A. K. 2010. Inhibition of crystallization in drug-in-
adhesive-type transdermal patches. International Journal of 
Pharmaceutics, 394, 68-74. 
JANISZEWSKA-TURAK, E. 2017. Carotenoids microencapsulation by 
spray drying method and supercritical micronization. Food Res Int, 99, 
891-901. 
JOYE, I. J., DAVIDOV-PARDO, G. & MCCLEMENTS, D. J. 2014. 
Nanotechnology for increased micronutrient bioavailability. Trends in 
Food Science & Technology, 40, 168-182. 
JOYE, I. J. & MCCLEMENTS, D. J. 2013. Production of nanoparticles by 
anti-solvent precipitation for use in food systems. Trends in Food 
Science & Technology, 34, 109-123. 
JUN, S. W., KIM, M.-S., KIM, J.-S., PARK, H. J., LEE, S., WOO, J.-S. & 
HWANG, S.-J. 2007. Preparation and characterization of 
simvastatin/hydroxypropyl-β-cyclodextrin inclusion complex using 
supercritical antisolvent (SAS) process. European Journal of 
Pharmaceutics and Biopharmaceutics, 66, 413-421. 
JUNYAPRASERT, V. B. & MORAKUL, B. 2015. Nanocrystals for 
enhancement of oral bioavailability of poorly water-soluble drugs. 
Asian Journal of Pharmaceutical Sciences, 10, 13-23. 
References 
162 
KAKRAN, M., SAHOO, N. G., TAN, I.-L. & LI, L. 2012. Preparation of 
nanoparticles of poorly water-soluble antioxidant curcumin by 
antisolvent precipitation methods. Journal of Nanoparticle Research, 
14, 757. 
KALEPU, S. & NEKKANTI, V. 2015. Insoluble drug delivery strategies: 
review of recent advances and business prospects. Acta Pharmaceutica 
Sinica B, 5, 442-453. 
KALOGEROPOULOS, N., KONTELES, S., MOURTZINOS, I., 
TROULLIDOU, E., CHIOU, A. & KARATHANOS, V. T. 2009. 
Encapsulation of complex extracts in beta-cyclodextrin: an application 
to propolis ethanolic extract. J Microencapsul, 26, 603-13. 
KAMADA, H., TSUTSUMI, Y., YAMAMOTO, Y., KIHIRA, T., 
KANEDA, Y., MU, Y., KODAIRA, H., TSUNODA, S. I., 
NAKAGAWA, S. & MAYUMI, T. 2000. Antitumor activity of tumor 
necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid 
tumors in mice. Cancer Res, 60, 6416-20. 
KANAZE, F. I., KOKKALOU, E., NIOPAS, I., BARMPALEXIS, P., 
GEORGARAKIS, E. & BIKIARIS, D. 2010. Dissolution rate and 
stability study of flavanone aglycones, naringenin and hesperetin, by 
drug delivery systems based on polyvinylpyrrolidone (PVP) 
nanodispersions. Drug Dev Ind Pharm, 36, 292-301. 
KAWABATA, Y., WADA, K., NAKATANI, M., YAMADA, S. & 
ONOUE, S. 2011. Formulation design for poorly water-soluble drugs 
based on biopharmaceutics classification system: Basic approaches and 
practical applications. International Journal of Pharmaceutics, 420, 1-
10. 
KHADKA, P., RO, J., KIM, H., KIM, I., KIM, J. T., KIM, H., CHO, J. M., 
YUN, G. & LEE, J. 2014. Pharmaceutical particle technologies: An 
approach to improve drug solubility, dissolution and bioavailability. 
Asian Journal of Pharmaceutical Sciences, 9, 304-316. 
KHAN, J., ALEXANDER, A., AJAZUDDIN, SARAF, S. & SARAF, S. 
2014. Luteolin-phospholipid complex: preparation, characterization and 
biological evaluation. J Pharm Pharmacol, 66, 1451-62. 
KHAN, W. H. & RATHOD, V. K. 2014. Process intensification approach 
for preparation of curcumin nanoparticles via solvent–nonsolvent 
nanoprecipitation using spinning disc reactor. Chemical Engineering 
and Processing: Process Intensification, 80, 1-10. 
KHAZAEI, K. M., JAFARI, S. M., GHORBANI, M., KAKHKI, A. H. & 
SARFARAZI, M. 2016. Optimization of Anthocyanin Extraction from 
Saffron Petals with Response Surface Methodology. Food Analytical 
Methods, 9, 1993-2001. 
KHURSHID, Z., NASEEM, M., ZAFAR, M. S., NAJEEB, S. & ZOHAIB, 
S. 2017. Propolis: A natural biomaterial for dental and oral healthcare. 
References 
163 
Journal of Dental Research, Dental Clinics, Dental Prospects, 11, 265-
274. 
KOGERMANN, K., PENKINA, A., PREDBANNIKOVA, K., JEEGER, K., 
VESKI, P., RANTANEN, J. & NAELAPÄÄ, K. 2013. Dissolution 
testing of amorphous solid dispersions. International Journal of 
Pharmaceutics, 444, 40-46. 
KRAUSZ, A. E., ADLER, B. L., CABRAL, V., NAVATI, M., DOERNER, 
J., CHARAFEDDINE, R. A., CHANDRA, D., LIANG, H., 
GUNTHER, L., CLENDANIEL, A., HARPER, S., FRIEDMAN, J. M., 
NOSANCHUK, J. D. & FRIEDMAN, A. J. 2015. Curcumin-
encapsulated nanoparticles as innovative antimicrobial and wound 
healing agent. Nanomedicine, 11, 195-206. 
KROL, W., BANKOVA, V., SFORCIN, J. M., SZLISZKA, E., CZUBA, Z. 
& KUROPATNICKI, A. K. 2013. Propolis: properties, application, and 
its potential. Evid Based Complement Alternat Med, 2013, 807578. 
LABUSCHAGNE, P. W., ADAMI, R., LIPAROTI, S., NAIDOO, S., SWAI, 
H. & REVERCHON, E. 2014. Preparation of rifampicin/poly(d,l-
lactice) nanoparticles for sustained release by supercritical assisted 
atomization technique. The Journal of Supercritical Fluids, 95, 106-
117. 
LAFKA, T.-I., SINANOGLOU, V. & LAZOS, E. S. 2007. On the extraction 
and antioxidant activity of phenolic compounds from winery wastes. 
Food Chemistry, 104, 1206-1214. 
LAOT, C. M., MARAND, E. & OYAMA, H. T. 1999. Spectroscopic 
characterization of molecular interdiffusion at a poly(vinyl 
pyrrolidone)/vinyl ester interface. Polymer, 40, 1095-1108. 
LEE, S. Y., YU, G. & KIM, I. W. 2013. Effects of Polymeric Additives on 
the Crystallization and Release Behavior of Amorphous Ibuprofen. 
Journal of Nanomaterials, 2013, 7. 
LEVY, G. & NELSON, E. 1961. United States Pharmacopeia and National 
Formulary standards, Food and Drug Administration regulations, and 
the quality of drugs. N Y State J Med, 61, 4003-8. 
LIN, S. Y., HSU, C. H. & SHEU, M. T. 2010. Curve-fitting FTIR studies of 
loratadine/hydroxypropyl-beta-cyclodextrin inclusion complex induced 
by co-grinding process. J Pharm Biomed Anal, 53, 799-803. 
LIN, Y., SHI, R., WANG, X. & SHEN, H. M. 2008. Luteolin, a flavonoid 
with potential for cancer prevention and therapy. Curr Cancer Drug 
Targets, 8, 634-46. 
LIPAROTI, S., ADAMI, R., CAPUTO, G. & REVERCHON, E. 2013. 
Supercritical Assisted Atomization: Polyvinylpyrrolidone as Carrier for 
Drugs with Poor Solubility in Water. Journal of Chemistry, 2013, 5. 
LIPAROTI, S., ADAMI, R. & REVERCHON, E. 2012. PEG micronization 
by supercritical assisted atomization, operated under reduced pressure. 
The Journal of Supercritical Fluids, 72, 46-51. 
References 
164 
LIPAROTI, S., ADAMI, R. & REVERCHON, E. 2015. Supercritical 
Assisted Atomization: effect of operative conditions on PVP 
microparticle size and morphology. The Journal of Supercritical Fluids, 
97, 31-35. 
LIPINSKI, C. A., LOMBARDO, F., DOMINY, B. W. & FEENEY, P. J. 
2001. Experimental and computational approaches to estimate solubility 
and permeability in drug discovery and development settings1PII of 
original article: S0169-409X(96)00423-1. The article was originally 
published in Advanced Drug Delivery Reviews 23 (1997) 3–25.1. 
Advanced Drug Delivery Reviews, 46, 3-26. 
LOH, Z. H., SAMANTA, A. K. & SIA HENG, P. W. 2015. Overview of 
milling techniques for improving the solubility of poorly water-soluble 
drugs. Asian Journal of Pharmaceutical Sciences, 10, 255-274. 
LOKSUWAN, J. 2007. Characteristics of microencapsulated β-carotene 
formed by spray drying with modified tapioca starch, native tapioca 
starch and maltodextrin. Food Hydrocolloids, 21, 928-935. 
LOTFI, L., KALBASI-ASHTARI, A., HAMEDI, M. & GHORBANI, F. 
2015. Effects of sulfur water extraction on anthocyanins properties of 
tepals in flower of saffron (Crocus sativus L). Journal of Food Science 
and Technology, 52, 813-821. 
LOTITO, S. B. & FREI, B. 2004. Relevance of apple polyphenols as 
antioxidants in human plasma: contrasting in vitro and in vivo effects. 
Free Radical Biology and Medicine, 36, 201-211. 
MACHADO, A. P. D. F., RUEDA, M., BARBERO, G. F., MARTÍN, Á., 
COCERO, M. J. & MARTÍNEZ, J. 2018. Co-precipitation of 
anthocyanins of the extract obtained from blackberry residues by 
pressurized antisolvent process. The Journal of Supercritical Fluids, 
137, 81-92. 
MACHADO, B. A., BARRETO GDE, A., COSTA, A. S., COSTA, S. S., 
SILVA, R. P., DA SILVA, D. F., BRANDAO, H. N., DA ROCHA, J. 
L., NUNES, S. B., UMSZA-GUEZ, M. A. & PADILHA, F. F. 2015. 
Determination of Parameters for the Supercritical Extraction of 
Antioxidant Compounds from Green Propolis Using Carbon Dioxide 
and Ethanol as Co-Solvent. PLoS One, 10, e0134489. 
MAHDAVEE KHAZAEI, K., JAFARI, S. M., GHORBANI, M. & 
HEMMATI KAKHKI, A. 2014. Application of maltodextrin and gum 
Arabic in microencapsulation of saffron petal's anthocyanins and 
evaluating their storage stability and color. Carbohydrate Polymers, 
105, 57-62. 
MARTÍN, A. & COCERO, M. J. 2008. Micronization processes with 
supercritical fluids: Fundamentals and mechanisms. Advanced Drug 
Delivery Reviews, 60, 339-350. 
MARTIN, L., LIPAROTI, S., DELLA PORTA, G., ADAMI, R., 
MARQUÉS, J. L., URIETA, J. S., MAINAR, A. M. & REVERCHON, 
References 
165 
E. 2013. Rotenone coprecipitation with biodegradable polymers by 
supercritical assisted atomization. The Journal of Supercritical Fluids, 
81, 48-54. 
MARTINS, R. M., PEREIRA, S. V., SIQUEIRA, S., SALOMÃO, W. F. & 
FREITAS, L. A. P. 2013. Curcuminoid content and antioxidant activity 
in spray dried microparticles containing turmeric extract. Food 
Research International, 50, 657-663. 
MATTEA, F., MARTÍN, Á., MATÍAS-GAGO, A. & COCERO, M. J. 2009. 
Supercritical antisolvent precipitation from an emulsion: β-Carotene 
nanoparticle formation. The Journal of Supercritical Fluids, 51, 238-
247. 
MEHVAR, R. 2000. Dextrans for targeted and sustained delivery of 
therapeutic and imaging agents. J Control Release, 69, 1-25. 
MELLA, M., MOLLICA, L. & IZZO, L. 2015. Influence of charged 
intramolecular hydrogen bonds in weak polyelectrolytes: A Monte 
Carlo study of flexible and extendible polymeric chains in solution and 
near charged spheres. Journal of Polymer Science Part B: Polymer 
Physics, 53, 650-663. 
MENESES, M. A., CAPUTO, G., SCOGNAMIGLIO, M., REVERCHON, 
E. & ADAMI, R. 2015. Antioxidant phenolic compounds recovery from 
Mangifera indica L. by-products by supercritical antisolvent extraction. 
Journal of Food Engineering, 163, 45-53. 
MERISKO-LIVERSIDGE, E. & LIVERSIDGE, G. G. 2011. Nanosizing for 
oral and parenteral drug delivery: a perspective on formulating poorly-
water soluble compounds using wet media milling technology. Adv 
Drug Deliv Rev, 63, 427-40. 
MEZHERICHER, M., LEVY, A. & BORDE, I. 2007. Theoretical Drying 
Model of Single Droplets Containing Insoluble or Dissolved Solids. 
Drying Technology, 25, 1025-1032. 
MISHRA, R. K., DATT, M. & BANTHIA, A. K. 2008. Synthesis and 
Characterization of Pectin/PVP Hydrogel Membranes for Drug 
Delivery System. AAPS PharmSciTech, 9, 395-403. 
MOSHARRAF, M. & NYSTRÖM, C. 1995. The effect of particle size and 
shape on the surface specific dissolution rate of microsized practically 
insoluble drugs. International Journal of Pharmaceutics, 122, 35-47. 
MURTHY, P. S. & NAIDU, M. M. 2012. Recovery of Phenolic 
Antioxidants and Functional Compounds from Coffee Industry By-
Products. Food and Bioprocess Technology, 5, 897-903. 
NEUHOUSER, M. L. 2004. Dietary flavonoids and cancer risk: evidence 
from human population studies. Nutr Cancer, 50, 1-7. 
NEWMAN, A., KNIPP, G. & ZOGRAFI, G. 2012. Assessing the 
performance of amorphous solid dispersions. Journal of 
Pharmaceutical Sciences, 101, 1355-1377. 
References 
166 
NORI, M. P., FAVARO-TRINDADE, C. S., MATIAS DE ALENCAR, S., 
THOMAZINI, M., DE CAMARGO BALIEIRO, J. C. & CONTRERAS 
CASTILLO, C. J. 2011. Microencapsulation of propolis extract by 
complex coacervation. LWT - Food Science and Technology, 44, 429-
435. 
NYKAMP, G., CARSTENSEN, U. & MÜLLER, B. W. 2002. Jet milling—a 
new technique for microparticle preparation. International Journal of 
Pharmaceutics, 242, 79-86. 
O'DONNELL, P. B. & MCGINITY, J. W. 1997. Preparation of 
microspheres by the solvent evaporation technique. Advanced Drug 
Delivery Reviews, 28, 25-42. 
PACHECO, C., MAGALHÃES, R., FONSECA, M., SILVEIRA, P. & 
BRANDÃO, I. 2016. Accidental intoxication by dichloromethane at 
work place: Clinical case and literature review. Journal of Acute 
Medicine, 6, 43-45. 
PARADKAR, A., AMBIKE, A. A., JADHAV, B. K. & MAHADIK, K. R. 
2004. Characterization of curcumin–PVP solid dispersion obtained by 
spray drying. International Journal of Pharmaceutics, 271, 281-286. 
PATRA, D. & SLEEM, F. 2013. A new method for pH triggered curcumin 
release by applying poly(L-lysine) mediated nanoparticle-congregation. 
Anal Chim Acta, 795, 60-8. 
PAVIANI, L. C., SAITO, E., DARIVA, C., MARCUCCI, M. C., 
SÁNCHEZ-CAMARGO, A. P. & CABRAL, F. A. 2012. Supercritical 
CO2 extraction of raw propolis and its dry ethanolic extract. Brazilian 
Journal of Chemical Engineering, 29, 243-251. 
PEDRO, A. S., VILLA, S. D., CALICETI, P., MELO, S. A. B. V. D., 
ALBUQUERQUE, E. C., BERTUCCO, A. & SALMASO, S. 2016. 
Curcumin-loaded solid lipid particles by PGSS technology. The Journal 
of Supercritical Fluids, 107, 534-541. 
PETROSINO, S., SCHIANO MORIELLO, A., CERRATO, S., FUSCO, M., 
PUIGDEMONT, A., DE PETROCELLIS, L. & DI MARZO, V. 2016. 
The anti-inflammatory mediator palmitoylethanolamide enhances the 
levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 
cation channels. British Journal of Pharmacology, 173, 1154-1162. 
PIQUER, J., LLÁCER, J. L., ROVIRA, V., RIESGO, P., RODRIGUEZ, R. 
& CREMADES, A. 2014. Fluorescence-Guided Surgery and Biopsy in 
Gliomas with an Exoscope System. BioMed Research International, 
2014, 6. 
PRIAMO, W. L., DE CEZARO, A. M., BENETTI, S. C., OLIVEIRA, J. V. 
& FERREIRA, S. R. S. 2011. In vitro release profiles of β-carotene 
encapsulated in PHBV by means of supercritical carbon dioxide 




PROCHÁZKOVÁ, D., BOUŠOVÁ, I. & WILHELMOVÁ, N. 2011. 
Antioxidant and prooxidant properties of flavonoids. Fitoterapia, 82, 
513-523. 
PROSAPIO, V., REVERCHON, E. & DE MARCO, I. 2015. Coprecipitation 
of Polyvinylpyrrolidone/β-Carotene by Supercritical Antisolvent 
Processing. Industrial & Engineering Chemistry Research, 54, 11568-
11575. 
PUHL, A. C., FAGUNDES, M., DOS SANTOS, K. C., POLIKARPOV, I., 
DA SILVA, M. F. D. G. F., FERNANDES, J. B., VIEIRA, P. C. & 
FORIM, M. R. 2012. Preparation and characterization of polymeric 
nanoparticles loaded with the flavonoid luteolin, by using factorial 
design. 2012, 3, 16. 
PULIGUNDLA, P., MOK, C., KO, S., LIANG, J. & RECHARLA, N. 2017. 
Nanotechnological approaches to enhance the bioavailability and 
therapeutic efficacy of green tea polyphenols. Journal of Functional 
Foods, 34, 139-151. 
PURAMA, R. K., GOSWAMI, P., KHAN, A. T. & GOYAL, A. 2009. 
Structural analysis and properties of dextran produced by Leuconostoc 
mesenteroides NRRL B-640. Carbohydrate Polymers, 76, 30-35. 
RAHMAN, S. M. H., TELNY, T. C., RAVI, T. K. & KUPPUSAMY, S. 
2009. Role of Surfactant and pH in Dissolution of Curcumin. Indian 
Journal of Pharmaceutical Sciences, 71, 139-142. 
RECHARLA, N., RIAZ, M., KO, S. & PARK, S. 2017. Novel technologies 
to enhance solubility of food-derived bioactive compounds: A review. 
Journal of Functional Foods, 39, 63-73. 
REKSAMUNANDAR, R. P., EDIKRESNHA, D., MUNIR, M. M., 
DAMAYANTI, S. & KHAIRURRIJAL 2017. Encapsulation of β-
carotene in poly(vinylpyrrolidone) (PVP) by Electrospinning 
Technique. Procedia Engineering, 170, 19-23. 
REVERCHON, E. 2002. Supercritical-Assisted Atomization To Produce 
Micro- and/or Nanoparticles of Controlled Size and Distribution. 
Industrial & Engineering Chemistry Research, 41, 2405-2411. 
REVERCHON, E. & ADAMI, R. 2006. Nanomaterials and supercritical 
fluids. The Journal of Supercritical Fluids, 37, 1-22. 
REVERCHON, E. & ADAMI, R. 2013. Supercritical assisted atomization to 
produce nanostructured chitosan-hydroxyapatite microparticles for 
biomedical application. Powder Technology, 246, 441-447. 
REVERCHON, E., ADAMI, R., CAMPARDELLI, R., DELLA PORTA, G., 
DE MARCO, I. & SCOGNAMIGLIO, M. 2015. Supercritical fluids 
based techniques to process pharmaceutical products difficult to 




REVERCHON, E., ADAMI, R. & CAPUTO, G. 2007. Production of 
cromolyn sodium microparticles for aerosol delivery by supercritical 
assisted atomization. AAPS PharmSciTech, 8, E114-E114. 
REVERCHON, E., ADAMI, R., CARDEA, S. & PORTA, G. D. 2009. 
Supercritical fluids processing of polymers for pharmaceutical and 
medical applications. The Journal of Supercritical Fluids, 47, 484-492. 
REVERCHON, E., ADAMI, R., MARCO, I. D., LAUDANI, C. G. & 
SPADA, A. 2005. Pigment Red 60 micronization using supercritical 
fluids based techniques. The Journal of Supercritical Fluids, 35, 76-82. 
REVERCHON, E., ADAMI, R., SCOGNAMIGLIO, M., FORTUNATO, G. 
& DELLA PORTA, G. 2010. Beclomethasone Microparticles for Wet 
Inhalation, Produced by Supercritical Assisted Atomization. Industrial 
& Engineering Chemistry Research, 49, 12747-12755. 
REVERCHON, E. & ANTONACCI, A. 2006a. Chitosan Microparticles 
Production by Supercritical Fluid Processing. Industrial & Engineering 
Chemistry Research, 45, 5722-5728. 
REVERCHON, E. & ANTONACCI, A. 2006b. Cyclodextrins micrometric 
powders obtained by supercritical fluid processing. Biotechnol Bioeng, 
94, 753-61. 
REVERCHON, E. & ANTONACCI, A. 2007a. Drug–polymer 
microparticles produced by supercritical assisted atomization. 
Biotechnology and Bioengineering, 97, 1626-1637. 
REVERCHON, E. & ANTONACCI, A. 2007b. Polymer microparticles 
production by supercritical assisted atomization. The Journal of 
Supercritical Fluids, 39, 444-452. 
REVERCHON, E. & DE MARCO, I. 2011. Mechanisms controlling 
supercritical antisolvent precipitate morphology. Chemical Engineering 
Journal, 169, 358-370. 
REVERCHON, E. & DELLA PORTA, G. 2003. Micronization of 
antibiotics by supercritical assisted atomization. The Journal of 
Supercritical Fluids, 26, 243-252. 
REVERCHON, E., DELLA PORTA, G., SPADA, A. & ANTONACCI, A. 
2004. Griseofulvin micronization and dissolution rate improvement by 
supercritical assisted atomization. J Pharm Pharmacol, 56, 1379-87. 
REVERCHON, E., LAMBERTI, G. & ANTONACCI, A. 2008. 
Supercritical fluid assisted production of HPMC composite 
microparticles. The Journal of Supercritical Fluids, 46, 185-196. 
REVERCHON, E., PORTA, G. D. & SPADA, A. 2003. Ampicillin 
micronization by supercritical assisted atomization. Journal of 
Pharmacy and Pharmacology, 55, 1465-1471. 
REVERCHON, E. & SPADA, A. 2004a. Crystalline Microparticles of 
Controlled Size Produced by Supercritical-Assisted Atomization. 
Industrial & Engineering Chemistry Research, 43, 1460-1465. 
References 
169 
REVERCHON, E. & SPADA, A. 2004b. Erythromycin micro-particles 
produced by supercritical fluid atomization. Powder Technology, 141, 
100-108. 
RIGHI, V., PARENTI, F., TUGNOLI, V., SCHENETTI, L. & MUCCI, A. 
2015. Crocus sativus Petals: Waste or Valuable Resource? The Answer 
of High-Resolution and High-Resolution Magic Angle Spinning 
Nuclear Magnetic Resonance. J Agric Food Chem, 63, 8439-44. 
ROCHA, B. A., RODRIGUES, M. R., BUENO, P. C. P., DE MELLO 
COSTA-MACHADO, A. R., DE OLIVEIRA LIMA LEITE VAZ, M. 
M., NASCIMENTO, A. P., BARUD, H. S. & BERRETTA-SILVA, A. 
A. 2012. Preparation and thermal characterization of inclusion complex 
of Brazilian green propolis and hydroxypropyl-β-cyclodextrin. Journal 
of Thermal Analysis and Calorimetry, 108, 87-94. 
RODRIGUEZ-ALLER, M., GUILLARME, D., VEUTHEY, J.-L. & 
GURNY, R. 2015. Strategies for formulating and delivering poorly 
water-soluble drugs. Journal of Drug Delivery Science and Technology, 
30, 342-351. 
RUSSO, A., CARDILE, V., SANCHEZ, F., TRONCOSO, N., VANELLA, 
A. & GARBARINO, J. A. 2004. Chilean propolis: antioxidant activity 
and antiproliferative action in human tumor cell lines. Life Sci, 76, 545-
58. 
SAGNELLA, S. M., DUONG, H., MACMILLAN, A., BOYER, C., WHAN, 
R., MCCARROLL, J. A., DAVIS, T. P. & KAVALLARIS, M. 2014. 
Dextran-Based Doxorubicin Nanocarriers with Improved Tumor 
Penetration. Biomacromolecules, 15, 262-275. 
SARAVANAKUMAR, G., JO, D. G. & PARK, J. H. 2012. Polysaccharide-
based nanoparticles: a versatile platform for drug delivery and 
biomedical imaging. Curr Med Chem, 19, 3212-29. 
SARDAS, S. 2003. The Role of Antioxidants in Cancer Prevention and 
Treatment. Indoor and Built Environment, 12, 401-404. 
SAVJANI, K. T., GAJJAR, A. K. & SAVJANI, J. K. 2012. Drug Solubility: 
Importance and Enhancement Techniques. ISRN Pharmaceutics, 2012, 
10. 
SCHIFILLITI, C., CUCINOTTA, L., FEDELE, V., INGEGNOSI, C., 
LUCA, S. & LEOTTA, C. 2014. Micronized Palmitoylethanolamide 
Reduces the Symptoms of Neuropathic Pain in Diabetic Patients. Pain 
Research and Treatment, 2014, 849623. 
SCHLOSSER, P. M., BALE, A. S., GIBBONS, C. F., WILKINS, A. & 
COOPER, G. S. 2015. Human Health Effects of Dichloromethane: Key 
Findings and Scientific Issues. Environmental Health Perspectives, 123, 
114-119. 
SEKIKAWA, H., NAKANO, M. & ARITA, T. 1978. Inhibitory Effect of 
Polyvinylpyrrolidone on the Crystallization of Drugs. CHEMICAL & 
PHARMACEUTICAL BULLETIN, 26, 118-126. 
References 
170 
SERRANO-DÍAZ, J., SÁNCHEZ, A. M., ALVARRUIZ, A. & ALONSO, 
G. L. 2013. Preservation of saffron floral bio-residues by hot air 
convection. Food chemistry, 141, 1536-1543. 
SHARMA, M., SHARMA, R. & JAIN, D. K. 2016. Nanotechnology Based 
Approaches for Enhancing Oral Bioavailability of Poorly Water Soluble 
Antihypertensive Drugs. Scientifica (Cairo), 2016, 8525679. 
SHEN, L. & JI, H. F. 2012. The pharmacology of curcumin: is it the 
degradation products? Trends Mol Med, 18, 138-44. 
SHEN, Y.-B., DU, Z., WANG, Q., GUAN, Y.-X. & YAO, S.-J. 2014. 
Preparation of chitosan microparticles with diverse molecular weights 
using supercritical fluid assisted atomization introduced by 
hydrodynamic cavitation mixer. Powder Technology, 254, 416-424. 
SHEN, Y.-B., GUAN, Y.-X. & YAO, S.-J. 2015. Supercritical fluid assisted 
production of micrometric powders of the labile trypsin and 
chitosan/trypsin composite microparticles. International Journal of 
Pharmaceutics, 489, 226-236. 
SIGFRIDSSON, K., LUNDQVIST, A. J. & STRIMFORS, M. 2009. Particle 
size reduction for improvement of oral absorption of the poorly soluble 
drug UG558 in rats during early development. Drug Dev Ind Pharm, 
35, 1479-86. 
SINGLETON, V. L. & ROSSI, J. A. 1965. Colorimetry of Total Phenolics 
with Phosphomolybdic-Phosphotungstic Acid Reagents. American 
Journal of Enology and Viticulture, 16, 144-158. 
SINHA, S., ALI, M., BABOOTA, S., AHUJA, A., KUMAR, A. & ALI, J. 
2010. Solid dispersion as an approach for bioavailability enhancement 
of poorly water-soluble drug ritonavir. AAPS PharmSciTech, 11, 518-
527. 
SKAPER, S. D., FACCI, L., FUSCO, M., DELLA VALLE, M. F., ZUSSO, 
M., COSTA, B. & GIUSTI, P. 2014. Palmitoylethanolamide, a naturally 
occurring disease-modifying agent in neuropathic pain. 
Inflammopharmacology, 22, 79-94. 
SOULAIROL, I., TARLIER, N., BATAILLE, B., CACCIAGUERRA, T. & 
SHARKAWI, T. 2015. Spray-dried solid dispersions of nifedipine and 
vinylcaprolactam/vinylacetate/PEG6000 for compacted oral 
formulations. International Journal of Pharmaceutics, 481, 140-147. 
SRIAMORNSAK, P., KONTHONG, S., LIMMATVAPIRAT, S. & 
SUTTIRUENGWONG, S. 2016. Dissolution improvement by solid 
dispersions composed of nifedipine, Eudragit® E and silica from rice 
husk. Asian Journal of Pharmaceutical Sciences, 11, 195-196. 
STELLA, V. J. & HE, Q. 2008. Cyclodextrins. Toxicol Pathol, 36, 30-42. 
STENEKES, R. J. H., TALSMA, H. & HENNINK, W. E. 2001. Formation 
of dextran hydrogels by crystallization. Biomaterials, 22, 1891-1898. 
References 
171 
SULAIMAN, G. M. 2015. In vitro study of molecular structure and 
cytotoxicity effect of luteolin in the human colon carcinoma cells. 
European Food Research and Technology, 241, 83-90. 
SUN, J., WANG, F., SUI, Y., SHE, Z., ZHAI, W., WANG, C. & DENG, Y. 
2012. Effect of particle size on solubility, dissolution rate, and oral 
bioavailability: evaluation using coenzyme Q₁₀ as naked nanocrystals. 
International journal of nanomedicine, 7, 5733-5744. 
SWIERCZEWSKA, M., HAN, H. S., KIM, K., PARK, J. H. & LEE, S. 
2016. Polysaccharide-based nanoparticles for theranostic nanomedicine. 
Adv Drug Deliv Rev, 99, 70-84. 
TAN, C. P. & NAKAJIMA, M. 2005. β-Carotene nanodispersions: 
preparation, characterization and stability evaluation. Food Chemistry, 
92, 661-671. 
TAUPITZ, T., DRESSMAN, J. B., BUCHANAN, C. M. & KLEIN, S. 2013. 
Cyclodextrin-water soluble polymer ternary complexes enhance the 
solubility and dissolution behaviour of poorly soluble drugs. Case 
example: itraconazole. Eur J Pharm Biopharm, 83, 378-87. 
TEMELLI, F. 2018. Perspectives on the use of supercritical particle 
formation technologies for food ingredients. The Journal of 
Supercritical Fluids, 134, 244-251. 
TERMENTZI, A. & KOKKALOU, E. 2008. LC-DAD-MS (ESI+) analysis 
and antioxidant capacity of crocus sativus petal extracts. Planta Med, 
74, 573-81. 
THORBALL, N. 1981. FITC-dextran tracers in microcirculatory and 
permeability studies using combined fluorescence stereo microscopy, 
fluorescence light microscopy and electron microscopy. Histochemistry, 
71, 209-33. 
TRUSHEVA, B., TRUNKOVA, D. & BANKOVA, V. 2007. Different 
extraction methods of biologically active components from propolis: a 
preliminary study. Chemistry Central Journal, 1, 13-13. 
TUBEROSO, C. I., ROSA, A., MONTORO, P., FENU, M. A. & PIZZA, C. 
2016. Antioxidant activity, cytotoxic activity and metabolic profiling of 
juices obtained from saffron (Crocus sativus L.) floral by-products. 
Food Chem, 199, 18-27. 
VANDANA, K. R., PRASANNA RAJU, Y., HARINI CHOWDARY, V., 
SUSHMA, M. & VIJAY KUMAR, N. 2014. An overview on in situ 
micronization technique – An emerging novel concept in advanced drug 
delivery. Saudi Pharmaceutical Journal, 22, 283-289. 
VASCONCELOS, T., SARMENTO, B. & COSTA, P. 2007. Solid 
dispersions as strategy to improve oral bioavailability of poor water 
soluble drugs. Drug Discovery Today, 12, 1068-1075. 
VEHRING, R. 2008. Pharmaceutical particle engineering via spray drying. 
Pharmaceutical research, 25, 999-1022. 
References 
172 
VICENTE, J., PINTO, J., MENEZES, J. & GASPAR, F. 2013. Fundamental 
analysis of particle formation in spray drying. Powder Technology, 247, 
1-7. 
VIPPAGUNTA, S. R., MAUL, K. A., TALLAVAJHALA, S. & GRANT, D. 
J. W. 2002. Solid-state characterization of nifedipine solid dispersions. 
International Journal of Pharmaceutics, 236, 111-123. 
WAGH, V. D. 2013. Propolis: A Wonder Bees Product and Its 
Pharmacological Potentials. Advances in Pharmacological Sciences, 
2013, 11. 
WANG, B., ZHANG, W., ZHANG, W., MUJUMDAR, A. S. & HUANG, L. 
2005. Progress in Drying Technology for Nanomaterials. Drying 
Technology, 23, 7-32. 
WANG, Q., GUAN, Y.-X., YAO, S.-J. & ZHU, Z.-Q. 2010. Microparticle 
formation of sodium cellulose sulfate using supercritical fluid assisted 
atomization introduced by hydrodynamic cavitation mixer. Chemical 
Engineering Journal, 159, 220-229. 
WANG, Q., GUAN, Y.-X., YAO, S.-J. & ZHU, Z.-Q. 2011. Controllable 
preparation and formation mechanism of BSA microparticles using 
supercritical assisted atomization with an enhanced mixer. The Journal 
of Supercritical Fluids, 56, 97-104. 
WANG, Y., LU, Z., LV, F. & BIE, X. 2009. Study on microencapsulation of 
curcumin pigments by spray drying. European Food Research and 
Technology, 229, 391-396. 
WASIAK, I., KULIKOWSKA, A., JANCZEWSKA, M., MICHALAK, M., 
CYMERMAN, I. A., NAGALSKI, A., KALLINGER, P., 
SZYMANSKI, W. W. & CIACH, T. 2016. Dextran Nanoparticle 
Synthesis and Properties. PLOS ONE, 11, e0146237. 
WEERAPOL, Y., LIMMATVAPIRAT, S., NUNTHANID, J., 
KONTHONG, S., SUTTIRUENGWONG, S. & SRIAMORNSAK, P. 
2017. Development and characterization of nifedipine-amino 
methacrylate copolymer solid dispersion powders with various 
adsorbents. Asian Journal of Pharmaceutical Sciences, 12, 335-343. 
WILKEN, R., VEENA, M. S., WANG, M. B. & SRIVATSAN, E. S. 2011. 
Curcumin: A review of anti-cancer properties and therapeutic activity in 
head and neck squamous cell carcinoma. Mol Cancer, 10, 12. 
WOJCIK, M., BURZYNSKA-PEDZIWIATR, I. & WOZNIAK, L. A. 2010. 
A review of natural and synthetic antioxidants important for health and 
longevity. Curr Med Chem, 17, 3262-88. 
WU, H.-T., HUANG, S.-C., YANG, C.-P. & CHIEN, L.-J. 2015. 
Precipitation parameters and the cytotoxicity of chitosan hydrochloride 
microparticles production by supercritical assisted atomization. The 
Journal of Supercritical Fluids, 102, 123-132. 
References 
173 
WU, H.-T. & YANG, M.-W. 2011. Precipitation kinetics of PMMA sub-
micrometric particles with a supercritical assisted-atomization process. 
The Journal of Supercritical Fluids, 59, 98-107. 
WU, H.-T., YANG, M.-W. & HUANG, S.-C. 2014. Sub-micrometric 
polymer particles formation by a supercritical assisted-atomization 
process. Journal of the Taiwan Institute of Chemical Engineers, 45, 
1992-2001. 
WU, J.-J., SHEN, C.-T., JONG, T.-T., YOUNG, C.-C., YANG, H.-L., HSU, 
S.-L., CHANG, C.-M. J. & SHIEH, C.-J. 2009. Supercritical carbon 
dioxide anti-solvent process for purification of micronized propolis 
particulates and associated anti-cancer activity. Separation and 
Purification Technology, 70, 190-198. 
XIE, M.-B., LI, Y., ZHAO, Z., CHEN, A.-Z., LI, J.-S., HU, J.-Y., LI, G. & 
LI, Z. 2015. Solubility enhancement of curcumin via supercritical CO2 
based silk fibroin carrier. The Journal of Supercritical Fluids, 103, 1-9. 
YANG, S.-J., WU, J.-J., WANG, Y.-C., HUANG, C.-F., WU, T.-M., 
SHIEH, C.-J. & CHANG, C.-M. J. 2014. Encapsulation of propolis 
flavonoids in a water soluble polymer using pressurized carbon dioxide 
anti-solvent crystallization. The Journal of Supercritical Fluids, 94, 
138-146. 
YI, J., LAM, T. I., YOKOYAMA, W., CHENG, L. W. & ZHONG, F. 2015. 
Beta-carotene encapsulated in food protein nanoparticles reduces 
peroxyl radical oxidation in Caco-2 cells. Food Hydrocolloids, 43, 31-
40. 
YI, X., ZUO, J., TAN, C., XIAN, S., LUO, C., CHEN, S., YU, L. & LUO, 
Y. 2016. KAEMPFEROL, A FLAVONOID COMPOUND FROM 
GYNURA MEDICA INDUCED APOPTOSIS AND GROWTH 
INHIBITION IN MCF-7 BREAST CANCER CELL. African Journal 
of Traditional, Complementary, and Alternative Medicines, 13, 210-
215. 
ZABIHI, F., XIN, N., LI, S., JIA, J., CHENG, T. & ZHAO, Y. 2014. 
Polymeric coating of fluidizing nano-curcumin via anti-solvent 
supercritical method for sustained release. The Journal of Supercritical 
Fluids, 89, 99-105. 
ZAJC, N., OBREZA, A., BELE, M. & SRČIČ, S. 2005. Physical properties 
and dissolution behaviour of nifedipine/mannitol solid dispersions 
prepared by hot melt method. International Journal of Pharmaceutics, 
291, 51-58. 
ZEKA, K., RUPARELIA, K. C., CONTINENZA, M. A., STAGOS, D., 
VEGLIO, F. & ARROO, R. R. J. 2015. Petals of Crocus sativus L. as a 
potential source of the antioxidants crocin and kaempferol. Fitoterapia, 
107, 128-134. 
ZHENG, W. & WANG, S. Y. 2001. Antioxidant activity and phenolic 








List of Symbols 
 
AC    Acetone 
AcEt   Ethyl acetate 
BC    β-carotene 
C    Concentration 
CO2    Carbon dioxide 
CUR   Curcumin 
DEX   Dextran 
DLS   Dynamic laser scattering 
DMSO   Dimethyl sulfoxide 
DPPH   2,2-Diphenyl-1-picrylhydrazyl 
EEP    Ethanolic extract of propolis 
EtOH   Ethanol 
FITC   Fluorescein isothiocyanate 
FTIR   Fourier Transform infrared 
GLR   Gas to liquid ratio 
HPβCD  Hydroxypropyl-β-cyclodextrin 
HPLC   High Performance Liquid Chromatography 
LUT   Luteolin 
MetOH   Methanol 
Mw    Molecular weight 
N2    Nitrogen 
NIF    Nifedipine 
NMP   1-Methyl-2-pyrrolidinone 
P    Pressure 
Pm    Pressure mixer 
PEA   Palmitoylethanolamide 
PGSS   Precipitation from Gas Saturated Solution 
PSD    Particle Size Distribution 
PVP    Polyvinylpyrrolidone 
RESS   Rapid Expansion of Supercritical Solutions 
SA    Scavenging Activity 
SAA   Supercritical Assisted Atomization 
SAILA   Supercritical Assisted Injection in a Liquid Antisolvent 
SAS    Supercritical Antisolvent 
SC-CO2  Supercritical carbon dioxide 
SCF    Supercritical fluid 
SEDS   Solution Enhanced Dispersion by Supercritical Fluid 
THF   Tetrahydrofuran 
Tp    Temperature precipitator 
Ts    Temperature saturator 
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